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In recent years evidence has accumulated which suggests that the brain may
not be the immunologically privileged site it was once considered to be. It is now
widely accepted that T lymphocytes perform surveillance functions in normal brain
parenchyma. However as yet there are no reports ofB lymphocytes entering brain
parenchyma in the healthy state.
This study aimed first to determine the prevalence of B lymphocytes in normal
human brain, and subsequently whether advancing human immunodeficiency virus
(HIV) infection leads to changes in the brain B lymphocyte population which might
contribute to the increased risk of lymphoma seen in aquired immunodeficency
syndrome (AIDS).
Our results show that B lymphocytes do enter all areas ofnormal brains in
very low numbers and that the B lymphocytes within the brain parenchyma display an
activated (CD23 positive) phenotype. In contrast intravascular B lymphocytes had a
much lower expression of activation markers. B lymphocytes were found in
increased numbers in both the brain parenchyma and perivascular spaces of pre-AIDS
brains. However brains from the majority ofAIDS subjects, including those with
primary central nervous system lymphoma (PCNSL) (out with the area of neoplastic
involvement) contained fewer B lymphocytes than normal or pre-symptomatic HIV
infected brains. A subset of AIDS brains, previously shown to have pleomorphic
lymphoid infiltrates in the perivascular spaces had significantly increased numbers of
B lymphocytes in both the brain parenchyma and perivascular spaces, which led us to
hypothesise that these may represent a pre-malignant PCNSL state. These
pleomorphic lymphoid infiltrates were shown to be polyclonal, as defined by
immunoglobulin gene re-arrangements, in contrast to PCNSL in which two of three
tumours were found to be monoclonal.
Virtually all AIDS related PCNSL are known to be EBV positive, in contrast
to non-HIV PCNSL and non-CNS AIDS related lymphomas. We examined the EBV
status of brain parenchymal B lymphocytes to investigate whether EBV positive B
lymphocytes are more frequent in HIV infected brains than normal thus explaining the
propensity for CNS lymphomas in AIDS. In-situ hybridisation (ISH) studies showed
EBV positive cells only in the tumours of AIDS related PCNSL cases. PCR based
studies detected high EBV copy numbers in PCNSL tumour tissue and low copy
II
numbers from AIDS cases with pleomorphic lymphoid infiltrates. As none of the B
lymphocytes in this latter group were EBV ISH positive, and this appears to be a
prerequisite for PCNSL development, we find no evidence that pleomorphic
infiltrates represent a pre-malignant PCNSL state. However both PCNSL and AIDS
associated pleomorphic infiltrates were associated with expression of the B
lymphocyte chemoattractant, stromal cell derived factor-1 (SDF-1) in the brain.
Humoral responses have been shown to play an important part in the immune
response to many neurtropic viruses, therefore we assessed the role of B lymphocytes
in HIV encephalitis (HIVE). Our results show that a slight increase in the brain B
lymphocyte population occurs in HIVE compared to non-HIVE AIDS brains.
However this response is far smaller than that seen either in pre-AIDS non-HIV
encephalitis or in non-immunocompromised viral encephalitis.
Finally we have shown that the presence ofB lymphocytes in the brain is not
associated with damage or disruption to the blood-brain barrier.
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In December 2001 the World Health Organisation (WHO) estimated that
approximately 40 million people worldwide were living with the human
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). The
majority of these (28.1 million) reside in Sub-Saharan Africa, while North America
and Western Europe account for only 1.5 million. In 2001 alone an estimated 5
million people were infected worldwide (3.4 million in Sub-Saharan Africa, 75,000 in
North America and Western Europe), and 3 million people died from the disease (2.3
million in Sub-Saharan Africa and 27,000 in North America and Western Europe). In
Sub-Saharan Africa HIV is now the leading cause of death and worldwide it is the 4th
highest cause of death (WHO/UNAIDS 2001).
Infection with HIV leads eventually to the development of AIDS, with a
progressive destruction of the immune system. Consequently there is an inability to
resist infection with opportunistic pathogens and a predisposition to certain types
cancer. There is as yet no cure or effective vaccine for HIV and although the
introduction ofhighly active anti-retroviral therapy (HAART) has allowed disease
progression to be slowed considerably this treatment is expensive (approximately
$15,000 per year) and is therefore only available in affluent countries and not in the
overburdened countries ofAfrica. Prevention ofviral transmission through education
of the populace in methods of safer sexual practices is undoubtedly the best way of
halting the epidemic at present. There is evidence from Zambia, one of the worst
affected countries, that a decreased incidence ofHIV in the urban population
correlates with the population reporting less sexual activity, fewer sexual partners and
more consistent use of condoms (Fylkesnes et al 2001). This suggests that education
can make a difference. A lack of education and understanding of the disease coupled
with the lack of preventative measures in some of the worst affected countries is
reflected in the prevalence ofHIV in the adult population. In Sub-Saharan Africa
8.4% of adults are infected, mostly through heterosexual sex. In comparison, the
prevalence in North America is 0.6% with infection occurring through needle sharing
of intravenous drug users (IDU), homosexual receptive sex and heterosexual sex. In
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Western Europe the rate is even lower at 0.3% of adults (WHO/UNAIDS 2001). In
contrast to many African countries, UK education programs have been in place for
nearly 20 years. Although initially these proved effective in limiting the spread of
HIV, there now appears to be a growing complacency over the risks ofHIV infection.
This is represented in a recent increase in the number ofHIV infected individuals in
the country. The figures for the year 2000 published by the Public Health Laboratory
Service (PHLS 2000) represented a 14% increase over the previous year (3,500 in
2000). HIV is therefore still a major health problem in the UK and worldwide a
catastrophic problem.
Individuals infected with HIV are estimated to be at 1000 fold increased risk
of developing primary central nervous sysytem lymphoma (PCNSL) in comparison to
the general population (Larocca et al 1998). PCNSL is reported at autopsy in 5-10%
ofHIV infected patients (Auperin et al 1994, Flinn & Ambinder 1996) and develops
late in HIV infection with an extremely poor prognosis. As yet the pathogenesis of
PCNSL is not fully understood, however in HIV there is a 100% association with the
gamma herpes Epstein Barr Virus (EBV) (MacMahon et al 1992). All AIDS PCNSL
are ofB lymphocyte origin and although it would seem that B lymphocyte entry to
the brain is a pre-requisite for tumour formation there are as yet no reports ofB
lymphocytes entering normal brain.
The majority of cases used in the study are taken from the Edinburgh brain
bank, most ofwhom were local residents in the Edinburgh area. In Edinburgh a large
number ofHIV infected individuals are intravenous drug users (IDU) and therefore
the abuse of drugs has to be considered as a potential confounding factor within this
study.
The epidemic of injecting drugs in Edinburgh started around 1980 peaking in
1983-4 (Robertson et al 1986). HIV first infected IDUs in 1983 and was spread
rapidly by sharing of contaminated needles (Peutherer et al 1985). Between 1982 and
1985 51% of 164 heroin injectors attending a general practice clinic were HIV
positive (Robertson et al 1986). To March 1997, 1176 HIV infections had been
reported in Edinburgh and the surrounding area ofwhich 52% were due to injecting
drug use (Davies, Cormack & Richardson 1999). A survey undertaken in 1992-94
found 19.3% of IDU HIV positive (Davies et al 1995), twice the rate of the nearby
larger city of Glasgow where a higher percentage of young adults inject drugs. The
high prevalence ofHIV in IDUs in Edinburgh appears to stem from a limited supply
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injecting equipment during the 1980's. The shortage came about from restrictions by
pharmacists on the sale of needles and syringes, as well as from the removal of
equipment by police during searches (Burns et al 1995). Drug suppliers then began
forcing users to inject on site, so that they left free of incriminating evidence. This
resulted in all the clients of a supplier using the same equipment (Bums et al 1995),
which in turn allowed rapid spread ofHIV among the drug using community. The
HIV infected population ofEdinburgh IDUs have been show to be at increased risk of
mortality with up to 15% ofHIV IDU in one study dying before the onset ofAIDS
(Seaman, Brettle, Gore 1997). The Edinburgh brain bank contains brains from this
group which provides a unique opportunity to study both the effects ofHIV within the
brain before the onset ofAIDS and the progression from pre-AIDS to AIDS.
1.2 The immune system
The organs and cells of the immune system provide the body with protection
against invading pathogens, and are essential to the survival of complex organisms.
There are two arms of the immune system; innate and adaptive. The innate immune
response is a non-specific immediate response that is directly activated by infectious
agents, inflammation and tumours. It cannot be modified during life and is therefore
essentially inherited. Although innate responses are fast they lack any specificity,
have no memory ofpreviously encountered pathogens and often induce bystander
damage to nearby tissue. In contrast an adaptive immune response develops during
the lifetime of an individual in response to a specific antigen and in most cases
confers lifetime immunity to a pathogen once it has been encountered.
1.2.1 Innate immunity
Innate immunity is provided by phagocytic macrophages, natural killer (NK)
cells and neutrophil cells (see glossary for definition of cell types). These form the
first line of defence against invading pathogens. They recognise and can bind
extracellular pathogens (e.g. bacteria) via receptors on their cell surface. Receptor
binding induces phagocytosis of the pathogens and release of cytokines (proteins
made by cells which affect the behaviour of other cells by binding to cytokine
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receptors on the cell's surface) such as interferon y (INF-y) which attracts further
immune cells into the area.
The innate system is non-specific and cannot always eliminate pathogens.
Furthermore the cells that provide innate immunity cannot recognise all pathogens
and therefore many pathogens are invisible to the innate system (e.g. most viruses).
The innate system is however critical for early defence of the body after entry of
pathogens such as bacteria and protozoa, as the second highly targeted arm of the
immune system, the adaptive system, takes 4-7 days to respond to foreign antigens.
1.2.2 Adaptive immunity
Adaptive immunity is provided by B and T lymphocytes. In contrast to the
phagocytes of the innate system, which bearmultiple receptors specific for many
different target antigens, the lymphocytes have only one receptor type, specific for
one peptide. In simplistic terms there are 3 main types of lymphocytes: B
lymphocytes which secrete antibody, CD8 T lymphocytes which kill virus infected
cells, and helper CD4 T lymphocytes required to activate many B and CD8
lymphocytes. CD4 cells play a crucial role in determining whether an immune
reaction will be cell mediated (CD8 driven) or humoral (antibody mediated). This is
controlled by the differentiation of CD4 cells from T helper (TH) 0 cells to either TH1
(cell mediated) or TH2 (humoral) helper cells. Which type of cell THO CD4 cells
differentiate into is determined by the type, size and amount of antigen presented to
them, and by cytokines present in the microenvironment. TH1 cells secrete INFy
which suppresses TH2 cells and interleukin-2 (IL-2) which activates T lymphocytes.
TH2 cells secrete transforming growth factor (3 (TGF(3) and IL-10, which suppress
TH1 cells, and also IL-4 and IL-6 which stimulate B lymphocytes. Therefore an
immune reaction is a balance between TH1 and TH2 responses, with the predominant
response determined by the pathogen and local cytokine levels.
The specificity of lymphocyte receptors is determined genetically during
lymphocyte development in the bone marrow (B lymphocytes) and thymus (T
lymphocytes). Each lymphocyte has a different specificity allowing detection of an
almost infinite number of potential antigens. The specificity of each lymphocyte is
determined by the construction of the surface immunoglobulin (Ig) receptor expressed
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on B lymphocytes (see Figure 1) and the T cell receptor (TCR) expressed on T
lymphocytes.
Lymphocytes are capable ofbinding antigen and recognising it when it is
presented in the correct manner. CD4 T lymphocytes recognise antigen presented on
major histocompatability complex (MHC) class II molecules. Peptides displayed on
MHC II are extracellular in origin and are degraded in cellular vesicles before
presentation as peptide fragments. In contrast cytosolic antigens are presented on
MHC class I to CD8 T lymphocytes. MHC class I is present on nearly all nucleated
cells, with rare exception including neurones, although it can be induced on these
cells (Fujimaki et al 1996, Neumann et al 1997). MHC class II is only expressed on
specialised antigen presenting cells of the immune system including the professional
antigen presenting dendritic cells and the non-professional antigen presenting
macrophages and B lymphocytes.
1.2.2.1 Diversity of B lymphocyte Immunoglobulin and T
lymphocyte T cell receptors
The B lymphocyte Ig receptor is composed of 4 protein chains, the 2 heavy
and 2 light Ig chains (see Figure 1). The heavy chain is composed of 4 regions: a
variable (V), diversity (D), joining (J) and constant (C) region. The light chain in
contrast has only 3 regions: V, J and C. Each region of the chain is coded for by a
family of genes. The heavy chain genes are located on chromosome 14 and in
humans there are 86 V, 30 D, 9 J, and 11 C genes (Cook & Tomlinson 1995). There
are 2 types of light chains, kappa (k) and lamda (X), either of which is paired with a
heavy chain. There are 52 V A. genes, 7 J and 7 C genes located on chromosome 22.
The k genes are located on chromosome 2 where there are 76 V, 5 J and 1 C gene.
Any of the individual V, J and C k and X genes can be combined to produce either a k
or X light chain, giving a potential of 2548 X and 380 k combinations. In the same
way, any of the heavy V,D,J and C genes can be combined to produce a heavy chain,
giving a potential of approximately 255,000 Ig heavy chains. Any light chain can be
paired with any heavy chain giving a possible -734,000,000 combinations of Ig,
although it should be noted that not all combinations produce functional Ig.
As discussed later, additional variability is introduced by the mechanism used
to join the V,(D),J, and C genes together, further increasing the diversity of Ig
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produced and increasing the number ofpotential foreign antigens which can be
recognised. Although the genes used to create the TCR in T lymphocytes are
different to the Ig genes, the principles of diversity generation and joining of the
segments is the same. Construction of the TCR will not be discussed further as it is
not central to this thesis.
1.2.2.2 Immunoglobulin genes
Figure 2 shows a schematic representation of the layout of the Ig heavy chain
genes on chromosome 14. The genes coding for V, J and C in k and X are laid out in a
similar way. The heavy chain variable genes provide a large percentage of the
diversity of the heavy chains. The genes encoding V heavy segment of the Ig chain
are divided into 6 families based on their DNA sequence homology, with members of
each family showing at least 70% homology (Matsuda & Honjo 1996). The families
are termed variable heavy (VH)-l to VH-6 (see diagram 2). Within each family there
are areas ofhighly conserved sequence, termed framework (FR) 1-4, and areas of
high variability (HV). Figure 3 shows that the areas of high variability within each
family corresponds to the areas of the protein involved in the binding to antigen.
There is a bias in the usage of variable heavy chain families, with the VH3
family providing the greatest contribution to the functional Ig repertoire (51 genes),
followed by VH1 (17 genes) and VH4 (13 genes). VH2, VH5 and VH6 each
contribute a relatively small number of functional members, with 4, 3 and 1 gene
respectively (Cook & Tomlinson 1995).
1.2.2.3 Immunoglobulin gene re-arrangements
In order to create a viable Ig heavy or light chain, one gene from each section (V, [D],
J and C) must be juxtaposed, to allow transcription of a single re-arranged gene and
hence production of the Ig heavy or light chain protein. The mechanism by which the
genes are brought together is called somatic recombination. This involves the
splicing out of intermediate sections ofDNA leading to the juxtaposition of genes
from each of the sections of the chain. Figure 4 gives a representation of how this
occurs. Cleavage of intervening DNA is carried out by a complex of proteins
including the enzymes RAG1 and RAG2 (recombination activating genes), which are
expressed only in lymphocytes.
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Figure 2: Schematic representation of immunoglobulin heavy
chain genes
Immunoglobulin heavy chain genes in humans can be grouped into families (VH1-
VH6) by their nucleotide sequence, however there distribution in the genome is
random as demonstrated below.
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Figure 3: Variability of the immunoglobulin
heavy chain genes
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Figure 4: Representation of immunoglobulin heavy chain VDJ
recombination



















The process ofjoining genes from each region is key to providing increased diversity
and variation in the antibody repertoire. Figure 5 demonstrates how the cleaved ends
of the two genes are joined together. The generation of P nucleotides (palindromic
nucleotides are an inverse repeat of the sequence at the end of the adjacent gene
segment) and N nucleotides (a variable number of nucleotides randomly inserted into
the joint between variable genes by the enzyme terminal deoxynucleotidyl
transferase) during the ligation of the two ends ofDNA introduces further variability
into the Ig heavy and light chains. This further increases the diversity of the Ig
repertoire and hence increases the potential number of foreign antigens that can be
recognised by the system.
The whole process in B lymphocytes takes place in the bone marrow during B
lymphocyte development, and the choice of Ig genes used is essentially random.
There is however a bias in the use of k light chains over A, light chains in humans.
The heavy chain genes are re-arranged first, and production of a functional Ig heavy
chain results in re-arrangement of the k light genes. If there is a failure to produce a
functional k light chain then the cell will re-arrange its A, light chains (approximately
70% of Ig's are constructed using k light chains in humans). Failure to produce a
functional Ig results in apoptosis in B lymphocytes. (For a review ofV(D)J
recombination see Schatz, Oettinger & Schlissel 1992).
The huge potential repertoire of Ig antigen receptors and the random manner
in which they are produced means that there is a high potential for creating
lymphocytes able to bind to normal human proteins (self-antigens). Recognition of
self-antigens leads to the induction of autoimmune disease, and therefore to avoid this
occurring apoptosis is induced in B lymphocytes that recognise self-antigens before
they leave the bone marrow.
1.2.2.4 Activation of lymphocytes
Lymphocytes continually re-circulate between the blood and secondary
lymphatic organs (spleen, lymph node). In order for lymphocytes to become antigen
specific effector cells able to act against their antigen, they must first be activated.
This is triggered by antigen binding to lymphocyte receptors and is a complex multi-
step process that ensures that immune reactions only occur when necessary, thus
avoiding unnecessary bystander tissue damage which is associated with inflammatory
immune reactions.
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nucleotides and DNA polymerase
completes the new joint
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Phagocytes in the peripheral tissues take up antigen produced by infectious
organisms. They then travel to the lymph nodes via the afferent lymphatic system
where they present their antigen to B and T lymphocytes, causing lymphocyte
activation.
CD4 T lymphocytes are activated by the presentation of their specific antigen
by antigen presenting cells (dendritic cells, B lymphocytes and macrophages) on class
II MHC which is only expressed on antigen presenting cells (Reviewed in
Guermonprez et al 2002). The presented antigen is bound by the TCR of the CD4
lymphocyte, providing the first of 2 signals required for CD4 T lymphocyte
activation. The second signal is also supplied by the antigen presenting cells, by
expression of one or other of the B7 proteins (CD80 or CD86) on its surface which
binds to CD28 on the surface of the CD4 T lymphocyte providing the second signal
for activation (see figure 6). Activation leads to expression of IL-2 and IL-2 receptor
in the CD4 cell, which operates in an autocrine system to stimulate proliferation and
differentiation of the CD4 T lymphocyte.
CD4 helper T lymphocytes are required for most B lymphocyte responses to
antigen. Activation of B lymphocytes also requires 2 signals, the first is supplied by
the binding of antigen to the cell surface Ig molecule, and the second which is
provided by CD4 cells by the ligation ofCD40 on the B lymphocyte surface with
CD40 ligand (CD 154) on the CD4 cell surface. In addition, as mentioned above,
CD4 cells also provide cytokines for proliferation and differentiation ofB
lymphocytes. Activated B lymphocytes display activation markers including CD23, a
dual role cell surface protein involved in enhanced antigen presentation to CD4 cells
and binding of both soluble cell free CD21 and cell surface bound CD21 present on
other B lymphocytes; inducing B lymphocyte aggregation (Bonnefoy et al 1995,
Bjorck et al 1993). CD23 is displayed on mature B lymphocytes which have been
activated, therefore it is a useful marker in determining the activation status ofB
lymphocytes.
B lymphoctes are capable of producing different classes of Ig each with
differing properties. Figure 7 shows the maturation process for B lymphocytes in
terms of Ig production and the specific functions of each class of Ig. The Ig class
present on B lymphocyte surface is dependent on the class of Ig constant heavy chain
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Figure 6: Two signals are required for Helper T cell
activation
Antigen











Signal 1 is provided through binding of the T cell receptor to
antigen presented on MHC class II molecule.
Signal 2 is provided by ligation ofCD28 molecule on the T cell
surface with B7 (CD80 or CD86) molecule on the antigen
presenting cell.
Both signals are required for activation of T helper cells
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Figure 7: Maturation of naive human B
lymphocytes
IgM
Mature naive B lymphocyte with re-arranged
VDJ heavy chain genes expressing p and a
constant heavy chain genes by alternative
splicing, which produces IgM and IgD on the
cell surface.
B lymphoblast (which has been exposed to
antigen) secretes IgM
Memory B lymphocyte has undergone
isotype switching to express heavy constant
y,a or s genes which produce IgG, IgA or
IgE on the cell surface respectively.
Plasma cell secretes either IgG, IgA or IgE
depending on constant chain used.
T
Properties of antibodies:
IgM weakly neutralising, strongly activates complement,
found in plasma
IgG (1-4) Neutralising, opsonising (IgG 1,3), sensitisation for
killing by NK cells (IgGl,3), activate complement,
diffuse into extra vascular sites
IgA Neutralising, diffuse into extracellular sites, transport
across epithelium (particularly gut) into secretions
IgE Sensitisation ofmast cellsT
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being expressed. Figure 7 demonstrates the process of Ig constant heavy chain gene
switching and the type of antibody produced by each gene. Upon activation B
lymphocytes enter primary lymphoid follicles in lymph nodes, where they begin to
proliferate and form germinal centres. Primary follicles contain follicular dendritic
cells (FDC) (distinct from dendritic cells) which are thought to play an important role
in controlling antibody responses to antigen. The function ofFDC is to prevent
apoptosis and support proliferation of germinal centre B lymphocytes, in contrast to
the role ofT lymphocytes in the germinal centre which induce differentiation ofB
lymphocytes. Rapid proliferation ofB lymphocytes (centroblasts) in the germinal
centre greatly increases the number ofB lymphocyte centroblasts specific for the
antigen that initiated the response. Most B lymphocytes in a germinal centre are
therefore derived from 1 or a few founder cells. Re-arranged Ig genes of dividing
centroblasts accumulate mutations at a rate of 1 base in every 10,000 per cell division.
This high mutation rate (most other somatic cells have a rate of 1 base in 1010) means
that approximately every second cell produced will have 1 amino acid change in its Ig
receptor. The consequence of these changes, called somatic hypermutation, is that
occasionally a cell is produced which has a greater binding affinity for the antigen
that invoked the immune reaction than the original founder cell. This cell is then
selected over weaker binding cells for proliferation, whereupon the process begins
again. Cells that accumulate mutations that weaken antigen binding undergo
apoptosis. In contrast those with strong affinity for antigen have expression of anti-
apoptotic genes induced (e.g. BcF). The result of this process is a continual evolution
of the Ig receptor and consequently greater antibody/antigen affinity.
CD4 T lymphocytes can only recognise antigen when it is presented on MHC
class II molecules. The main class of antigen presenting cells are dendritic cells,
which express MHC class II and reside in T cell areas of lymphoid tissue. Immature
dendritic cells are found in non-lymphoid tissue, however these cells do not appear to
stimulate T cell responses until they are activated and migrate to lymphoid tissues.
An additional function of B lymphocytes is the ability to act as antigen presenting
cells to CD4 T lymphocytes, when activated to express MHC class II. This allows
CD4 cells to bind their antigen and be activated by the B lymphocytes. CD4 cells in
turn further stimulate the pool ofB lymphocytes enhancing and amplifying the
humoral immune response. The process of antigen presentation by B lymphocytes is
less efficient than that of dendritic cells.
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CD8 lymphocytes are activated through recognition of antigen presented on
class I MHC in conjunction with expression of the B7 protein (CD80 or CD86) by the
antigen presenting cell which is required for a second signal. Some CD8 cells require
additional stimuli to become activated, this involves the binding of a CD4 cell to the
same antigen presenting cell as the CD8. The CD4 cell can then release IL-2 to
stimulate the CD8 cell or alternatively provide stimulation of the dendritic cell to
induce B7 expression.
1.2.3 The Blood brain barrier (structure and function)
The BBB is essential for the maintenance and regulation of the brain
microenvironment. It regulates and controls the entry of nutrients, electrolytes,
vitamins, minerals, free fatty acids, peptides and regulatory proteins (Reviewed in
Banks 1999). This regulation ensures that ionic composition of the interstitial fluid of
the CNS remains stable despite any fluctuations in the blood circulating through the
brain. In addition the BBB is involved in the regulation and control of entry of
immune cells to the brain, via expression of adhesion molecules on the endothelial
cell surface (Banks 1999).
The BBB is comprised of several different components, many ofwhich are not
found in the construction of peripheral blood capillaries. Figure 8 compares the
capillaries found in the brain to those found at peripheral sites. Brain microvascular
endothelial cells (BMVEC) form a continuous layer of cells and extracellular matrix.
In addition BMVECs form tight junctions between the endothelial cells, these
structures are absent in the intercellular junctions ofperipheral capillaries (Reviewed
in Kniessel & Wolburg 2000). Tight junctions are modified areas of cell surface
membrane composed of numerous proteins including occludin and zonnula occludin
(ZO)-l (Fanning et al 1998). These have been shown to link the extracellular
component of the tight junction with the actin cytoskeleton of the cell (Fanning et al
1998). Antibodies against ZO-1 and occludin have been used to study the integrity of
the BBB in healthy and diseased brains (Dallasta et al 1999). In healthy brains
staining with either of these antibodies can be visualised as a continuous line of
staining around blood vessels of the brain. In contrast diseased brains in which BBB
breakdown has occurred (e.g. multiple
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Figure 8: Diagram of a cross section of a brain








sclerosis and HIV encephalitis) show fragmented staining or a complete absence of
these tight junction proteins (Dallasta et al 1999, McQuaid 2002). The tight
junctions between BBB endothelial cells leads to high endothelial electrical
resistance, in the range of 1500-2000 G, as compared to 3-33 f2 in other tissues
(Crone and Christensen 1981, Butt et al, 1990). The net result of this elevated
resistance is low paracellular permeability.
Another important component of the BBB, which is not found in peripheral
capillaries, is astrocyte foot processes. While these do not actually form a physical
part of the barrier, their presence is essential for development of the BBB and for the
decreased permeability ofBMVECs compared to peripheral endothelial cells (Miller
1999). Without astrocytes, in-vitro cultured BMVECs show similar barrier properties
to peripheral endothelial cells in terms of solute transport and cellular migration
through a layer of endothelial cells. However, if the BMVECs are co-cultured with a
layer of astrocytes below the layer ofBMVEC cells many of the functions of the BBB
seen in vivo are restored (Goldstein 1988, Hurwitz et al 1993)
Additional differences found between brain and peripheral capillaries include
a decrease in the number ofpinocytic vesicles in BMVECs, an increase in the number
ofmitochondrial organelles found in BMVECs and a lack of fenestrations in the
BMVECs (Broadwell 1989). There are also
The effectiveness of the BBB is demonstrated by the cerebrospinal fluid to
serum albumin ratio of 1:200, which is one of the largest gradients found in the
human body (Banks 1999).
1.3 Immunology of the brain
Until recent years the brain has been considered to be one of several
immunologically privileged sites within the body; other sites include the anterior
chamber of the eye, the testis, and the uterus (Janeway & Travers 1997). The immune
privilege status results from the effects ofboth physical barriers to cell and antigen
migration into the site, and from local soluble immunosuppressive mediators. The
BBB effectively isolates the brain from changes in blood concentrations of ions and
sugars maintaining a constant and regulated environment for the neuronal cells of the
brain. Immune suppression within the brain results from production of cytokines
such as TGFp which suppress expression of class II MHC on microglia and
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suppresses microglial activation and proliferation (Suzumura et al 1991, Lodge &
Sriram 1996, O'Keefe, Nguyen & Benveniste 1999). The combined effect of the
physical BBB and immunosuppressive cytokines is to limit ionic changes in the
extracellular fluid of the brain and to prevent immune reactions occurring, both of
which may cause irreparable damage to non-regenerative neurones of the brain.
This concept of immune privilege of the brain was based on early studies that
showed that allografts survived better in the central nervous system (CNS) than in
peripheral sites (Woodruff 1960). The prevalent view at this time was that the CNS
lacked both lymphatic drainage (Gell & Coombs 1968) and antigen presenting cells.
In addition, the BBB was believed to prevent the entry of immune effector cells.
However in recent years evidence has accumulated to suggest that the CNS is not
excluded from regular surveillance by the immune system (see Perry et al 1997 for
review). CD4 T lymphocytes enter the CNS in an apparently random manner
(Hickey, Hsu & Kimura 1991). Only T lymphocytes that are activated are able to
enter the normal CNS and those that fail to encounter antigen leave within one to two
days of entry. T lymphocytes capable of reacting with antigen located in the brain
parenchyma remain in the CNS, or cyclically re-enter, and thereby initiate
inflammation (Hickey, Hsu & Kimura 1991).
Astrocytes, microglia, endothelial cells and pericytes are all capable of antigen
presentation (Male, Pryce & Hughes 1987, Fabry, Raine & Hart 1994). Although in
the normal brain there is little or no expression ofMHC molecules, some cells of the
CNS can be induced to express MHC. MHC class I can be induced on microglia,
astrocytes and oligodendrocytes by the presence of INFy. INFy and TNFa can also
induce Class II MHC on endothelial cells, pericytes, microglia and astrocytes (Dories
2001, Male, Pryce & Hughes 1987). CD4 T lymphocytes are capable of supplying
the inflammatory mediators necessary for upregulation ofMHC in resident brain
cells. The induction ofMHC class II is ofparticular importance in microglia as these
are the intrinsic immune cell of the CNS, they are the brain's resident macrophages
and are the first line of defence should the BBB be breached. Microglia are capable
of phagocytosis ofboth damaged tissue and foreign antigen, and of subsequent
antigen presentation.
An important part of the normal immune response in a tissue is the transport
of antigen from that tissue via the lymphatic system to local lymph nodes where
lymphocytes can be activated and an immune reaction initiated. Although there is no
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lymphatic drainage from the brain it is now recognised that antigen from the brain can
drain to the cervical lymph nodes (Aloisi, Ria & Adorini 2000). The most likely path
is via the cerebral spinal fluid (CSF) which constantly leaks at the junctions where the
meninges meet the sensory cranial nerves; this is most prevalent at the cribiform plate
where the olfactory nerves penetrate the base of the skull (Dorries 2001).
While some antigen drainage has been shown to occur from the CNS and
certain cell types have been shown to be capable of antigen presentation, it should be
noted that the brain is devoid of dendritic cells (the most potent type of antigen
presenting cells). Dendritic cells can however be found in choroid plexus and in the
meninges covering the brain (Aloisi, Ria & Adorini 2000).
In light of recent advances in our understanding of the functioning of the
immune system within the brain, it seems that the concept of the brain existing as a
completely immune privileged site must now be reconsidered. It is clear that the BBB
tightly regulates entry ofmolecules, cells and pathogens to the brain in order to
maintain a constant environment for neuronal cells. However regulation does not
imply complete exclusion. In the case of the brain unnecessary inflammatory
reactions could cause irreparable damage, therefore it appears logical that cells
capable ofmediating such damage are restricted in entry. Nevertheless, despite the
presence of the BBB many pathogens are capable of entering the CNS and causing
damage, therefore the immune system must be able to deal with these infections. In
essence the brain would appear to have a restricted or lowered level of immune
surveillance, rather than an absence.
With regard to the humoral arm of the immune response, there are as yet no
reports of B lymphocytes entering the normal foreign antigen free CNS (Williams &
Hickey 1995, De Angelis 1999, Hickey 2001). This contrasts with the previously
mentioned evidence of random entry to the brain of activated T lymphocytes in an
antigen independent manner. Several in vitro studies, using models of the BBB, have
shown that while B lymphocytes may adhere to cerebral endothelium, it is CD4 T
lymphocytes which migrate most effectively through the barrier (Pryce, Santos, Male
1994). These models are constituted from layers of endothelial cells cultured on
membranes with astrocytes grown on the other side of the membrane. While these
models are useful for studying individual aspects of cell transmigration into the CNS,
e.g. adhesion molecule usage and interaction, the model can never fully replicate the
in vivo functions of the BBB. It is known that B lymphocytes are capable of
21
responding to antigen within the CNS. For instance Knopf et al (1998) showed that
infusion of antigen (OVA) through an indwelling brain parenchymal catheter, in rats
naive to the antigen, was followed by recruitment ofB lymphocytes and production of
antibody despite the presence of an intact BBB. When the experiment was repeated
in pre-immunised rats the B lymphocyte response was even stronger. This suggests
that antigen can be detected behind the BBB and furthermore that antigen-specific B
lymphocytes can respond to antigen within the brain.
1.3.1 Viral infections of the brain: role of B and T lymphocytes
Since the focus of this thesis is viral infections of the brain (in particular HIV
and EBV) only immune reactions to viral entry and persistence in the CNS will be
further discussed, however, there is evidence of immune reactions to other pathogens
occurring within the brain for example toxoplasma (Deckert-Schluter et al 1999).
The main viruses capable of CNS infection are given in table 1.
Table 1: Neurotropic viruses
Viral family Viruses References
Enteroviruses polio Lohler 1981
Morbillivirus measles Lohler 1981
Paramyxovirus mumps Forsberg et al 1986
Herpes Herpes simplex,
cytomegalovirus,
human herpes vims 6
Lohler 1981
Lohler 1981




Eldadah et al 1981
Lanciotti et al 2000
Eldadah et al 1981
Lyssavirus Rabies virus Feiden et al 1985
Retrovirus HIV-1, HIV-2
human T cell leukaemia vims
Budka et al 1987, Sankale et al 1996
Gartner et al 1986
Papovavims JC vims Scweighardt & Atwood 2001
The detailed study of viral CNS interactions is not possible in humans except
at autopsy, however there are a variety of good animal model systems that allow in
depth study. In addition certain aspects of viral CNS infection can be studied in vitro.
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Neurotropic viruses entering the body generally undergo several rounds of
viral replication in the periphery before spreading to the CNS, and during this time the
peripheral immune system begins to mount an immunological response to the virus.
There are numerous potential routes of viral entry to the CNS form the periphery.
Herpes simplex virus (HSV)-l for example replicates in the epithelium of the oral
cavity. Also present in the oral cavity are sensory receptors for taste, pressure and
heat that are connected to neurones within the CNS. HSV nucleocapsids are capable
of entering axons and are then transported to the neurones in the trigeminal ganglia,
where the virus establishes a latent infection with few if any of its genes being
expressed. Alternative routes ofviral entry to the CNS include the use of adsorptive
endocytosis by virus such as Japanese encephalitis virus (Liou & Hsu 1998), a
mosquito born flavivirus, to cross the endothelial cells of the BBB in mice. The virus
binds to endothelial cells of the BBB and is absorbed into endocytic vesicles,
allowing transport into the brain endothelium from where it can spread into the CNS.
In contrast HIV is thought to be carried into the CNS by infected blood mononuclear
cells (CD4 T lymphocytes and macrophages) that normally traffic into the CNS
(Nottet et al 1996, Persidsky et al 1997).
Once within the CNS neurotropic viruses infect resident brain cells.
Replication of viruses within the CNS causes activation of local microglial cells to
produce INF a/(3 (Dorries 2001). The effects of this cytokine is to induce MHC class
I expression on CNS cells (Njenga et al 1997), which allows infected cells to present
viral peptides to CD8 lymphocytes (Morris et al 1987). Furthermore microglia
phagocytose cellular debris that accumulates as a result of the cytopathic effects of
viral infection of cells, inducing further cytokine release. The production of cytokines
and chemokines within the brain leads to an increase in adhesion molecule expression
on endothelial cells of the BBB allowing trafficking of activated T lymphocytes
(Male et al 1990). Both CD4 and CD8 lymphocytes enter the brain, with CD4
lymphocytes secreting TNFa and INFy which induces expression of class II MHC on
microglial cells allowing local presentation of antigen to the CD4 lymphocytes
(Hellendall & Ting 1997, Panek & Benveniste 1995).
Stohlman et al (1998) have demonstrated that CD4 lymphocytes are required
for maintenance of CD8 T lymphocyte viability within the CNS. Wild type and CD4
T lymphocyte depleted mice were infected with neurotropic JHM strains ofmouse
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hepatitis virus. In the wild type mice CD4 T lymphocytes entered the brain but
remained in the perivascular spaces. In contrast halfof the CD8 T lymphocytes
present migrated into the parenchyma. In the CD4 depleted mice the CD8 T
lymphocyte migration into the brain was not inhibited but the CD 8 cells underwent
apoptosis, suggesting the CD4 cells were required for CD8 cell viability.
In addition to antigen presentation in the brain, there has been speculation that
priming and activation ofT lymphocytes may also occur in the brain during viral
infection and multiple sclerosis. For this to occur expression ofB-7 molecules (CD80
or CD86) is required in addition to MHC on microglial cells (Windhagen et al 1995,
Soos et al 1999).
The role of T lymphocytes in eradication of virus from the CNS has been well
documented (reviewed in Dorries 2001). However humoral immunity has also been
suggested to play an important role in the control of viral infections in the CNS in
several animal model systems.
Lewis rats infected with Borna disease virus develop a non-lytic and persistent
CNS infection despite a vigorous immune response. The acute phase of the disease is
characterised by infiltration ofCD4 and CD8 T lymphocytes, macrophages and NK
cells, with a few B lymphocytes also being found. Studies of cytokine expression
during the acute phase show expression of IL-1, IL-2, IL-6, TNFa, INFy. These TH-1
type cytokines are thought to be expressed primarily by CD4 T lymphocytes within
the infiltrating mononuclear cells. As the infection progressed into the chronic phase
the expression of TH-1 cytokines decreased and was replaced by expression of TH-2
cytokines; IL-4 and TGF|3. The switch to TH-2 cytokine production is associated
with a change in the composition of infiltrating mononuclear cells, with B
lymphocytes becoming the dominant cell type and CD8 T lmphocytes almost
disappearing (Hatalski et al 1998a, 1998b).
A similar phenomenon occurs during infection of mice with encephalitis
inducing Sinbis virus. In the later stages of the inflammatory process there is a
prominent B lymphocyte response, and recovery from the infection is dependent on
the production of antiviral antibodies (Tyor, Moench & Griffin 1989). The first B
lymphocytes taking part in the immune response to Sindbis virus encephalitis express
surface IgM; this later switches to expression of IgG or IgA. In athymic mice
(lacking mature T lymphocytes) infected with Sindbis virus, the number of B
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lymphocytes found in the brain parenchyma in response to the CNS infection is
decreased. Those that are present are mostly IgM positive and the switch to IgG or
IgA is not seen in these mice (Tyor, Moench & Griffin 1989). This suggests that T
lymphocytes, presumably CD4 positive cells, are required to aid the recruitment ofB
lymphocytes into the brain and also for Ig isotype switching during Sindbis virus
encephalitis.
Other CNS viral infections in which antibodies have been shown to be
essential components of the immune response include rabies and measles viruses.
The transfer of specific antibodies into rats infected with measles virus results in a
limited viral gene expression, decreasing the severity of infection. In severe
combined immunodeficient (SCID) mice (which lack both B and T lymphocytes)
infected with rabies virus, the transfer of rabies specific antibodies leads to clearance
of the virus from CNS cells (Hatalski et al 1998a).
The preceding data demonstrate that both the cellular and humoral arms of the
immune system play important roles in control or eradication of viral CNS infections.
1.3.2 Lymphocyte transmigration into the CNS
In recent years a significant amount of research has been undertaken to
elucidate the mechanisms by which lymphocytes (particularly T lymphocytes) home
to the CNS (and other tissues) and cross the BBB. As yet there is no evidence of
CNS specific homing signals or adhesion molecules displayed on either lymphocyte
cell surfaces or by BMVECs. There are however data demonstrating at least parts of
the process of T lymphocyte transmigration from the blood into the brain
parenchyma. This is summarised in figure 9 (see Pryce, Male & Sarkar 1991 and
Hickey 1999 for review of leukocyte trafficking in the CNS).
1.3.3 Effects of drugs on the brain
The cohort ofHIV brains used in this study were mainly from the Edinburgh
brain bank. Edinburgh has a particularly high incidence ofHIV amongst its
population of IDU, and many of the cases included in this study were IDU. Therefore
it is important to consider the effects of drug use on the brain as well as possible




As cells pass through the terminal capillaries into venules their transit speed slows
and the shear force of blood flow decreases allowing those cells expressing
appropriate adhesion molecules to tether to the endothelium, providing it to is
expressing the correct adhesion molecules.
Step 2: Roling adhsion
Tethering of the cell to the endothelium allows the cell to role along the
endothelium in constant contact.
Step 3: Migration
At areas of endothelium expressing the correct migratory signals, or leaky areas of
the BBB in disease, cells can migrate through the barrier into the tissue. This
requires further expression of adhesion molecules and release ofmatrix
metalloproteinases which degrade the matrix protein network behind the
endothelium allowing passage of the immune cell into the tissue.
The process of transmigration of lymphocytes from the blood into brain is
controlled by the expression of adhesion molecules on the endothelial cells,
astrocytes and lymphocytes, in addition to the release of chemoattractants by cells
within the brain.
























VCAM-1 Vascular cell adhesion molecule-1 (CD106)
ICAM-1 Intercellular adhesion molecule—1 (CD54)
VLA-4 Verly late antigen -4 (CD49D)





secreted by T cell
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The literature concerning the effects of drugs and drug addiction on the BBB is
surprisingly small. In vitro models of the BBB exposed to opiates have increased
permeability to sugar and fluid, suggesting a partial disruption of the BBB. Opiates
could act directly on the BBB or act indirectly by releasing histamine or cytokines
(Banks 1999). Fiala et al (1998) showed that cocaine increases both monocyte
migration across in vitro BBB models and upregulates expression of adhesion
molecules on brain endothelial cells; most notably intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and platelet/endothelial cell
adhesion molecule-1 (PECAM-1). Gan et al (1999) have also demonstrated an up-
regulation of adhesion molecules on brain endothelial cells in conjunction with
increased leukocyte migration in response to exposure to cocaine. Morphine has been
shown to decrease the expression of IL-8 and macrophage inflammatory protein 1 (3
(MEP1 (3) while increasing expression of their receptors (CCR3 and CCR5) in
astrocytes (Mahajan et al 2002). The effects of this may be to enhance the
susceptibility of the CNS to HIV infection. HIV utilises several co-receptors in order
to enter cells including CCR5 and CCR3, expression of the normal ligand for these
receptors (IL-8 and MIP1 (3) provides competition for receptor binding sites
preventing HIV binding and entering cells, hence the effects ofmorphine may
increase HIV entry to CNS cells.
Within the brain tissue, Tomlinson et al (1999) have shown an increase in the
number of activated, CD68 positive and MHC II positive, microglial cells in both
HIV negative and HIV positive (pre-AIDS) IDU. However, they found no significant
difference between IDU and non-IDU in the number of astrocytes or T lymphocytes
present within the brain unless HIV was also present.
While the effects of drug abuse on the brain are of importance, of equal
importance is the failure, or partial failure, ofmany therapeutic drugs used in the
treatment ofHIV and other conditions to be effective within the CNS. The BBB
presents a major obstacle to the treatment ofAIDS associated CNS conditions in
terms of its function in isolating the brain from systemic therapeutic drug regimes.
This may result in the CNS becoming a reservoir for HIV and allows the virus to
evade the effective systemic treatments now being administered. While it has
generally been assumed that many of the drugs used to treat HIV have not been able
to penetrate the BBB (Aweeka et al 1999), there is some evidence to suggest that
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penetration is less of a problem than the highly efficient efflux systems, which
remove the drugs from the brain before they can induce any therapeutic effects
(Banks 1999).
1.4 HIV
HIV is the casual agent ofAIDS; it is a retrovirus with a 9.7kb RNA genome,
which was discovered in 1981 when the disease began to be evident in the United
States and Europe. The virus itself however has probably been circulating in the
human population for some time before this and evidence exists to show it was
present in humans in central Africa in the 1950's (Marx, Alcabes & Drucker 2001,
Sharp et al 2001). Two forms ofHIV are found in humans; HIV-1 and HIV-2. The
two viruses have a similar genome structure however they differ by more than 45% at
the nucleotide sequence level (Levine 1992). They also differ in their distribution and
pathogenicity, with HIV-1 found throughout the world in contrast to the less
pathogenic HIV-2 which is more localised in Western Africa. Although rare cases of
HIV-2 are found in the Europe and North America, the overwhelming majority of
infections are HIV-1. All of the HIV positive cases studied in this thesis were
infected with HIV-1 and therefore HIV-2 will not be discussed further and the
abbreviation HIV will be used for HIV-1. Figure 10a shows a schematic diagram of
HIV and its constituent components, while the layout ofHIV genes is given in figure
10b. The functions of each viral gene are given in table 2.
HIV has several modes of transmission, mostly via contact with blood. The
main routes are:
Homosexual sex (particularly receptive sex)
Heterosexual sex
Mother to child either via blood during birth, transplacental infection
or via breast milk (30% of untreated mothers pass the virus to their
child)
Needle sharing amongst IDU
Use of contaminated blood products, e.g. Factor VIII required by
haemophiliacs, prior to 1985 when blood screening for HIV started to
be introduced in western countries.
In the worldwide epidemic it is estimated that 75% ofHIV transmission is due to
heterosexual contact, with the chances of transmission and infection being increased
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Key: LTR - long terminal repeat
See table 2 for other genes
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Table 2: HIV genes coding for proteins, their function and cellular/virion
location




gag Pr55gag Polyprotein precursor for viron core Viron
proteins MA (pi7), CA(p24), NC(p9), nucleocapsid Yes
p7
pol Prl60gag~po1 Polyprotein precursor for viron Viron
enzymes: protease (plO), reverse nucleocapsid
Yes
transcriptase (p64), RNAse H (p51/66),
integrase (p32).
vif p23 Viral infectivity factor (function Cell cytoplasm
No
unresolved)
vpr pl5 Viron protein (function unresolved) Virion No
tat pl4 Transcriptional transactivator, binds tat Primarily in cell
response element and cell factors




rev pl9 Posttranscriptional transactivator, binds Primarily in cell
rev response element and cell factors




vpu pl6 Influences vims release, augments turn Integral cell
over ofCD4 antigen. membrane
protein
No
env gpl60 Precursor for envelope glycoprotein: Virion envelope
gpl20 (CD4 receptor binding), gp41 plasma protein Yes
(membrane fusion).
nef p27 Negative effector. Down regulates
CD4 receptor, increases T-cell
activation by increasing IL-2
production (Schibeci et a! 2000) and
protects cells against p53 mediated






Data taken from Fields Virology 1996
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by the presence of other sexually transmitted diseases (STD) such as syphilis,
gonorrhoea or genital herpes (Dukers et al 2002). Sores and ulcers caused by STD's
increase the likelihood ofblood contact and make access easier for HIV, while the
ongoing local infection ensures the presence of large numbers of inflammatory cells
in the area, including macrophages and CD4 T lymphocyte; the main target cell types
for HIV.
Once within the body HIV infects its target cells via binding of the viral gpl20
surface protein to CD4 molecules present on the surface ofT helper lymphocytes and
cells of the macrophage lineage. Entry requires binding ofHIV via additional co-
receptors (CXCR-4 on CD4 T lymphocytes and CCR5 for macrophage lineage cells,
both ofwhich are chemokine receptors present on the cell surface), before the virus
fuses with the cell membrane and enters its host cell. When HIV enters a cell its
RNA is reverse transcribed to DNA by a virally encoded enzyme reverse transcriptase
(RT). The double stranded DNA is then integrated into the host genome and is
therefore replicated with the cellular genome. Viral replication results in production
of new virons and eventually lysis of the cell. In addition to productive infection HIV
is capable of entering a latent state in which the viral DNA is preserved in the host
genome but no virus progeny or viral proteins are produced. The virus can remain
dormant in this state for long periods of time until some regulatory signal initiates
viral gene expression and hence viron production. Figure 11 shows a schematic
diagram of the entry ofHIV to a susceptible cell. Langerhans cells (LC) are a
specialized type of DC present in mucosal tissues which migrate from mucosal sites
to lymphoid tissue after activation. Infection of LC at mucosal sites therefore leads to
HIV being carried to the T cell areas of lymphoid tissues giving the virus easy access
to its primary target cell type; CD4 T lymphocytes. Lytic infection is quickly
established and the virus is able to enter CD4 T lymphocytes, replicate and lyse the
cell within 24 hours. In an ongoing infection HIV is able to produce 1011 new virons
per day and can destroy up to 109 CD4 T lymphocytes per day (Ho et al 1995). At the
same time as the virus is spreading by lytic infection some virons establish latency in
a pool ofCD4 T lymphocytes, probably before immune responses to HIV are
mounted by the host (Soudeyns & Pantaleo 1999). These latently infected cells are
crucial for the long term survival of the virus, as the virus remains hidden within them
from both the immune system and anti-retroviral therapies.
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Figure 11: HIV cell entry and replication
viral membrane and cellular membrane in CD4 T
lymphocytes. In macrophages endocytosis is thought to play
a role in viral entry.
Viral uncoating.
Reverse transcription of viral RNA to double stranded DNA
Double stranded DNA is transported to the nucleus where it
integrates into the host cell genome
Transcription of viral DNA to mRNA
• Translation of viral mRNA by cellular machinery to
produce viral proteins.
Viral proteins accumulate at the cell surface and viral
capsid is assembled
Virus buds out of cell and is released.
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1.4.1 Clinical features ofHIV
The majority ofHIV seroconversions are asymptomatic. In a small number of
individuals, a non-specific mononucleosis-type illness occurs 4-8 weeks after
exposure, lasting approximately 3 weeks. Symptoms include: fever, lethargy,
lymphadenopathy, sore throat, myalgia, maculopapular rash. Neurological symptoms
including headache, photophobia, and neuropathy are common, and occasional cases
of encephalitis are also seen. Following recovery, the duration of the asymptomatic
period varies between patients with a mean of 10 years.
In the absence of effective treatment the change from asymptomatic pre-
AIDS to AIDS is marked by the development of opportunistic infections and the
onset of one or more AIDS defining illness given below, and/or a decrease in the
patient's CD4 T lymphocyte count below 200 cells/ml.
AIDS defining illnesses: (in the absence of other causes of immunodeficiency)
(Alphabetical order)
Bacterial chest infection (recurrent in 12 month period)
Candidiasis
Cervical carcinoma
Cytomegalovirus disease (not in liver, spleen, or lymph nodes)
Encephalopathy (dementia) due to HIV








Toxoplasmosis of the brain
Wasting syndrome due to HIV (weight loss greater than 10% with no
other identifiable cause)
(CD4 T lymphocyte count below 200 cells/ml)
(Information taken from Kumar and Clark 1995)
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1.4.2 Treatment ofHIV
Three types of drugs have been used to combat the effects ofHIV.
1- Nucleoside analogue reverse transcriptase (RT) inhibitors (e.g.
Zidovudine). These nucleotides are incorporated into the expanding
DNA chain and stop synthesis ofDNA by terminating further
expansion of the chain.
2- Non-nucleoside RT inhibitors (e.g. Nevirapine) interfere with the viral
polymerase thereby inhibiting replication.
3- Protease inhibitors (e.g. Retonavir) prevent the viral protease from
cleaving precursor gag and gag-pol proteins into their active form.
Individually these types of drug are affective only for short periods of time
before resistant viral strains appear. HAART involves the use of at least 3 anti-
retroviral drugs in combination. It is now the standard treatment of choice in
countries able to afford the therapy. It has been shown to decrease the morbidity and
mortality in AIDS and prevent further decline of CD4 T lymphocyte counts as well as
decreasing plasma loads ofHIV (Palella et al 1998, Detels et al 1998).
1.4.3 Host response to HIV
HIV poses an unparalled challenge to the immune system. Not only is the
virus able to evade the immune system by entering a latent state, but it infects and
kills cells (CD4 T lymphocytes) which are critical in the control and regulation of
immune responses. In addition the virus has a huge replicative potential and a high
mutation rate that allows it to evolve quickly, again allowing viral evasion of both the
immune system and targeted vaccines and drugs.
1.4.3.1 Humoral immunity to HIV
HIV infected individuals produce a high concentration of antibodies against
many viral peptides throughout life. However most of the antibody responses have
weak anti-viral effects. Two primary reasons for the ineffectiveness of antibody
response to HIV are:
High mutation rate ofHIV proteins allows virus to escape antibody
responses through antigenic variation.
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Glycosylation of the viral envelope protein may mask important
antigens from recognition by antibody making neutralising antibodies
ineffective.
Not only are humoral anti-HIV responses largely ineffective but they may
inadvertently aid viral entry to certain cell types via antibody dependent enhancement
(ADE). This involves non-neutralising antibodies to HIV binding to the virus and
labelling it for phagocytosis by macrophages or follicular dendritic cells. The
antibody virus complex binds via the Fc portion of the antibody to Fc receptors on the
phagocytic cell surface (Levy 1990) and the complex is then internalised, thus
providing viral entry to the cell without the need for binding to CD4.
1.4.3.2 Cellular immunity to HIV
Anti-HIV CD8 cytotoxic T lymphocytes (CTL) provide the most potent
immune response to HIV. CTLs specific for HIV appear within weeks of infection
and are maintained until the onset ofAIDS. CTLs control HIV by two means; firstly
by recognising and killing infected cells displaying viral peptides on their cell surface
in conjunction with MHC I molecules, and secondly by secretion of (3-chemokines
e.g. MIP la, MIP 1 (3, RANTES which competitively bind to HIV co-receptors
thereby blocking viral entry to cells. The importance of CD8 CTLs is demonstrated
by the control of initial viraemia in acutely infected individuals when HIV specific
CTLs appear in the blood (Koup et al 1994).
The hallmark ofHIV infection is a progressive depletion ofCD4 T
lymphocytes. In HIV infected individuals who do not progress to AIDS (AIDS non-
progressors) there are generally strong CD 8 CTL response, which correlate with
strong CD4 T helper cell responses (Mollet et al 2000, Picker & Maino 2000).
Immunological control ofHIV is therefore dependent on both CD4 T helper cell and
CD8 CTL responses.
1.4.4 Effects of HIV on the immune system
1.4.4.1 Effects of HIV infection on B lymphocytes
Abnormalities in the control ofB lymphocytes in HIV infected individuals are
demonstrate by polyclonal activation (Birx, Redfield & Tosato 1986),
hypergammaglobulinemia (Nath et al 1987), a decreased response to T cell
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independent antigens and production of auto antibodies. B lymphocytes from HIV
patients spontaneously secrete IgG and IgM at high levels, produce increased levels of
cytokines, particularly IL-6 and IL-10, show increased expression of activation
markers (Martinez-Maza et al 1987), and decreased expression ofMHC class II
(Ginaldi et al 1998). Increases in cytokines such as IL-6 and IL-10 induce B
lymphocyte proliferation and differentiation which results in an increased number of
circulating activated B lymphocytes and subsequent decreased number of resting B
lymphocytes (Martinez-Maza et al 1987). These B lymphocyte perturbations precede
significant depletion ofCD4 T lymphocytes (Miedema et al 1988) and are not
corrected in vitro by the addition of normal T lymphocytes (Terpstra et al 1989),
suggesting that intrinsic B lymphocyte defects occur during HIV infection.
VH3 B lymphocytes (the largest Ig variable heavy chain gene family) have
been shown to be decreased during late stages ofHIV (Berberian et al 1991 and 1994,
Scamarra et al 2000). VH3 antibodies are particularly important in the clearance of
bacteria from the body and therefore loss of this group would further predispose HIV
patients to opportunistic infections. HIV gpl20 has been shown to bind to VH3 Ig at
a site other than the normal Ig antigen binding site (Goodlick et al 1995). Binding of
gpl20 induces Ig production in VH3 cells and eventually their depletion (Berberian et
al 1993). This has led to the suggestion that gpl20 acts as a superantigen for B
lymphocytes (Muller & Kohler 1997, Karray & Zouali 1997), although the method of
VH3 clonal deletion is as yet unclear. In addition to the decreased usage ofVH3
receptor family genes, there is an increase in the use ofVH1 and VH4 genes (David et
al 1995, David et al 1996, Wisnewski, Cavacini & Posner 1996). gp41 has also been
shown to induce polyclonal B lymphocyte activation. (Chirmule et al 1990).
Recently it has been suggested that HIV Tat may affect the normal B lymphocyte
differentiation process and increase proliferation of germinal centre B lymphocytes
which could predispose to AIDS associated B cell lymphoma (Lefevre et al 1999).
In addition to the superantigen effect of gpl20 and increased B cell
proliferation induced by other HIV proteins, a combination of decreased T cell control
and/or increased cytokine production, particularly IL-4, IL-6 and IL-10 can further
stimulate B lymphocyte proliferation. Uncontrolled B cell proliferation, particularly
in the presence of oncogenic viruses such as EBV (see section 1.5), may lead to
malignant transformation of cells.
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1.4.4.2 Effects of HIV infection on other immune cell types
CD4 T helper cells are most affected by HIV. There is a gradual decrease in
cell numbers throughout the course ofHIV infection due to both indirect and direct
cytopathic effects ofHIV. Direct viral cytopathic effects include cell lysis during
viral replication, altered cell membrane permeability in infected cells, induction of
apoptosis by binding ofHIV gpl20 to the cell surface (Banda et al 1992). In
addition, gpl20 released from infected cells can bind to CD4 on uninfected cells
which can lead to their recognition by CD8 CTLs or NK cells and subsequently their
destruction. Finally, CD4 T helper cells can be damaged indirectly by cytokine
toxicity caused by the induction of aberrant cytokine production by HIV. CD4 T
helper cells from HIV infected individuals show decreased proliferative responses to
recall antigens and decreased production of IL-2 (required for T cell activation)
(Creemers et al 1988, Chou et al 1994).
The total number of circulating CD4 T lymphocytes is determined by the
number of cells lost in the periphery and the production of new CD4 T lymphocytes
in the bone marrow. In addition to the effects ofHIV on circulating T lymphocytes,
HIV also disrupts the production of new T lymphocytes in the bone marrow. As with
circulating CD4 T lymphocytes, HIV has direct and indirect effects on production of
new T lymphocytes by haematopoietic progenitor cells. Direct effects result from
infection ofprogenitor cells and subsequent cell death. Indirect effects result from
immunosuppression which allows opportunistic infections such as CMV within the
bone marrow leading to further disruption ofblood cell production. Production of
other blood cells by the bone marrow are often disrupted in untreated HIV patients
resulting in anaemia, neutropenia and thrombocytopenia in addition to lymphopenia.
These cytopenias are usually reversed with effective anti-retroviral therapy.
CD8 CTLs from HIV infected individuals show decreased antigen specific
proliferation and decreased antigen specific cytotoxic activity, particularly in late
stage AIDS. Prior to the onset ofAIDS there is loss of CTL responses to HIV
antigens. The loss in CD8 CTL activity has until recently been attributed to aberrant
cytokine production and loss of CD4 T helper cell stimuli. However in recent years
there have been reports ofHIV infection of CD8 lymphocytes (Saha et al 2001,
Imlach et al 2001). Imlach et al (2001) have demonstrated that activated CD8
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lymphocytes can co-express CD4, allowing HIV infection. They demonstrated that
CD4, CD8 double positive lymphocytes accounted for between 3 and 72% of total
HIV pro-viral load in peripheral blood mononuclear cells from 5 HIV positive
individuals. The specific targeting of responding CD8 T cells may provide a
functional explanation for the previously observed impairment ofCTL function
disproportionate to their numerical decline in AIDS.
Macrophages isolated from HIV infected individuals demonstrate a decrease
in antigen presenting ability, decreased responses to chemoattractants and aberrant
cytokine production, in comparison to normal macrophages (Nath et al 1999).
Dendritic cells also demonstrate a decreased capacity to act as antigen presenting
cells, as well as a decreased ability to stimulate primary T lymphocyte proliferation
and to increase antibody production in B lymphocytes.
1.4.4.3 Effects ofHIV infection on lymphoid tissue
A sub-group of asymptomatic HIV infected patients develop persistent
generalised lymphadenopathy (PGL) before the onset of symptomatic HIV disease
and AIDS defining illnesses. Lymph nodes are enlarged early in HIV infection
reflecting the increase in number ofpolyclonal B lymphocytes being activated and
proliferating. The normal architecture of the lymph node is slowly lost as CD4 T
lymphocytes are depleted, with lymph nodes becoming fibrous. In addition to CD4 T
lymphocyte loss there is destruction of FDC due either to direct HIV infection
(Spiegel et al 1992) or to toxic aberrant cytokine production by cells activated in
response to HIV (Emilie et al 1990). Loss of FDC leads to a decrease in antigen
presentation and hence the inability of the immune system to respond to HIV, while
HIV infection ofDC has been shown to block antigen presentation (Knight &
Macatonia 1991).
1.4.4.4 Effects of HIV infection on cytokine production
HIV infection affects production ofmany cytokines in both peripheral systems
and the CNS. Of fundamental importance to the pathogenesis ofB lymphocyte
proliferation and subsequent development ofB cell lymphoma is the change in
balance of TH1 and TH2 cytokines seen in HIV infection. In addition to the
increased production of TH2 cytokine IL-6 by monocytes, described earlier, the other
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major TH2 cytokines are also increased (Klein et al 1997). Levels of IL-4 and IL-10
both begin to rise after seroconversion, peaking at the onset ofAIDS. In contrast TH1
cytokines e.g. IL-2 begin to fall soon after infection and continue to decrease until
death (Levy 1993). The effects of these changes in cytokine production are reflected
in the immune response mounted by HIV infected individuals being skewed towards
TH2 (humoral) responses (Barcellini et al 1994, Clerici & Shearer 1993), which as
discussed earlier are less effective at combating HIV than cellular responses and may
predispose to B cell lymphoma formation.
1.4.5 Effects of HIV on the brain
80% ofuntreated and 60% of treated HIV infected individuals have CNS
pathology at autopsy, with 20-30% of terminally ill AIDS patients having AIDS
dementia (Jellinger et al 2000). The CNS ofHIV infected individuals is particularly
vulnerable to opportunistic infections (including cytomegalovirus and toxoplasma),
progressive mulitfocal leucoencephalopathy and high grade B cell lymphomas are
also common (Bell 1998a). In addition to opportunistic infections, pathological
evidence ofHIV encephalitis (HIVE) is found in 40% ofAIDS patients (Bell et al
1998b). A number of autopsy studies have demonstrated damage and induction of
apoptosis in neurons ofHIV infected individuals, in addition to axonal damage (Hill
et al 1993, An et al 1997, Gray et al 2000).
Although in pre-AIDS no evidence ofHIVE, opportunistic infections or
lymphoma has been found at autopsy, there is often a low grade T lymphocyte
infiltration, particularly in the meninges and around blood vessels. This T
lymphocyte infiltration is thought to be a response to early invasion of the CNS by
HIV, although the exact timing of viral entry to the CNS is as yet unknown (Bell et al
1998a).
1.4.5.1 HIV entry to the CNS
The most plausible method ofHIV entry to the CNS is via infected
macrophages/monocytes migrating from the peripheral blood across the BBB. HIV
infected CD4 T lymphocytes migrating into the CNS may also potentially introduce
HIV to the brain. However infected macrophages/monocytes are a more likely source
39
ofpersistent viral infection as strains ofHIV capable of infecting monocytes (M-
tropic strains) are also able to infect the resident brain microglial population, unlike
the T-tropic strains found in CD4 T cells (Gorry et al 2001). Monocytes infected with
HIV have been shown to increase expression of adhesion molecules, which increases
monocyte aggregation and in addition increases binding ofmonocytes to endothelial
cells. There is also increased expression ofmatrix metalloproteinase 9 (MMP9), an
enzyme required for matrix degradation during transendothelial migration (Nottet et
al 1996). The increased adhesive properties ofHIV infected monocytes to
endothelium can be replicated by treatment ofmonocytes with HIV tat protein,
suggesting this is responsible for the increased potential to bind and transmigrate
(Laffenie et al 1996a, Lafrenie et al 1996b). HIV infection within the brain induces
increasing transendothelial migration ofmonocytes into the brain and secretion of
pro-inflammatory cytokines which are neurotoxic (Nottet et al 1999). Increased
transendothelial migration ofmonocytes is mediated by an increase in expression of
adhesion molecules in astrocytes and endothelial cells of the BBB in response to
either HIV infection of these cells or cytokines released by HIV infected microglia
(Woodman et al 1999). In addition HIV infected microglia release a monocyte
chemoattractant monocyte chemoattractant protein-1 (MCP-1) (Mengozzi et al 1999).
While it is entirely plausible that monocyte derived cells carry HIV into the
brain and initiate infection of the CNS, there has to be an initial stimulus to attract
monocytes into the brain in the first place. It is therefore unclear whether HIV gains
access via another route to the brain and then the initiation ofHIV infection draws
monocytes/macrophages into the brain. Alternatively some non-HIV stimulus may
attract HIV infected monocytes/macrophages into the brain, thus initiating HIV
infection of the CNS.
An alternative method of cell free virus entry to the CNS has also been
proposed (Banks et al 2001). Gpl20, an HIV surface glycoprotein, can act as a lectin
at the BBB inducing virus binding to the endothelium and adsorptive endocytosis into
endothelial cells. HIV is not destroyed in the lysosomes of the endothelial cells and
therefore could escape and enter the cytoplasm and hence eventually spread to other
brain cell types. There have been several reports ofHIV infection of brain endothelial
cells (Moses 1997, Stins et al 2001). However there remains doubt over the
reproducibility of these studies. Nottet et al (1996) failed to infect BMVECs in vitro
with either cell free virus or infected monocytes. This method could provide entry for
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cell free virus to the brain and also enhance entry of virally infected circulating
immune cells expressing gpl20 on their surface.
1.4.5.2 HIV encephalitis (HIVE)
The hallmark ofHIVE is productive viral replication in brain macrophages
and microglia, with the formation ofmultinucleated giant cells (Persidsky et al 2000),
which are found predominantly in the central white matter and deep grey matter of the
brain (Bell 1998a). These cells express both CD4 and the (3-chemokine receptor
CCR5, making them permissive to macrophage tropic strains ofHIV, although
microglia normally only show low level expression ofCD4 (Choe et al 1996, He et al
1997).
Several studies have shown the presence ofHIV in astrocytes in brain tissue
sections using in situ hybridisation with probes specific for HIV nefmRNA (Ranki et
al 1995). However there is a consistent lack of evidence of structural HIV protein
expression indicative ofproductive HIV infection in these cells. A restricted form of
HIV infection of astrocytes has also been described in vitro (Brack-Werner et al
1992) despite the absence of surface CD4 expression. In HIV replication, structural
proteins are produced from incompletely spliced and unspliced mRNAs which retain
a specific recognition element for the HIV Rev regulatory factor (Rev response
element (RRE)). Rev binds to RRE mediating nuclear export of these mRNAs and
promoting their translation. In the absence ofRev only a very low level production of
structural viral proteins occurs. Ludwig et al (1999) have shown that in astrocytes
infected with HIV there is a diminished capacity for Rev to transactivate synthesis of
HIV structural proteins and that an accumulation ofRev in the cytoplasm of these
cells occurs. The significance of this restricted form of viral infection is as yet
unclear.
Other neuropathological features seen in addition to giant cells in HIVE
include microglial nodules, macrophage infiltrations, white matter atrophy, reactive
glyosis, myelin pallor and slight neuronal loss in the basal ganglia (Petito et al 1986).
Interestingly HIVE is more common in drug users than homosexual AIDS patients,
with 59% ofAIDS drug users developing HIVE compared to 15% ofAIDS
homosexuals in one study (Bell et al 1996).
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The presence ofHIVE does not correlate with the clinical signs and symptoms
ofHIV dementia. Patients may have evidence ofHIVE at autopsy without having
shown clinical signs ofHIV dementia during life, and giant cells associated with
HIVE are present in only half of patients with clinical signs of dementia (Wiley &
Achim 1994).
The introduction of effective therapy for HIV has changed incidences and the
spectrum of diseases HIV positive individuals develop. With respect to the CNS,
HAART has been shown to have beneficial therapeutic effects on cognitive
processing in HIV infected patients and is superior to Zidovudine monotherapy or
dual anti-retroviral therapy (Husstedt et al 2002, Chang et al 1999). The introduction
ofHAART has also decreased the incidence ofAIDS dementia complex (ADC),
however a recent study in Australia (Dore et al 1999) has shown that the decrease in
incidence ofADC does not parallel the larger decrease seen in other AIDS defining
illnesses since the introduction ofHAART. As regards the incidence of non-
Hodgkin's lymphoma (NHL) since the introduction ofHAART, several studies have
indicated decreases in the incidence ofNHL (Kirk et al 2001, Chow et al 2001,
Rabkin 2001, Gates & Kaplan 2002).
1.4.5.3 HIV induced Blood brain barrier (BBB) damage
BBB disruption has been demonstrated in both HIVE in humans (Dallasta et
al 1999) and in animal model systems utilising simian immunodeficiency virus
encephalitis (SIVE) in macaque monkeys (Luabeya et al 2000). Disruption of the
BBB was demonstrated by aberrant immuno reactivity of both occludin and ZO-1
tight junction proteins. Additional observations in regions of tight junction
disruption included the perivascular extravasation of the plasma protein fibrinogen,
and a decrease in the metabolic BBB marker glucose transporter isoform-1 (GLUT-
1).
In both HIVE and SIVE, BBB disruption was associated with accumulations
ofperivascular macrophages (Dallasta et al 1999, Luabeya et al 2000). It cannot
however be ascertained whether these changes in the BBB allow the accumulation of
macrophages to occur or if the BBB changes observed occur as a result of
accumulating macrophages. HIV infection ofmicroglial cells has been shown to
modulate the migration ofmonocyte/macrophages into the brain. In addition HIV
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infected monocytes/macrophages have been shown to down regulate the expression of
tight junction proteins at the BBB and also disrupt transport systems in BMVEC
(Persidsky et al 2000).
1.4.5.4 Neurotoxicity in HIV infection
Neurodegenerative changes in AIDS include dendritic abnormalities, neuronal
loss and increased vascular permeability (Petito et al 1999). Neuronal loss from the
cerebral cortex in AIDS is not restricted to cases ofHIVE and it does not correlate
well with HIV dementia. The best correlate ofHIV dementia is the presence of
activated macrophages in brain tissue (Tyor et al 1995). The observed
neurodegenerative changes, particularly neuronal loss, are thought to be an indirect
result ofHIV infection of the brain as neuronal cells are not permissive for HIV
infection. The infected cells of the brain, macrophages and microglia, are thought to
cause indirect damage to neuronal cells via the release of neurotoxic cytokines and
chemicals such as tumour necrosis factor (TNF) a, stromal cell derived factor (SDF)-
1 and quinolinic acid (Giulian et al 1990, Esser et al 1991, Smith et al 2001). TNFa
is produced by activated microglial cells and reactive astrocytes and has been
proposed as a neurotoxin that may be responsible for the neuronal apoptosis seen in
AIDS brains (Petito et al 1999). TNFa mediates signalling events such as NF-kB
activation, calcium mobilisation and release of oxidative oxygen species which have
been associated with neurotoxicity. In addition TNFa upregulates expression of IL-6
(Aliosi et al 1992). The (3 chemokine SDF-1 has been shown to be produced by
astrocytes in culture (Bajetto et al 1999). SDF-1 can bind to CXCR4 receptors
present on neurones which in turn can lead to neuronal apoptosis. Activated
macrophages produce quinolinic acid, a neurotoxin, in several inflammatory brain
diseases including AIDS. HIV proteins Nef, Tat and gp41 have been shown in vitro
to increase production of quinolinic acid by macrophages, suggesting that some of the
neurotoxic effects ofNef, Tat and gp41 may be mediated by this route (Smith et al
2001).
In addition to toxic cytokine release induced by HIV infection many of the
proteins produced by HIV are also neurotoxic. HIV gpl20 can bind to CXCR4
receptors present on neurones again inducing neuronal apoptosis (Kaiser, Offerman &
Lipton 1990, Petito et al 1999). HIV Vpr protein has also been shown in vitro to be
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neurotoxic, via induction of apoptosis in neuronal cells in a manner similar to gpl20
(Patel et al 2002). HIV Tat has been shown to bind to the cell membrane of rat
glioma cells and murine neuroblastoma cells inducing a large depolarisation of the
cell membrane, which modifies cell permeability (Sabatier et al 1991). Tat has also
been shown to induce TNFa primarily in macrophages but also in astrocytic cells
(Chen et al 1997), inducing effects similar to those described above.
1.5 Epstein Barr Virus (EBV)
EBV is an oncogenic DNA double stranded gamma herpes virus with a 172kb
linear genome. It was discovered in 1964 in B lymphocytes cultured from an endemic
African Burkitt's lymphoma (Epstein 1964). The virus latently infects circulating B
lymphocytes, with viral DNA being maintained as an episome, replicated together
with host cell DNA and stably inherited in daughter cells. Viral infection ofB
lymphocytes is mediated by the binding of the viral envelope glycoprotein gp340 to
the cellular CD21 complement receptor (CR2) (Nemerow et al 1987).
EBV persistently infects over 90% of the worlds adult population (reviewed in
Crawford 2001). Infection is normally sub-clinical, however under certain
circumstances EBV can cause disease; particularly, although not exclusively, in the
immunosuppressed where there are strong aetiological links between EBV and
several tumour types (Beral et al 1991, Neri et al 1991, Hamilton-Dutoit et al 1993).
Spread ofEBV between individuals occurs through close oral contact (Yao,
Rickinson & Epstein 1985), and primary infection usually occurs as a sub-clinical
seroconversion in childhood (See Crawford 2001 for review ofEBV biology).
Certain individuals, particularly in affluent areas ofwestern countries do not
seroconvert until late in adolescence. In these individuals approximately 30-50%
suffer from a benign lymphoproliferative disease called infectious mononucleosis
(IM) (Steven 1996). IM presents with fever, pharyngitis, generalised
lymphadenopathy, fatigue, and in some cases splenomegaly, and hepatomegaly. The
disease is characterised by lymphocytosis consisting of atypical lymphocytes which
are largely antigen driven oligoclonal CD8 T cells specific for EBV latent and lytic
antigens (Callan et al 1996). The most probable cause of the symptoms is
lymphokines secreted by these T lymphocytes. During IM up to 2000/104 circulating
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B lymphocytes are infected with EBV (Laroche et al 1995) in comparison to between
5 and 500 per 107 B lymphocytes in a healthy carrier (Miyashita et al 1995).
Following silent seroconversion or IM a persistent life long infection is
established which includes virus production in the throat and release of virus into
saliva. Persistent infection is controlled primarily by CD8 cytotoxic T lymphocytes,
which are specific for latent and lytic EBV proteins.
In vitro EBV is capable of immortalising B lymphocytes. In vivo EBV is
thought to be important in tumourogenesis and shows a variable association with a
wide range of tumours including Burkitt's lymphoma, Hodgkin's lymphoma, non-
Hodgkin's lymphoma, nasopharyngeal carcinoma and gastric carcinoma. Three types
of viral latency pattern have been described expressing combinations of the latent
viral genes.
1.5.1 Latent EBV proteins
Table 3 gives the viral genes expressed in each type of latency and the main
tumour types with which each latency pattern is associated.
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Key: EBER (Epstein-Barr viral small RNA), EBNA (Epstein-Barr nuclear antigen),
LMP (Latent membrane protein), LP (leader protein)
+ Expression of viral gene
No expression of viral gene
45
EBERs 1 and 2 are untranslated RNAs and are the most abundantly expressed
EBV transcripts in latently infected cells. Their function is unknown although
Swaminathan, Tomkinson and Keiff (1991) demonstrated that deletion of viral
EBERs genes has no effect on growth or immortalisation of B lymphocytes.
However studies by Komano et al (1999) have suggested that EBERs may contribute
to apoptosis resistance in malignant Burkitt's lymphoma cells.
EBNA-1 is the only EBV encoded protein found in all EBV associated
malignancies (Klein 1994). Despite the fact that EBNA-1 is antigenic and induces
antibody responses (Dillner et al 1984), CTL responses are usually absent (Rickinson
& Moss 1997). This is due to inhibition of the ubiquitin/proteasome dependant
degradation pathway by the glycine-alanine repeat sequence ofEBNA-1. Ubiquitin
labels proteins within a cell for degradation by proteasomes (cylindrical shaped
complex of proteases which degrades protein), and this process is essential for antigen
presentation to occur as only small peptide fragments of the original protein can be
displayed on MHC. Certain protein N-terminal repeats, including glycine-alanine of
EBNA-1, prevent degradation of the protein by proteasomes, therefore preventing
fragments of the protein being displayed on class I MHC (Lavitskaya et al 1995).
EBNA-1 is essential for maintenance of the viral episome through binding to
the EBV origin of replication, and is also responsible for the portioning of progeny
EBV genomes to daughter cells during mitosis, through association with the host cell
chromosome (Davenport & Pagano 1999). EBNA-1 has been shown to increase
activity of recombinase activating genes (RAG) involved in Ig gene V(D)J re¬
arrangements (Srinivas & Sixby 1995). Aberrant V(D)J recombination in EBV
infected cells could potentially facilitate translocation of the c-myc oncogene to Ig
loci, inducing disregulation ofmyc (Klein 1986).
EBNA-2 expression is essential for B lymphocyte immortalisation by EBV.
EBNA-2 is expressed early after infection of a B lymphocyte with EBV and
upregulates LMP-1 and 2, transactivates a number of cellular genes including CD21,
CD23 (Cordier et al 1990, Wang et al 1991) and the proto-oncogene c-myc (Kaiser et
al 1999), as well as inducing cytokines including TNFa (a growth promoting
cytokine) (Spender et al 2001). EBNA-2 can interact with components of the basal
transcription machinery but has no intrinsic DNA binding activity. EBNA-2 also
suppresses IgM expression in B lymphocytes (Jochner et al 1996) and inhibits B
lymphocyte differentiation. In coordination with EBNA leader protein (LP) EBNA-2
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can induce cell cycle progression form Go to Gi (Sinclair et al 1994) inducing cell
proliferation. The combined expression ofEBNA-2 and EBNA-LP within B
lymphocytes induces expression of a Gi cyclin, cyclin D2. EBNA-2 activates the
cyclin D2 promoter resulting in indirect activation of cyclin D2 (Spender et al 2001).
Gi cyclins bind to cyclin dependant kinases activating them, which induces DNA
synthesis and moves the cell into S-phase of the cell cycle. Therefore EBNA-2 is vital
in the process of immortalisation ofB lymphocytes by EBV.
EBNA-3a and c are essential for B cell immortalisation by EBV. EBNA-3c
has similar properties to cellular pRB, driving the cell cycle through Gi under
conditions which would normally signal growth arrest (Parker et al 1996). EBNA-3b
upregulates expression of CD40 on B lymphocytes, which is required for B cell
activation.
LMP-1 is expressed on the cell surface of infected B lymphocytes, with both
protein termini residing in the cytoplasm (Liebowits, Wang & Kieff 1986). LMP-1 is
an EBV oncogene and is essential for immortalisation ofB lymphocytes (Kaye, Izumi
& Kieff 1993). Expression of LMP-1 leads to upregulation ofB lymphocyte
activation markers (including CD23), adhesion molecules, and induction ofDNA
synthesis (Peng & Lundgren 1992). It has recently been shown, in vitro, to be
secreted by infected cells and have a direct immunosuppressive effect through
suppression of T lymphocyte activation (Dukers et al 2000). LMP-1 aggregates on
the cell surface and mimics constitutively active CD40 cellular receptor inducing cell
activation. It has also been shown to upregulate NF-kB responsive genes (Mosialos et
al 1995) and anti apoptotic genes including Bcl-2 (Rowe et al 1994). LMP-1 has
diffuse and profound effects on B lymphocyte growth, inducing activation and
differentiation through several different pathways (Izumi et al 1999), and also
upregulation of expression ofMMP-9 which aids B lymphocyte entry to
tissues(Takeshita et al 1999).
In addition to the range of genes expressed during latency, given in table 3
(page 45), there is a family of transcripts derived from the Bam HI-A region of the
EBV genome that may also be related to latency. These include the transcripts from
the open reading frame BARF0 (Bam HI-A rightward open reading frame 0), the
function ofwhich is unknown. Deletion of the region ofEBV genome containing this
open reading frame has no effect on EBV immortalisation ofB lymphocytes in vitro.
However the consistent expression of these transcripts in EBV associated epithelial
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and B cell tumours implies that they may be making a contribution in vivo (Chen et al
1999).
1.5.2 EBV persistence
Like all other human herpes viruses, EBV establishes persistent infection in
the immunocompetent host. Seropositive healthy individuals harbour low levels of
EBV infected B lymphocytes in the circulation, between 5 and 500 per 107 B
lymphocytes are infected (Miyashita et al 1995). The majority of evidence favours B
lymphocytes as the site ofpersistent latent infection, and Thorley-Lawson & Babcock
have suggested that EBV utilises normal B lymphocyte biology to enter the long lived
B lymphocyte memory compartment, where it can reside long term in a latent state
undetected by the immune system (Thorley-Lawson & Babcock 1999). They have
suggested that the different latent states it is able to utilise may allow EBV infected B
lymphocytes to emulate activities that occur in normal B lymphocytes to allow the
virus to enter the memory B lymphocyte compartment (Thorley-Lawson & Babcock
1999).
B lymphocytes activated by antigen enter lymph nodes and proliferate to form
germinal centres, each with a clone of antigen specific B lymphocyte (centroblasts).
Centroblasts eventually mature into either short lived Ig secreting plasma cells or re¬
circulating long lived memory cells, however this maturation process requires 2
signals. The first is given by antigen binding to the Ig receptor and the second by
CD40 on the B lymphocyte surface ligating with its ligand (CD40L) on CD4 T helper
cells. Thorley-Lawson & Babcock have suggested that when EBV activated B
lymphocytes reach germinal centres a switch from full latent gene expression (latency
III), to latency II occurs. In latency II EBNA-1 and LMP 1 and 2a are expressed but
not EBNA-2 which inhibits B lymphocyte differentiation (Rowe et al 1992). The
infected cell can then differentiate into a centroblast, with the virus able to provide the
two signals required for further maturation in the form of LMP-1 and LMP-2a
expression. These viral proteins can mimic the functions of CD40 and Ig receptor
respectively allowing infected cells to mature into plasma cells or memory cells. The
process allows infected cells to survive long term in the memory B lymphocyte
population where they express a restricted form of latent gene expression. As yet the
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exact viral phenotype of these cells is unclear, but LMP2a expression is likely to
inhibit further activation and lytic cycle entry.
Occasionally these infected memory B lymphocytes will be activated by
antigen and therefore return to the lymph node to form new germinal centres and
hence produce more infected short lived plasma cells and infected long lived memory
cells, replenishing the circulating population of infected memory cells. The
production of antibody in Ig producing cells (plasma cells) has been linked to viral
entry into the lytic cycle (Crawford & Ando 1986). Infected plasma cells which home
to epithelial sites or tonsil could therefore produce virons that may infect other B
lymphocytes at the site and may also allow viral transmission from human to human
via the saliva.
1.5.3 Host response to EBV infection
Despite the transforming potential ofEBV the virus persists and is maintained
as an asymptomatic infection in immunocompetent individuals. The humoral and
cellular immune responses to EBV arise during primary infection, and are maintained
throughout life. CD8 cytotoxic T lymphocytes are ofparticular importance in the
control ofEBV infection. Following primary infection long term memory T
lymphocytes against EBV latent and lytic antigens provide immune surveillance to
control persistent infection (Murray et al 1992). Cytotoxic T lymphocyte responses
in healthy seropositive individuals can be detected against all EBNA proteins except
EBNA-1 (Murray et al 1988 & 1992, Bogedain et al 1995, Steven et al 1997).
Cytotoxic T lymphocytes also play a role in protection against lytic infection, with
cytotoxic T lymphocyte directed against lytic immediate early proteins (BZLF-1,
BRLF-1) and early lytic proteins (BMLF-1, BMRF-1, BALF-2) commonly found
(Steven et al 1997). CD4 cytotoxic T lymphocyte responses may also play a role in
control of both latent and lytic infection, with CD4 cytotoxic T lymphocyte responses
detected against gp340 and EBNA-1 and 2 (Khana et al 1997, Pothen, Rickert &
Pearson 1991, Paludan 2002).
EBV also induces a humoral immune response. During the acute phase of IM
the humoral response is directed primarily towards the viral antigens of the lytic
cycle, while antibody responses to EBNA-1 and EBNA-2 are delayed until the
recovery period. In healthy seropositive individuals serum antibodies against lytic
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antigens can be detected in addition to anti-EBNA-1 antibodies, but anti-EBNA-2, 3a,
3b, 3c, LP antibodies are not normally detected (Khanna, Burrows & Moss 1995).
1.5.4 EBV associated malignancies
EBV is associated with various proliferative and malignant diseases which are listed
in table 4.
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Hodgkin's lymphoma (rare) 100%
EBNA-l,
LMP-l,2a,2b
T cell lymphoma (rare) 40%
EBNA-l,
LMP-l,2a,2b
Data taken from Crawford 2001, * Beral 1991 and Hamilton-Dutoit 1993
50
Of the diseases described above this thesis will focus only on those commonly
associated with AIDS (BL and BLPD).
1.5.4.1 Non-HIV associated Burkitt's lymphoma
Burkitt's lymphoma (BL) is often multifocal and almost always arises in
extranodal sites, most commonly the jaw, ovary, mammary gland, liver, intestine and
kidneys. Tumours occur in high incidence in equatorial Africa and low incidence
throughout the rest of the world. Histologically BL cells resemble germinal centre B
lymphocytes with a non-cleaved appearance. In endemic African BL 96% of tumours
are EBV positive. In contrast only around 20% of sporadic non-African BL are EBV
positive (Sixby 2000). The EBV genome is present in BL as multiple nuclear
episomes, and has been shown to be clonal, suggesting infection occurred before
clonal proliferation and tumourigenesis (Raab-Traub & Flinn 1986). Only EBNA-1
protein, EBERs and BARFO RNA are expressed in BL (latency I), which has raised
doubts over the role ofEBV in tumour formation, as EBNA-1 is not recognised as a
potent oncogenic protein, at least in vitro and neither EBERs or BARFO viral
transcripts are required for transformation ofB lymphocytes (Swaminathan,
Tomkinson & Keiff 1991, Robertson et al 1994). On the other hand, however,
Wilson, Bell & Levine (1996) have shown that EBNA-1 transgenic mice develop
lymphoid tumours, suggesting EBNA-1 may have oncogenic properties in vivo.
Furthermore, EBERs have been shown in vitro to induce Bcl-2 (Komano et al 1999)
an anti-apoptotic gene, and BARFO is consistently expressed in several EBV
associated epithelial and B lymphocyte tumours (Chen et al 1999). These findings
suggest that EBV may play a role in tumourigenesis in BL.
All BLs, EBV positive or negative, have 1 of 3 chromosomal translocations
(8:14, 8:2, 8:22) which brings the c-myc oncogene on chromosome 8 under the
influence of the constitutively expressed Ig heavy chain gene promoters on
chromosome 14 or alternatively one of the light Ig chain promoters on chromosome 2
or 22 (Zech et al 1976). The expression of c-myc causes the cell to enter the cell
cycle and begin proliferation, therefore bringing c-myc under the control of Ig
promoters induces cell proliferation, aiding tumour growth. In addition Carbone et al
(1997) has shown that 11 of 11 BL tumours expressed BCL-6.
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The pathogenesis ofBL differs depending on the type ofBL, but regardless of
type it is likely to be a multistep process. (The pathogenesis ofBL is reviewed in
Crawford 2001) In EBV associated African BL the process is thought to include the
following steps:
Recurrent bouts ofmalaria, which induces immunosuppression (Whittle et al
1984) leading to increased lytic EBV replication and hence increase infection of
naive B lymphocytes
Malarial antigens induce polyclonal B lymphocyte activation, causing blast
transformation ofEBV infected memory B lymphocytes (Wahlgren et al 1986)
Expression ofEBNA-1 and EBERs in EBV infected cells (Rowe et al 1986,
Minarovits et al 1992)
Reciprocal chromosomal translocation between Ig genes and c-myc, leading to
constitutive expression of c-myc and increased cell proliferation (Manolov et al
1986)
Additional genetic abnormalities e.g. p53 mutation in tumour cells (Farrell et al
1991)
1.5.4.2 Non-HIV B lymphoproliferative disease
Patients receiving allograft transplants require immunosuppression to prevent
graft rejection by the host's body immune system. This predisposes a small number
of patients to EBV associated BLPD (1-10%, Penn 1991). During
immunosuppressive therapy there is an increase in EBV viral load. This is either due
to an increase in proliferation of virus carrying latently infected cells or increased
lytic replication with infection of bystander B lymphocytes. In either case this results
from iatrogenic T cell suppression which induces a decrease in EBV specific CTL
activity (Haque et al 1997). Patients who are EBV seronegative at transplant and
become infected thereafter are at increased risk ofBLPD. They can acquire EBV
from the donor organ (Haque et al 1996) or from normal transmission routes via
saliva.
BLPD presents clinically in 2 ways. In around 50% of cases there is an IM
like illness in the first year after transplant, particularly in younger patients and in
particular those seronegative at transplant (Epstein & Crawford 1998). The second
type of presentation generally occurs in older patients, with localised masses
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developing often in the gut, CNS or transplanted organ. These are usually large cell
monoclonal lymphomas with a heavy infiltrate of CD4 T cells present (Perera et al
1998). Although tumours are monoclonal, polyclonal B cell proliferation probably
occurs early in the disease leading to outgrowth of a monoclonal tumour. There is
usually expression of all EBV latency genes (latency III)(Young et al 1989)
suggesting that EBV plays a key role in the transformation process.
Remission can be induced by decreasing immunosuppressive therapy,
however this can lead to organ rejection and re-introducing therapy again allows
relapses to occur which become progressively more resistant to treatment. The death
rate from BLPD is therefore high with 40-60% of organ transplant patients with
BLPD dying and 90% ofbone marrow transplant patients (Benkerrou et al 1998).
1.5.4.3 EBV associated malignancy in HIV infection
It is estimated that 20% of all HIV infected patients will develop B cell
lymphoma at some point in their life (Rodriguez-Alfagame 1998). Furthermore
lymphoma is the second most common malignancy in HIV infection (after Kaposi's
sarcoma) (Goedert et al 1998), with infected individuals 60 times more likely to
develop NHL than the general population (Tulpule & Levine 1999). HIV lymphomas
differ from those seen in non-HIV infected individuals in terms of both the aetiology
and the pathogenesis. The most characteristic feature ofAIDS lymphomas is that 70-
90% are located at extra nodal sites (Tulpule & Levine 1999), with CNS being the
most common (26%), followed by bone marrow (22%), gastro-intestinal tract (17-
25%) and liver (12%). Histologically 60% of lymphomas are peripheral large cell,
20% peripheral Burkitt's (small non-cleaved), and 20% PCNSL (Beral et al 1991,
review of 2500 cases). In addition to the Burkitt's and large cell peripheral
lymphomas, there are several rarer lymphomas which can occur in the setting ofHIV.
These are listed in table 4 above and will not be discussed further.
1.5.4.4 Primary central nervous system lymphoma (PCNSL) in
AIDS
Presenting symptoms ofPCNSL can include: seizures, focal neurological
dysfunction, headache, and cranial nerve palsies, all attributable to a mass lesion in
the brain. However patients can present with merely subtle changes in mental status
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as the only clinical manifestation of disease. Patients who develop PCNSL generally
have severe underlying HIV infection and median CD4 counts at diagnosis is only
34/mm3 (Tulpine & Levine 1999).
Diagnosis is usually by radiological assessment, which shows 1 or 2 2-4 cm
lesions in the parenchyma. Although similar results can be seen with toxoplasma in
the CNS, toxoplasma tends to produce multiple smaller lesions (Scaravilli & Cook
1997). Diagnosis is confirmed by brain biopsy or failure of toxoplasma treatment.
Recently less invasive methods of diagnosis have been introduced. Assessment of
EBV viral load levels in lumbar puncture CSF samples by PCR (polymerase chain
reaction) has been shown to be useful diagnostic tool. Cingolani et al (1998) showed
an 80% success rate in predicting PCNSL in HIV patients with focal brain lesions,
with presence ofEBV in CSF being very specific for PCNSL (sample size 122, of
which 42 were diagnosed with PCNSL).
The prognosis for PCNSL is extremely poor with median survival with no
treatment only 1.5 months. Radiation therapy can induce complete remission in up to
50%, however median survival is still 6.3 months, with death due to opportunistic
infection accompanied by multiple neurological disorders. The introduction of
HAART has further increased median survival times to 16 months (Hoffman et al
2001).
Morphologically these tumours are homogenous diffuse large cell lymphomas
ofB lymphocyte origin occurring in the brain parenchyma in a perivascular cuffing
pattern, and may occur as a single or small number ofparenchymal lesions. In
contrast metastatic peripheral lymphomas involving the brain are typically localised
to the meninges. The classification of diffuse large cell lymphoma can be subdivided
into 2 groups. Depending on the presence of immunoblastic plasmacytoid features
PCNSL may be classified as large non-cleaved cell lymphoma or immunoblastic
plasmocytoid lymphoma. In HIV both types ofPCNSL are found, however in non-
HIV PCNSL only large cell non-cleaved lymphoma is seen.
Molecular features of these tumours are homogenous, with almost all being
monoclonal as defined by Ig gene re-arrangements, in common with the tumours
found in non-HIV infected individuals (Meeker et al 1991, Bashir et al 1993). There
is a universal association with EBV (MacMahon et al 1992, Auperin et al 1994) in
HIV associated PCNSL, in contrast to only 15% association in non-HIV PCNSL in
immunocompetent individuals (203 cases studied) (Jellinger & Palus 1995).
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Differences are also found between HIV and non-HIV PCNSL in terms of EBV gene
expression in those tumours with virus present. Auperin et al (1994) showed that 10
of 11 EBV positive HIV PCNSLs expressed both LMP-1 and EBNA-2, while just 1
of 11 expressed only LMP-1 and not EBNA-2. In contrast 4 of 5 EBV PCR positive
non-HIV PCNSLs examined showed expression of LMP-1, with no expression of
EBNA-2 in any samples. Neither HIV nor non-HIV PCNSLs demonstrated any
expression of lytic antigens (Auperin et al 1994). However Bashir et al (1993)
reported expression of lytic antigen VCA (viral capsid antigen) in 1-5% of cells in 5
out of 5 HIV PCNSLs. This suggests that although most tumour cells present are
latently infected, demonstrating latency III phenotype, perhaps a very few cells within
the tumour switch to lytic replication at some stage in lymphomagenesis.
With regard to expression of oncogenes in PCNSL, there is no evidence of c-
myc or Bcl-6 translocations (Meeker et al 1991, Larocca et al 1998). However there
is data which suggests that a large percentage of tumour cells have mutation in the 5'
non-coding region of the BCL-6 gene (Gaidano et al 1997). Bcl-6 gene codes for a
transcription factor which is involved in regulation of both B lymphocyte activation
and differentiation. In a study by Larocca et al (1998) 9 of 9 HIV associated large
cell non-cleaved PCNSLs showed evidence ofmutation in the 5' non-coding region
of the Bcl-6 gene, furthermore 13 of 13 non-HIV large cell non-cleaved PCNSLs also
demonstrated mutations in this region. Molecular analysis of the mutations showed
that most consisted of between 2 and 4 transition or transversion mutations. No
mutations were detected in any of the 7 HIV associated immunoblastic plasmacytoid
PCNSLs tested. Inhibition of BCL-6 is required for a plasmacytoid cell phenotype
(Shaffer et al 2000), which may explain why Bcl-6 expression is only seen in non-
cleaved large cell PCNSL and not immunoblastic plasmacytoid PCNSL. Lurthermore
Bcl-6 is only expressed in germinal centre or post germinal centre B lymphocytes,
suggesting that, as all non-cleaved large cell PCNSL appear to express BCL-6, these
tumours are derived from a post germinal centre cell.
In addition to Bcl-6, the study by Larocca also examined expression ofEBV
LMP-1 and cellular Bcl-2 in the same cases. Bcl-2 is believed to prolong cell survival
by blocking apoptosis rather than increase proliferation (Camilleri-Broet 2000). Bcl-2
expression was found only in tumours demonstrating expression of LMP-1, and
furthermore the dual expression ofBcl-2 and LMP-1 was only detected in HIV
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immunoblastic plasmacytoid PCNSL. LMP-1 has been shown in vitro to
transactivate Bcl-2 (Henderson et al 1991, Finke et al 1992).
This data demonstrates that differences exist between the two histological
types ofPCNSL in terms of gene expression and pathogenesis.
1.5.4.5 Peripheral lymphomas in AIDS
The 2 main types of systemic lymphoma seen in HIV (Burkitt's and NHL)
differ both in their morphology and pathogenesis. The pathogenesis ofAIDS BL is
thought to be similar to that of endemic African BL (see 1.5.4) with HIV infection
replacing malaria in the process. HIV infection provides the immunosupression
allowing increased lytic replication ofEBV, and also induces polyclonal B
lymphocyte activation which provides the proliferative stimuli for EBV infected cells.
Up to 50% ofAIDS BL are associated with EBV (Beral et al 1991). HIV associate
BL, in comparison to HIV associated PCNSL, generally occurs much earlier in HIV
infection when median CD4 counts are still greater than lOOcells/cm .
In contrast to BL HIV associated large cell lymphomas occur much later in
HIV disease and are associated with a far poorer prognosis. Molecularly, large cell
lymphomas are more heterogeneous than BL. As with BL there is variable
association with EBV with typical studies suggesting between 31% and 66% are EBV
positive (Meeker et al 1991, Shibata et al 1993, Beral et al 1991). Unlike BL c-myc
translocations and BCL-6 translocations occur in only a subset of large cell
lymphomas. In contrast to both HIV associated BL and PCNSL, approximately 40%
of large cell lymphomas are polyclonal as defined by Ig gene re-arrangements (Beral
et al 1991). In a study containing 25 HIV associated large cell lymphomas Beral et al
showed expression of LMP-1 in 12 of 25 lymphomas ofwhich 5 also expressed
EBNA-2. This suggests a latency III phenotype for 5 of 25 tumours, intermediate
latency II phenotype for 7 of 25 and latency I for 13 of 25 (Beral et al 1991).
Development ofNHL during AIDS is thought to be attributed to a loss in EBV
specific cellular immunity. Recently Van Baarle et al (2001) have shown that during
infection with HIV there is no loss ofEBV specific cytotoxic T lymphocytes in terms
of total cell numbers, however there is a decrease in the functional ability of these
cells. Cytotoxic T lymphocytes showed a progressive loss in their ability to produce
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INFy in response to EBV peptides. This loss of function correlated with lower CD4 T
lymphocyte numbers and was accompanied by an increase in the EBV viral load.
1.6 Summary
Infection with EBV produces an ideal environment for B lymphocyte tumours
to develop. Hyperstimulation of the humoral arm of the immune system by HIV,
EBV and other antigens leads to increased B lymphocyte proliferation. B lymphocyte
proliferation is aided by aberrant production ofTH2 cytokines. In addition the loss of
FDC and CD4 lymphocytes leads to a loss in negative regulatory factors for B
lymphocyte proliferation. Furthermore decreased T lymphocyte mediated cytotoxic
killing allows inappropriate B cell proliferation to continue unchecked. While the
effects ofHIV infection are prominent throughout the body the CNS may be at
increased risk due to its already restricted immune surveillance.
Given the oncogenic capability ofEBV it is unsurprising to find that it is
associated with a large number ofmalignancies in HIV. Furthermore as EBV shows a
100% association with PCNSL in AIDS it is clearly plays an important role in the
pathogenesis. Both histological types ofPCNSL are EBV infected and demonstrate a
latency III phenotype, which includes expression of the viral oncogenes EBNA-2 and
LMP-1.
HIV subverts the immune system and provides an environment favourable to
B lymphocyte proliferation. EBV takes opportunistic advantage of this new
environment further stimulating proliferation ofB lymphocytes in order to promote
its own replication and survival. Inevitably in some cases this uncontrolled
proliferation leads to tumour formation.
The question, which remains unanswered, is why these EBV related tumours
preferentially develop in the CNS? Given that no evidence exists ofB lymphocytes
entering the normal brain (Williams & Hickey 1995, De Angelis 1999, Hickey 2001)
it seems paradoxical that these EBV related tumours should develop preferentially in
the CNS in immunosuppressed individuals.
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1.7 AIMS
It is widely accepted that activated T lymphocytes routinely enter the normal
CNS where they perform antigen surveillance functions (Hickey et al 1991). As yet
there is no evidence ofB lymphocytes entering the normal human CNS (Williams &
Hickey 1995, De Angelis 1999, Hickey 2001). However it is known that antigen
specific B lymphocytes are capable of responding to antigens within the CNS (Knopf
et al 1998).
HIV infected individuals are 60 times more likely to develop PCNSL than
non-HIV infected individuals (Tulpule & Levine 1999). These malignancies are all of
B lymphocyte origin and are universally associated with EBV (MacMahon 1992).
This study aimed to determine the prevalence of B lymphocytes in normal
brain when, presumably, no exogenous immunological challenge originates from
CNS tissue. Subsequently we aimed to determine whether advancing HIV infection
leads to changes in the brain B lymphocyte population which might contribute to the
increased risk of lymphoma seen in AIDS. We sought to characterise any B
lymphocytes found within the brain, in terms of activation status of the lymphocytes,
clonality of any large populations ofB lymphocytes found, and EBV infection status.
Finally, we wished to assess the effects of damage to the BBB on B lymphocyte
accumulation in the brain, and to determine ifHIV infection of the brain enhanced
expression of B lymphocyte chemoattractants or expression of B lymphocyte
proliferative chemokines within the brain.
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2.4 Pathological samples and control material
Postmortem brain tissue from 8 patient groups was used in the study.
These cases were part of the Edinburgh HIV brain bank and use of this
resource in research is approved by the Lothian Ethics ofResearch
committee.
Group 1 - Normal brains (n=7). All these cases died as a result of
accidents and had no evidence of CNS disease at autopsy, or
history of illness relating to the CNS. Five cases were male
and 2 female. The age range was 16-31 years (mean age 24
years).
Group 2 - Non-HIV Intravenous Drug abusers (n=5). These
individuals were all HIV negative drug users who died of drug
related accidents. Four were male and one female; age range
20-34 years (mean age 27 years).
Group 3 - Pre-symptomatic HIV infected patients (n=6). These
individuals were all HIV positive drug users infected by needle
sharing who died of drug related accidents before developing
an AIDS defining illness. Post mortem examination confirmed
a lack ofAIDS defining illness in all cases. All were male and
the age range was 28-40 years (mean age 32 years).
Group 4 - AIDS patients with no significant CNS pathology (n=5).
These patients died ofnon-CNS related AIDS conditions, but
displayed no evidence of PCNSL, CNS opportunistic infections
nor ofHIV encephalitis. Two cases in this group had evidence
of systemic lymphoma without CNS involvement. Three
patients in this group were drug users (one female), the
remainder were homosexual men. The age range was 32-45
years (mean age 37 years).
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Group 5 - AIDS patients with non-neoplastic lymphoid infiltrates in
the CNS (n=5). Despite relatively high T lymphocyte counts
in two individuals in this group, all had symptoms ofAIDS. At
routine neuropathological examination these subjects displayed
pleomorphic perivascular lymphoid infiltrates in all or many
areas of the brain. These infiltrates contained occasional
plasmacytoid cells and were not considered morphologically
malignant. Careful examination of these brains had revealed no
evidence of other significant CNS pathology apart from one
case that had a single ependymal focus of cytomegalovirus
infection. Three cases were drug users, all female. The other
two comprised a homosexual man and an African child. The
child died of systemic cytomegalovirus and Pneumocystis
infection and was part of a study in Abidjan (Bell et al 1997).
The age range of the adult cases was 23-38 years (mean age 32
years) and the age of the African child was 6 months.
Group 6 - AIDS patients with HIVE (n=6). These patients were all
diagnosed at autopsy as having HIVE, characterised by the
presence of giant cells and positive immunohistochemical
staining for p24 HIV antigen. Four were male and two female,
four were drug users, and the age range was 28-59 years (mean
age 40 years).
Group 7- AIDS PCNSL cases (n=6). Five individuals had focal deposits
of neoplastic B lymphoid aggregates in the CNS perivascular
compartment and also invading the brain tissue locally, while
one individual had widespread disseminated CNS B cell
lymphoma. Full autopsy in these patients failed to reveal
evidence of lymphoma outwith the CNS. None had HIV
encephalitis but three displayed immunohistochemical evidence
of a focal, low level cytomegalovirus infection in addition to
lymphoma. Five of the group were homosexual men, one was
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an IDU, and the age range was 28-36 years (mean age 31
years).
Group 8 - Non-HIV viral encephalitis (n=3). These patients were all
diagnosed at autopsy with encephalitis of various viral origins.
(1 Case of herpes simplex encephalitis, and in 2 cases the
causative virus was not identified). All were HIV negative.
None had a history of immunosuppression. The age range was
24-68 years (mean age 50 years).
Additional Case - One pre-AIDS drug user which did not fit the criteria
for group 3 because there was evidence ofnon-HIV
viral encephalitis. Female, age 32 years.
In all the subjects described above, the brain was removed at autopsy
and fixed intact in formalin for 2-3 weeks. Blocks were removed for histology
from the frontal, parietal and occipital lobes, central white matter, temporal
hippocampus, basal ganglia, thalamus, midbrain, pons, medulla and
cerebellum. All samples were paraffin embedded and 5 pm sections were cut
from each block. Relevant clinical data is given for each individual case in
section 2.6.1 Table 5.
2.4.1 Clinical information
Table 5 below gives details of each of the cases used in this study and
any relevant clinical information which was available.
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Table 5: Clinical details of individual cases
Case
number/type








l Neg - Nil in CNS 31M NA
2 Neg - Nil in CNS 16M NA
3 Neg - Nil in CNS 26M NA
4 Neg - Nil in CNS 22M NA
5 Neg - Nil in CNS 24F NA
6 Neg - Nil in CNS 28F NA
7 Neg - Nil in CNS 23M NA
Group 2 Non-HIV drug users
8 Neg + Nil in CNS 31M NA
9 Neg + Nil in CNS 34M NA
10 Neg + Nil in CNS 20F NA
11 Neg + Nil in CNS 20M NA
12 Neg + Nil in CNS 32M NA
Group 3 Pre-AIDS






























Group 4 AIDS with no CNS pathology
19 AIDS + Nil in CNS 34M 4/27
20# AIDS - Nil in CNS 45M 41/110





















Group 5 AIDS infiltrate
24 AIDS + Pleomorphic
infiltrate
29F 248/1154
25# AIDS + Pleomorphic
infiltrate
38F 85/302








28 AIDS - Pleomorphic
infiltrate
NA NA
Group 6 AIDS HIVE
29 AIDS - HIVE 59M 6/unknown
30 AIDS - HIVE 28M 60/300
31 AIDS + HIVE 35F 23/418
32 AIDS + HIVE 28M 90/520
33 AIDS + HIVE 41M 10/767





















41 # AIDS -
CNS lymphoma

























Key: # indicates frozen tissue was available for this case in addition to FFPE tissue.
In addition to the formalin fixed paraffin embedded (FFPE) tissue
described above, frozen samples were available from some of the HIV
cases in the groups above and additionally from some normal cases for
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which no FFPE sections were available. Table 6 lists the additional
normal frozen tissue and CSF samples used. HIV cases with frozen tissue
available are marked in table 5 above with a #.











52 Normal Frontal lobe
53 Normal Frontal lobe
54 Normal Frontal lobe
No clinical data was available for any of these cases other than
their HIV status, which was negative for all.
2.4.2 Formalin fixed paraffin embedded tissues
All tissue samples used in this study were from the Edinburgh brain
bank, and had been previously processed to paraffin for long term storage.
All sections used in this study were cut using a microtome, to a thickness of
5pm for immunohistochemistry and in situ hybridisation, and 20-25pm for
PCR. Sections were then floated on a waterbath (at 37°C) to flatten out the
section before being placed on superfrost slides (BDH). Sections were then
left overnight at 37°C.
Sections used for in situ hybridisation and PCR were cut and handled
using latex gloves to prevent degradation ofRNA/DNA or contamination.
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2.4.3 Frozen tissues
All frozen tissue samples used in this study were obtained from the
Edinburgh HIV brain bank. The samples removed from the brain bank were
used only for DNA extraction. Due to the infectious nature of the material
extra safety precautions were taken when handling this material. Samples were
only removed from their storage containers inside a Class 2 extraction hood,
and samples were kept here until well digested with proteinase K. Double
gloves were worn at all time when handling tissue containers, and all plastic
wear used was soaked in Tigidor disinfectant before being autoclaved and
disposed of. The hood was cleaned after use with Tigidor and the built in
U.V. lamp left on overnight.
2.4.4 Blood samples and peripheral blood mononuclear cell
(PBMC) separation
Upon informed consent, 20-50 ml of heparinized blood was obtained
from several healthy members of the laboratory staff at the Royal Dick Vet
School.
Heparin treated fresh whole blood (10 IU/ml) was layered onto an
equal volume ofFicoll-Histopaque and centrifuged at 540g for 20 minutes.
The interface layer, between the plasma layer and Ficoll, containing PBMCs
was harvested and washed twice in PBS by centrifugation at 160g for 5
minutes.
2.4.5 PHA stimulation of PBMCs
PBMCs were diluted to a concentraion of 4x106 in 4 ml of culture
medium, then lOOpl ofPHA (phytohaemagglutinin) was added. The mixture
was pipetted into 4 wells of a 24 well plate and incubated over night at 37°C
with 5% CO2. Cells were then transferred to sterile eppendorf tubes and




The cell lines shown in table 7 were used as experimental controls as
described in the appropriate sections:
Table 7: Control cell lines
Cell line Description Reference
Namalwa
Burkitt's lymphoma tumour
derived cell line containing
1-2 copy ofEBV genome
per cell





lymphoma derived cell line
Steinitz & Klein 1975
Akata Burkitt's lymphoma tumour Takada et al 1991
Raji Burkitt's lymphoma tumour Epstein et al 1966
P3HR1 Burkitt's lymphoma tumour Hinuma et al 1967
MOLT-4 T cell leukaemia tumour Takada et al 1974
HUT-78 T cell leukaemia tumour Seon et al 1984
U937 Monocyte cell line Larrick et al 1980
Cell lines were cultured in a humidified incubator at 37°C with 5%
CO2. They were feed twice weekly with RPMI containing 10% foetal calf
serum, L-glutamine and penicillin/streptomycin.
2.4.6.1 Cell viability assay and cell counts
Cell viability was assessed using the principle that live cell are able to
prevent the uptake of the dye Trypan blue, whereas dead cells take up the
dye. lOpl of 0.5% w/v Trypan blue in PBS solution was mixed with lOpl
of cell suspension, and the mixture placed in a haemocytometer chamber.
Viable cells were counted by light microscopy.
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2.4.6.2 Thawing cells
Frozen cells were thawed in a water bath at 37°C then added to 10ml
of culture medium in a universal tube. Cells were centrifuged at 160g for
5 minutes, resuspended in culture medium at a concentration of lxl06
cells/ml, and transferred to a 25ml tissue culture flask. Cells were
propagated at 37°C with 5% CO2.
2.4.6.3 Cell line Dilution series
Ten fold dilution series of cell lines were created to provide a means of
quantifying PCR sensitivity. Cells were counted as described above and
diluted in culture medium to a concentration of 106 cells per ml. Serial
dilutions ofNamalwa (EBV positive) cells, from 106 cells to 1 cell, were
made by removing 1ml from 10ml ofmedium containing 107 cells and
adding it to 9ml of fresh medium to give 106 cells in 10ml and leaving
9xl06 cells in the original tube. This was repeated down to 10 cells in
10ml, then 1 ml was removed from each dilution and added to 1 ml of
EBV negative BJAB cells (concentration 106 cells/ml), to give a dilution
series from 106Namalwa cells in a background of 106 BJAB cells down to
1 Namalwa cell in a background of 106 BJAB cells. Cells were then
centrifuged at 160g for 5 minutes and resuspended in 1 ml ofPBS. DNA
was then extracted from the cells as described in 2.6.3.1.
Akata cell line dilution series was created in the same way as described
above by substituting Akata for Namalwa and U937 for BJAB
2.5 Techniques
2.5.1 Immunohistochemistry
A list of antibodies used for immunohistochemistry is given in table 8.
72
2.5.1.1 Preparation for use of formalin fixed paraffin
embedded (FFPE) sections (Re-hydration of
sections)
Paraffin wax sections were de-waxed by immersion in xylene twice for
4 minutes each time. Sections were re-hydrated by two immersions in
99% ethanol, and two immersions in 70% ethanol. This was followed by a
12 minute immersion in picric acid, and finally rinsing in running tap
water.
2.5.1.2 Antigen retrieval pre-treatments
Fixation of tissue in formalin can create crosslinking bonds within the
tissue which can make it difficult or impossible for antibodies to penetrate
and reach their target antigens. There are several antigen retrieval pre-
treatment methods which can be utilised to un-mask antigens. Table 9 lists
the antigen retrieval pre-treatments used in this study.
2.5.1.3 ABC immunohistochemistry procedure
(peroxidase and alkaline phosphatase)
Sections were de-waxed and re-hydrated as described above. Sections
requiring antigen retrieval pre-treatments to un-mask antigen affected by
formalin bond formation were treated at this point, see table 9. After pre-
treatments sections were rinsed in running water, then incubated for 10
minutes in 3% H2O2 to block endogenous peroxidase enzyme activity.
Sections were then rinsed in running water, followed by PBS, then loaded
into a Sequenza. 150pL of filtered blocking serum, diluted 1 in 5 in PBS,
was then applied for 10 minutes (see table 8). This was followed by
incubation with the primary antibody diluted in appropriate filtered and
diluted blocking serum (see table 8 for list of antibodies used and
concentrations) for 30 minutes at room temperature. Sections were then
rinsed twice for 5 minutes with PBS, and incubated with biotinylated
73
secondary antibody, again diluted in appropriate blocking serum, for 30
minutes at room temperature. The sections were again washed twice in
PBS, then incubated with streptavidin/peroxidase complex (DAKO ABC)
or streptavidin/alkaline phosphatase complex (Vector ABC-AP), for 30
minutes at room temperature. Sections were then rinsed twice with PBS
and removed from the Sequenza. A visualising agent was then applied
(see table 8). Sections were then rinsed in running water before being
counterstained in haematoxylin for 20 seconds, washed again, blued in
lithium carbonate, and finally rinsed again. Sections were mounted as
described in 2.7.1.7
2,5.1.4 Tyramide signal amplification (TSA)
Sections were de-waxed and re-hydrated as described above. Sections
requiring antigen retrieval pre-treatments were treated at this point, (see
table 9). Sections were rinsed in running water, then immersed in H2O2 for
15 minutes, rinsed again in running water, then rinsed in PBS before being
placed in a sequenza slide holder. 150p.L of filtered blocking serum,
diluted 1 in 5 in PBS, was then applied for 15 minutes (see table 8),
followed by 150pl ofTNB for 20 minutes. After a brief rinse in PBS the
primary antibody was added (see table 8 for: concentration, incubation
period and incubation temperature). Sections were then rinsed twice for 5
minutes with PBS, and incubated with biotinylated secondary antibody,
diluted in appropriate blocking serum, for 30 minutes at room temperature.
The sections were again washed twice in PBS, then incubated with
streptavidin horseradish peroxidase (strept HRP) diluted 1/500 in TNB for
30 minutes at room temperature. Sections were rinsed 3 times for 5
minutes with TNT. Biotinylated tyramide was diluted 1/350 in boric acid
and H2O2 (3ml boric acid + lpl 30% H2O2). Sections were incubated with
diluted biotinylated tyramide for 10 minutes at room temperature, then
rinsed three times in TNT. StreptHRP diluted as above for 30 minutes,
then rinsed 4 times for 5 minutes with PBS. DAB was then applied to
sections, sections rinsed in water, counter stained in haematoxylin and
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blued in lithium carbonate, and finally rinsed again. Sections were
permanently mounted as described in 2.7.1.7.












































































































Key: SARBO swine anti-rabbit biotinylatcd antibody, RAMBO rabbit anti mouse biotinylated antibody, ABC
avidin biotin complex (horse radish peroxidase), AP alkaline phosphatase, TSA tyramidc signal amplification,
DAB diaminobenzidine, EDTA ethylene diamine tetraacetic aicd
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Table 9: Antigen retrieval pre-treatments
Pre-treatment Procedure
Citric acid 0.01M pH6.0
Microwave sections in 500ml for 15 minutes,
allow to cool in solution for 10 minutes
Citric acid 0.01M pH6.0
Pressure cook sections in 1L for 20 minutes,
allow to cool in solution for 10 minutes
EDTA 0.5mM pH8.0
Microwave sections in 500ml for 15 minutes,
allow to cool in solution for 10 minutes
EDTA 0.5mM pH8.0
Pressure cook sections in 1L for 20 minutes,
allow to cool in solution for 10 minutes
Trypsin 0.1%, CaCl2
0.1%
Digest sections in 500ml for 20 minutes at
37°C
Protease 25mg in 50ml
TBS pH7.8
Digest sections in 500ml for 15 minutes at
37°C
2.5.1.5 Double antigen labelling immunohistochemistry
This technique was used to label two antigens on one section. In order
to avoid cross reactions, in all experiments using this technique, the first
antigen was labelled using a rabbit anti human antibody and the second
antigen labelled using a mouse anti human antibody.
The procedure described in 7.2.2 was followed using
streptavidin/peroxidase complex (DAKO ABC) for the first antigen.
Sections were then re-incubated in 3% H2O2 for 10 minutes, rinsed in
running water, followed by PBS, then re-loaded into the Sequenza. 150pL
of filtered blocking serum, diluted 1 in 5 in PBS, was then applied for 10
minutes (see table 8). Then an avidin/biotin blocking kit (Vector) was used
to block biotin and avidin molecules added to visualise the first antigen.
The kit was used in accordance with the manufacturers instructions - 15
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minute incubation with avidin blocking agent, 15 minute incubation with
biotin blocking agent, sections were then rinsed with PBS. The primary
antibody was then added, and the protocol in 7.2.2 followed from that
stage. Streptavidin/alkaline phosphatase complex (Vector ABC-AP) was
used in the visualisation of the second antigen. Sections were permanently
mounted as described in 2.7.1.7.
2.5.1.6 Antibody removal from sections after antigen
labelling
This technique was used where it was necessary to determine if two
antigens were expressed on the same cell. It was used in preference to
double antigen labelling (7.2.6) in situations where only two mouse
monoclonal antibodies were available for labelling the antigens of interest.
By photographing previously stained sections, then removing the antibody
and stains before re-staining a second antigen, the problems of cross
reactivity associated with double antigen labelling using two primary
antibodies raised in the same species are avoided.
Sections which had been previously stained using the technique
described in 7.2.2 using streptavidin/alkaline phosphatase complex (Vector
ABC-AP), and mounted in aqueous mounting medium (see 7.2.8), were
photographed, using an Olympus BX40 light microscope with Roper
scientific camera and image pro plus computer software, and the
coordinates of cells of interest noted. Sections were then left in running
water for 1-2 hours until the coverslips slid off. Sections were then placed
in an antibody stripping solution (see 5.1) for 12 minutes on a shaker.
Following this they were de-stained in 0.5% Na2S205 for 1 minute, on a
shaker. Sections were then rinsed in running water for 10 minutes, before
being re-stained for a second antigen as described in 7.2.2. After labelling




Sections to be aqueous mounted were dehydrated by brief sequential
immersion in 70% ethanol, 99% ethanol, 100% ethanol (absolute alcohol).
They were then briefly air dried before coverslips were added using Aqua
mount.
Sections to be permanently mounted were dehydrated by brief
sequential immersion in 70% ethanol, 99% ethanol, 100% ethanol
(absolute alcohol), followed by immersion in xylene. Sections were then
removed from xylene and mounted while still damp using pertex. Excess
xylene was removed with paper tissue.
2.5.2 In-situ hybridisation
Dako PNA detection kit was used in conjunction with DAKO PNA
probes (EBER, kappa and lambda). The kit was used in accordance with
the manufacturers instructions. Sections were de-waxed and re-hydrated
as follows: 2 rinses in xylene (5 minutes), 2 rinses in 99% ethanol (5
minutes), 2 rinses in 95% ethanol (5 minutes). Sections were then air
dried for 5 minutes and tissue encircled with DAKO PAP pen. Sections
were rinsed in RNAse free water then 150pl of the supplied proteinase K
was added for 25 minutes. Sections were rinsed again in RNAse free
water (5 minutes) then briefly immersed in 95% ethanol for 10 seconds,
then air dried. 2 drops of DAKO PNA probe was added, sections
coversliped and placed in 37°C incubator in a humidity chamber for 1.5
hours. Sections were then washed in the supplied stringent wash buffer
(diluted 1/60 in RNAse free water) for 25 minutes at 55°C with stirring.
Sections were briefly immersed in TBS, then 3 drops of supplied anti-
FITC/AP (alkaline phosphotase labelled antibody) were added for 30
minutes at room temperature. Sections were rinsed twice in TBS for 3
minutes, then twice in distilled H2O for 1 minute. Three drops of supplied
substrate was added for 30 minutes at room temperature. Sections were
then rinsed in running water for 5 minutes and lightly counterstained with
haematoxylin (not supplied in kit), before being aqueous mounted as
described in 2.7.1.7.
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2.5.3 Quantitation of cells in immunohistochemistry
sections
Cells were quantified manually using a cell counter and light microscope.
Sections were scanned at magnification of x 100 in the pattern shown
below. Care was taken not to omit any areas of tissue present on the slide.
All quantitations were carried out 'blind' with regard to HIV status and
group.
2.5.4 Polymerase chain reaction (PCR)
PCR amplification was used to detect and quantify EBV gene
sequences, and to detect re-arranged immunoglobulin heavy chain genes.
2.5.4.1 DNA extraction
Nucleic acids were extracted from paraffin embedded sections, frozen
brain tissue, frozen CSF samples and fresh PBMCs. During each
extraction care was taken to avoid contamination of samples with
amplified PCR products which could give rise to false positive results.
This was accomplished by using separate areas in the laboratory for
storage ofPCR products and for extraction ofDNA. In addition PCR
reactions were performed in a designated PCR only area and using sterile
plasticware kept only for the procedure.
DNA was extracted from 20pm paraffin embedded sections using a
Nucleon HT kit. DNA was extracted as follows, in accordance with the
manufacturers instructions.
All DNA extractions from frozen tissue, HIV infected and uninfected,
were carried out in class 2 hood following the precautions described
earlier. A stock solution of extraction buffer was made (5ml TNE + 250pl
19mg/ml proteinase K + 33pl 2mg/ml PolyA). A small piece of frozen
tissue was removed from the frozen sample and placed in a sterile
eppendorff tube. 500pl of extraction buffer was added to each tube.
Tubes were then incubated at 55°C for 2.5 hours. 450pl of
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phenol:chloroforom:iso-amyl alcohol was added to each tube and tubes
shaken for 2 minutes. Tubes were then centrifuged for 5 minutes at 1300g.
400|ul of aqueous phase was transferred to a fresh tube. 40pl sodium
acetate pH 5.2 (3M) was added, the 800pl of ethanol (chilled to -20°C),
and the tubes stored at -20°C for over night. Tubes were then centrifuged
at 1300g for 15 minutes, the supernatant discarded and 600pl of 80%
ethanol (chilled to -20°C) added. Tubes were centrifuged at 1300g for 5
minutes, then the supernatant removed. The remaining pellet was dried at
37°C for 10-15 minutes, before being re-dissolved with 50pl of nuclease
free water. Tubes stored at 4°C overnight to allow pellets to dissolve.
DNA concentrations reading were taken. Samples were then stored at
-20°C until required.
2.5.4.2 DNA extraction from frozen CSF samples, cell
lines and fresh PBMCs
DNA extractions from frozen CSF samples and PBMCs were carried
out in a class 2 hood. PBMCs were separated from whole blood as
described above. The pellet obtained was re-disolved in 200pl ofPBS
ready for extraction. Culture cells were diluted to the appropriate
concentration in culture medium, then centrifuged and re-suspended in
200pl of PBS. CSF samples were thawed by leaving them in the hood at
room temperature. 200pl was then removed from each sample and
transferred to a sterile eppendorf.
A High pure viral nucleic acid kit was used to extract nucleic acid from
all sample types. In accordance with the manufacturers instruction, 200pl
ofbinding buffer (binding buffer + Poly A) was added to each tube. Then
50pl of supplied proteinase K was added and tubes incubated at 37°C for
10 minutes. lOOpl of isopropanol was then added. The contents of the
tube were then transferred to a spin column and centrifuged at 1300g for 1
minute. 500pl of inhibitor remover was then added and the column re-
centrifuged as before. This was followed by two rinses with wash buffer
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again centrifuged through the column. A fresh collection tube was added
to the column and 50pl of elution buffer was added and the column
centrifuged. The final elutant was removed and transferred to a sterile
eppendorff. The DNA concentration readings were taken. Extracted DNA
was stored at -20°C until required.
2.5.4.3 (3-Globin PCR
3-globin PCR was used to confirm the presence of amplifiable DNA in
samples after DNA extraction. This PCR is routinely used in our
laboratory and has been previously standardised. Primer sequences and
product sizes are given in Appendix E, reaction conditions are given
below:
5pi lOx PCR buffer
3pi 25mM MgCl2
0.5pl 20mM dNTP
0.5pl of each primer lOOpM/pl
0.5pi Taq polymerase 5U
40.5pl nuclease free water
1 pg DNA
2.5.4.4 Semi-quantitative EBV (BamW) PCR
Bam W PCR used to detect the presence ofEBV in samples and to
quantify the number ofEBV genomes in samples. This PCR is also
routinely used in our laboratory and has been previously standardised.
Primer sequences and product sizes are given in appendix E, reaction
conditions are given below:
5pi lOx PCR buffer
3pi 25mM MgCl2
0.5pl 20mM dNTP
0.5pl of each primer lOOpM/pl
0.5pi Taq polymerase 5U
40.5pl nuclease free water
1 pg DNA
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In order to evaluate the EBV copy number a semi-quantitative PCR
method was employed. A 10 fold serial dilution ofNamalwa cells (1-2
copies ofEBV genome per cell) from 106 cells down to 1 cell in a
background of 106 EBV negative BJAB cells was created (see 2.6.5.3).
DNA was extracted from the cell mixtures and PCR performed to amplify
the highly conserved Bam HI W region of the EBV genome (Wagner et al
1992). Following electrophoresis and southern blotting of the PCR
products, autoradiographs were analysed by scanning densitometry to
determine the density and area of amplified bands. The densitometry
readings from the dilution series were plotted on a graph, and then
densitometry readings from samples were read off the graph to give a
semi-quantitative assessment of the number ofEBV genomes present in a
sample.
2.5.4.5 FR3 PCR
FR3 PCR amplifies re-arranged Ig heavy chain genes at the junction
between the variable heavy chain gene and the diversity heavy chain gene.
The two primers bind to highly conserved regions of the two genes. The
technique has been previously described by Trainor et al 1990, and was
standardised as described in section 3.4.2. The optimised PCR reaction
mixture contained:
5pi lOx PCR buffer
4.5pi 25mM MgCl2
0.5pi 20mM dNTP
0.5pl of each primer lOOpM/pl
0.75pl Taq polymerase 5U
3 8pi nuclease free water
1 pg DNA
The optimised reaction conditions were as follows:
92°C for 2 minutes
34 cycles of - 92°C for 45 seconds
5 5 °C for 36 seconds
72°C for 45 seconds




FR1 PCR also amplifies re-arranged Ig heavy chain genes. Six PCRs
are used one specific for each variable heavy chain family of genes (VH1,
VH2, VH3, VH4, VH5 and VH6). The primer sequences are given in
appendix E. Each 5' primer is specific for 1 variable heavy chain family
of genes and binds to a region highly conserved within that family, the 3'
primer is common to all six reactions and binds to a highly conserved
region of the Ig heavy diversity gene. This technique has been previously
published by Inghirami et al (1993), and the reaction conditions were
optimised as described in 3.4.3. Optimal PCR reaction mixture for each of
the 6 PCRs is given below:
5pi 1 Ox PCR buffer
4.5pl 25mM MgCl2
0.5pl 20mM dNTP
1 pi of each primer 1OOpM/pl
0.5pi Taq polymerase 5U + 0.5pi Taq start
3 8pi nuclease free water
lpgDNA
PCR programs are given in table 10.
Table 10: FR1 PCR programe
Program VH1, VH2, VH5, VH6 VH3, VH4
Initial denature °C
(time: minutes)









72°C (72) 72°C (72)






PCR products were resolved and visualised using gel elecropheresis.
A 2.5% gel was made by melting NuSieve 3:1 agarose (3 parts agarose, 1
part Sea Kem agarose) by microwaving in IX TBE buffer. The gel was
then cooled under running water and lOpl ethidium bromide (EtBr)
(lOpg/ml)/ 100ml gel was added. The gel was poured into a casting try
with combs inserted and allowed to set. The gels were placed in an
electrophoresis tank (Scot Lab), covered with lx TBE buffer, and the
combs removed.
20pl of PCR products were mixed with 4pl of lOx loading buffer and
pipetted into appropriate wells in the gel. Two sets ofDNA size markers
were used; lOObp DNA ladder and DIG VIII ladder (both Gibco BRL).
Electrophoresis was carried out at 80mA and EtBr staining was visualised
under a UV transilluminator system (UVP) and a photograph taken to
record the image.
2.5.5 Reverse transcriptase (RT) PCR
RT PCR was used to asses cytokine gene expression in frozen brain
tissue. RNA extracted from PHA stimulated fresh PBMCs was used as
control material for all RT-PCR reactions.
2.5.5.1 RNA extraction
Total cellular RNA was extracted by homogenisation of small pieces
of frozen brain tissue or PBMC cell pellets in RNAzol B solution.
Samples were homogenised using sterile RNAse free homogeniser rods.
Following disruption of cells/tissue in RNAzol B, lOOpl of chloroform
was added per 1ml ofhomogenate, the samples were capped and shaken
for 30 seconds, then left on ice for 5 minutes. The mixture was then
centrifuged at 1300g for 15 minutes. The upper aqueous phase was then
removed to a fresh RNAse free eppendorf. RNA was precipitated by
addition of an equal volume of isopropanol and the mixture left on ice for
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15 minutes. The RNA was pelleted by centrifugation at 1300g for 15
minutes, and the supernatant removed. The RNA was washed once in
75% ethanol and centrifuged at 1300g for 8 minutes. The supernatant was
removed and the RNA pellet re-suspended in 50pl of nuclease free water.
RNA concentration was determined by spectophotometry. Samples were
then stored at -70°C.
2.5.5.2 Complementry DNA (cDNA) synthesis
cDNA was synthesised by reverse transcription of 5pg of total RNA
using oligo dT primers (Invitrogen RT kit). Volume ofRNA was adjusted
to 38pl with DEPC water. 3pi of oligo dT primers were added and the
mixture incubated at 65°C for 5 minutes. The reaction was then cooled at
room temperature for 10 minutes. The following reaction components
were then added in order:
5pi lOx first strand buffer
lpl RNAse block ribonuclease inhibitor (40u/pl)
2pl ofMMLV (Moloney murine leukaemia virus) Reverse
transcriptase (50u/pl)
The mixture was incubated at 37°C for 1 hour. Then heated to 90°C
for 5 minutes and finally placed on ice. cDNA samples were stored at —
20°C.
2.5.5.3 RT-PCR
In order to confirm that amplifiable DNA had been produced in 2.7.4.2
a GapDH PCR was performed on each sample. PCR reaction mixture
contained the following in each reaction tube:
5pi lOx PCR buffer
3pi MgCl2
0.5pi dNTP pi
0.5pi of each primer
0.5pi Taq polymerase 5U/pl
40pl nuclease free water
5pi cDNA
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Reaction conditions were as follows:
94°C for 2 minutes
30 cycles of -
72°C for 10 minutes
cool to 4°C
Products were visualised on EtBr gels as described above. Primer
sequences and band sizes are given in appendix E.
2.5.5.4 IL-2, IL-4, IL-6, IL-10, and INFy RT-PCR
IL-2,4,6,10 and IFNy PCR were performed in cDNA generated from
RNA extracted from frozen brain tissue. PHA stimulated PBMCs were
used as a source of control RNA. Reaction conditions for each PCR are
given below and PCR programs given in table 11. Primer sequences and
band sizes are given in appendix E. All reaction mixtures consisted of the
following:
5 p.1 1 Ox PCR buffer
3p.l 25mM MgCl2
0.5pl 20mM dNTP
0.5pl of each primer 100pM/p.l
0.5pil Taq polymerase 5U/pl
40pl nuclease free water
5jol cDNA
Products were visualised on EtBr gels as described above.
2.5.6 Southern blotting and probing of blots
EtBr gels from BamW PCR and all RT-PCRs were Southern blotted
and probed.
2.5.6.1 Southern blotting
Following electrophoresis ofPCR products, the DNA was transferred
onto a nylon membrane using the technique described by Southern (1975).
The gel was rinsed in distilled H20 and soaked in an alkaline denaturing
94°C for 30 seconds
58°C for 30 seconds
72°C for 30 seconds
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solution for 15 minutes, then transferred to a neutralising solution pH 7.2
for 15 minutes. The gel was then placed on 3MM blotting paper (soaked
in xlO SSC) laid across a plastic brace which was supported over a tray
containing xlO SSC solution. Both ends of the paper hung over the edges
into the solution to act as a wick. The area surrounding the gel was
covered with cling film. A piece of nylon membrane (Roche) was cut to
Table 11: PCR programs for IL-2,4,6,10 and INFy
Primers/
Program























































Number of cycles 40 35 40 35 40
the exact size of the gel and placed over the gel. This was followed by
3 layers of 3MM paper also cut to size. A stack of dry paper towels was
placed on top followed by a glass plate and a 500g weight. The gel was
left over night, then removed and the DNA linked to the membrane by
crosslinking in a Stratalinker with 120,000 pJ UV.
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2.5.6.2 (Digoxigenin) DIG probing
DIG end labelling kit and DIG detection kit was used to label and
detect oligo probes.
Probes were labelled as follows:
1 pi (lOOpmol) probe added to 8pl water, on ice.
4pl of buffer added
4pi CoCl2
lplddUTP
1 pi Terminal transferase
lpldATP
Mixture was incubated at 37°C for 15 minutes, then cooled on ice and
2pl of 0.2M EDTA pH 8.0 added to stop the reaction. Labelled probe
were stored at -20°C. The sequences of probes used and the expected band
sizes are given in appendix E.
DNA was attached to nylon membranes as described in 2.7.5.1. DIG
detection kit was then used as follows:
Membranes were pre-hybridised at hybridisation temperature
(see table 12) for 30 minutes in DIG easy hyb (20ml/100cm2)
Pre-hybridisation buffer was poured off and 1,4pl of probe
diluted in 3.5ml ofpre-heated DIG easy hyb was added. Probe
was incubated for 2 hours at hybridisation temperature.
Probe was poured off and membranes rinsed twice in x2 SSC +
0.1% SDS at the temperatures given in table 12 for 5 minutes.
Membranes were then washed twice in xO. 1 SSC + 0.1 % SDS
for 15 minutes at the temperatures given in table 12.
100 ml ofxl block solution (diluted 12ml block in 108ml
maelic acid pH 7.5) was added to each membrane for 45
minutes at room temperature.
Block solution was poured of and anti-DIG AP (alkaline
phosphotase labelled antibody) was added (diluted 2pi in 20ml
of diluted block solution) for 30 minutes at room temperature.
Membranes were then rinsed twice with wash buffer (maelic
acid 0.1M pH 7.5 + 0.3% v/v tween) for 15 minutes.
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CSPD was diluted 1/100 in 2ml of detection buffer (0.1M tris-
HC1 + 0.1M NaCl pH 9.5) and membranes incubated for 5
minutes at room temperature.
Blots were sealed in plastic bags and incubated at 37°C for 15
minutes, then exposed to DIG luminescent film for 1-2 hours.










50 50 60 65 65
Wash temperature (2x SSC +
0.1% SDS) °C
20 20 20 50 65
Wash temperature (O.lx SSC +
0.1% SDS) °C
20 20 20 50 65
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3 Results
3.1 Prevalence of lymphocytes in brain tissue
Eight patient groups were used in the study. The cases were carefully
selected to fit within the definition of the group as in outlined 2.1 page 59,
thus minimising potential confounding variables. Tissue sections were stained
using immunohistochemical techniques described in 2.2.1 page 67. All tissue
sections were stained and assessed without prior knowledge of case groupings.
3.1.1 Prevalence of lymphocytes in normal brain
The aim of this experiment was to identify both the position and types
of lymphocytes found in normal human brain tissue, and to subsequently
quantify the different cell types. Immunohistochemistry was used to identify
both B and T lymphocytes in normal brain. An anti CD45 antibody was used
to identify all lymphocyte cell types. B lymphocytes were then identified
using antibodies against CD20 and CD79a, while T lymphocytes were
identified using antibodies against CD3 and CD8. No anti-CD4 antibodies
were available which would work on FFPE brain tissue sections that had been
fixed for long periods in formalin (over 2 weeks fixation).
Seven cases were used with an average of 6 sections from different
areas of the brain available for each case.
3.1.1.1 Optimisation of staining techniques for antibodies used to assess
numbers of lymphocytes in the brain
In order to optimise the antibody dilutions, each antibody was titrated
on control tonsil sections to determine the optimal primary antibody
concentration and their staining intensity was assessed with a variety of
antigen retrieval pre-treatments. Antibodies were assessed using the
concentrations and pre-treatments given in table 13. Each antibody was
assessed at the given concentrations for each pre-treatment.
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3.1.1.2 Quantitation of cells expressing CD45 in normal brain tissue
Sections from 7 normal brains (group 1) were stained using an anti-
CD45 antibody. Figure 12 shows a representative photograph of the staining
obtained using this antibody. The number of cells per section was deemed too
great to accurately quantify by manual counting. Automated computer
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counting of cells was also not feasible as the computer is unable to distinguish
between stained cells in the parenchyma and those present in blood vessels. In
addition the antibody did not distinguish between B and T lymphocytes and
therefore was felt to be ofminimal use.
3.1.1.3 Quantitation of cells expressing CD20 in normal brain tissue
Sections from 7 normal brains (group 1) were stained using an anti-
CD20 antibody. Where available sections from all 11 areas of the brain listed
in section 2.4 (page 66) were used for each case studied. Positive cells were
counted as using a light microscope and cell counter, and the average number
of cells per square centimetre of the section calculated (Area was calculated by
computer scanning sections then overlaying with a grid containing cm2 and
mm boxes, complete boxes were then counted to give area). The results for
each case are summarised in table 14 and the data from each individual section
given in table A1 (appendix A).













The results show that occasional CD20 positive B lymphocytes were found in
the parenchyma of 6 out of 7 normal brains (see figure 13). No CD20 positive B
lymphocytes were found in the perivascular space in any of these brains. An
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Figure 13: Single parenchymal CD20 positive B





average of 0.112 CD20 positive B lymphocytes were found per cm2 of normal
brain. Cells were found in all regions of the brains and there did not appear to be
any obvious homing of these cells to particular region of the brain.
3.1.1.4 Quantitation of cells expressing CD79a in normal brain
A second B lymphocyte antibody (anti-CD79a) was used to assess the
B lymphocyte population of the brain. As described earlier formalin fixation
can prevent or hinder antibody attachment to antigen present within the tissue.
The blocking effects of formalin fixation vary between different antibodies for
reasons that are not clear. Therefore 2 antibodies were assessed in order to
minimise the masking effects of formalin on B lymphocyte antigens.
Consecutive sections to those used in 3.1.1.2 were assessed for CD79a
positive cells. The results for each case are summarised in table 15.














The results show that occasional CD79a positive cells were found in
the parenchymal brain tissue of 5 out of 6 brains assessed. As with the CD20
antibody no perivascular CD79a cells were located. Overall the number of
CD79a positive cells found was lower than the number of CD20 positive cells,
an average of 0.057 CD79a cells/cm2 compared to 0.112 CD20 cells/cm2.
However a paired T-test showed no significant difference between the two
antibodies (p=0.163). The lower number ofB lymphocytes found using the
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CD79a antibody may perhaps be accounted for by the generally weaker
staining obtained with this antibody and also the use of different sections.
3.1.1.5 Quantitation of cells expressing CD3 in normal brain
Consecutive sections to those used in 3.1.1.4 were assessed for CD3
positive cells (see figure 14 and 15). CD3 is a pan T lymphocyte marker
present on both CD4 and CD8 lymphocytes. Results obtained using anti-CD3
antibodies were similar in terms of quantity to those obtained with the anti-
CD45 antibody. Given the low number of CD20 and CD79a positive cells
found in 3.2.1.3 and 3.2.1.4 this would suggest that the majority of cells
detected with anti-CD45 antibody in normal brains were T lymphocytes. The
number of CD3 positive cells was deemed too great to accurately count and
therefore only sections from one case were quantified in order to allow a crude
comparison of the number ofB lymphocytes present compared to T
lymphocytes. This showed approximately 50 fold greater number ofT
lymphocytes to B lymphocytes.
3.1.1.6 Quantitation of cells expressing CD8 in normal brain
Consecutive sections to those used in 3.1.1.5 were assessed for CD8
positive cells. The number of CD8 positive cells present in normal brain
tissue was found to be similar to the number ofCD3 cells present, suggesting
that the majority ofT lymphocytes present are of the CD8 phenotype. It was
not possible to assess the number ofCD4 positive cells present directly, as no
antibody was available that worked reliably in material fixed for long periods
in formalin, however based on these results the CD8 T lymphocytes appear to
be dominant over CD4 T lymphocytes within the brain.
3.1.1.7 Double immunohistochemistry (CD20 and Von Willebrand's
antibodies)
In order to be certain that B lymphocytes were located within the brain
parenchyma, rather than within brain capillaries, double immunohistochemical
staining was undertaken using an anti-CD20 antibody (B lymphocyte marker)
and an anti-Von Willebrand antibody (endothelial cell
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Figure 14: CD3 positive cells in a normal brain
Figure 15: CD3 positive cells in the perivascular
spaces of a normal brain
25(i.m
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marker). Von Willebrand antibody binds to Factor VIILVon Willebrand, a
component ofFactor VIII which is produced in endothelial cells and which
binds to Factor VIII:C (produced in liver cells) to produce the complete Factor
VIII molecule. Double immunohistochemical staining allowed the location of
cells to be determined with reference to blood vessels, and to be sure that cells
found within capillaries or small blood vessels were not being counted as
parenchymal cells.
3.1.1.7.1 Optimisation of double antigen labelling
immunohistochemistry
In order to use two antibodies effectively on a single section the
primary antibodies must be raised in different species to avoid cross reactions
between the secondary antibodies, which would make distinguishing between
2 labelled antigens on a single section impossible (see Figure 16 below). For
this reason a mouse monoclonal CD20 antibody was chosen to label B
lymphocytes and a rabbit polyclonal Von Willebrand antibody was chosen to
label endothelial cells in the section. Secondary antibodies were biotinylated
rabbit anti mouse for CD20 and biotinylated swine anti rabbit for the Von
Willebrand's antibody. The antibodies were first titrated separately, CD20 on
FFPE tonsil sections as described in 3.1.1.1 above, and Von Willebrand's on
FFPE sections from normal brain. Von Willebrand's antibody was tested at
each concentration given in table 16 for all of the antigen retrieval pre-
treatment method given.
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Figure 16: Cross reactions in double immunohistochemistry
No cross reaction using primary antibodies





















Potential cross reaction occurring using





































The two antibodies were then applied sequentially to the sections, Von
Willebrand's first to avoid potentially binding of its secondary antibody (swine
anti rabbit) to the secondary rabbit anti mouse used for CD20 if this was applied
first. The full procedure is described in 2.2.1.5 page 71. Initial staining showed
good staining of the endothelial vessels. However the B lymphocyte staining was
weak and difficult to detect in the background of strongly stained endothelial
cells. CD20 antibody concentration was therefore increased from 1/300 to 1/200
and finally to 1/100 to obtain a strong intensity of B lymphocyte staining.
3.1.1.7.2 Quantitation of CD20 positive cells in normal brain tissue using
double immunohistochemistry
Figure 17a shows a photomicrograph of a single CD20 positive cell
(purple) in the parenchyma of a normal brain, with nearby vessels stained
brown. Figure 17b demonstrates a CD20 positive cell situated within a blood
vessel. Figure 17c shows several perivascular CD20 positive cells in AIDS
brain with pleomorphic infiltrates. Case 90/23 (normal brain) was re-assessed
for numbers ofCD20 positive cells using this technique. The same areas
studied in 3.1.1.2 were used here although the sections were not consecutive to
those used in 3.1.1.2. The results were remarkably similar with 1 extra
parenchymal cell being found overall using the double
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Figure 17a: CD20 and Von Willebrand double
immunohistochemistry on a normal brain





Figure 17b: CD20 and Von Willebrand double
immunohistochemistry on a normal brain









Figure 17c: CD20 and Von Willebrand double
immunohistochemistry on a AIDS
brain with pleomorphic infiltrate
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immunohistochemistry. This therefore suggested that cells counted using only
the CD20 antibody in 3.1.1.2 had all been parenchymal cells, and that the
subjective process of deciding on the location of CD20 positive cells had been
carried out accurately.
3.1.2 Quantitation of CD20 positive cells in non-HIV drug
users.
Since 16 out of 30 patients in the pre-AIDS and AIDS groups (groups
3-7) were IDUs it was essential to asses the effects of drug abuse alone on the
CNS B lymphocyte population outwith the setting ofHIV infection. Group 2
consisted of 5 cases ofnon-HIV infected IDUs who had died accidentally.
Sections from all areas of the brain from each case were assessed for the
number ofCD20 positive B lymphocytes present. The results for each case
are summarised in table 17 and the data from each individual section given in
table A2 (appendix A).











CD20 positive parenchymal cells were found in sections from all 5
cases with a mean of 0.315 CD20 positive cells/cm2 ofbrain tissue. Although
this was higher than the number found in group 1 (normal brains) it was not
significantly different from the results found in these cases (p=0.183). The
majority of the increase was due to one outlier case (case 8) which showed far
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greater numbers of cells than any of the other cases in the group (0.96 CD20
cells/cm2 compared to an average of 0.154 CD20 cells/cm2 for the other cases
in the group). As with the normal cases CD20 positive cells were found in all
areas of the brain and there appeared to be no preferential site for CD20 cells
to accumulate. In one case (case 12) a single perivascular cell was found.
The fact that no significant difference was found between normal cases
(group 1) and non-HIV drug users (group 2) allowed the valid inclusion of
both drug users and non-drug users in groups 4,5,6 and 7 (AIDS no CNS
pathology, AIDS infiltrate, AIDS PCNSL, and AIDS HIVE).
3.1.3 B lymphocytes in HIV brains
The aim of these experiments was to study the effects of advancing
HIV disease on the B lymphocyte population of the brain. As before the
CD20 and CD79a antibodies were used to quantify B lymphocytes in the
brain. Six pre-AIDS cases (group 3), all drug users, and 24 AIDS cases were
available for study. The AIDS cases were separated into 4 separate groups on
the basis of their neuropathological findings at autopsy, as described in section
2.6.
3.1.3.1 Pre-AIDS brains
Sections from all areas of the brain from each case were assessed for
the number ofCD20 positive B lymphocytes present. Sections were then re¬
assessed using CD79a antibody.
The results for each case assessed for CD20 positive cells are
summarised in table 18 and the data from each individual section is given in
table A3 (appendix A).
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CD20 positive B lymphocytes were found in the parenchyma of all 6
cases and in the perivascular spaces of 5 out of 6 cases. The mean number of
2 •CD20 positive parenchymal cells for group 3 was 0.417 cells/cm , which did
not differ significantly from the results found in group 1 (normal cases)
(p=0.137) or group 2 (p=0.717). An average of 0.452 CD20 positive cells/cm2
were found in the perivascular space, this was significantly raised when
compared to the normal cases (group 1) and the non-HIV drug users (group 2),
p=0.02 and p=0.05 respectively.
Sections were then re-assessed using the CD79a antibody. Table 19
shows a summary of the CD79a results, with the CD20 results from each case
included for comparison.















N.B. Case 14 was omitted due to a shortage of tissue
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CD79a positive cells were found in the parenchyma of 4 out of 5 pre-
AIDS brains. As in group 1 (normal) the number of CD79a positive cells
found in each brain was lower than the number of CD20 positive cells found,
however the difference was less marked in this group with an average of 0.336
2 2CD79a cells/cm compared to 0.473 CD20 cells/cm for the same cases.
Paired T-test showed no significant difference in the number of cells detected
with the two antibodies (p=0.738). The slightly lower number ofCD79a cells
may be due to the weaker staining achieved with this antibody in comparison
to the CD20 antibody.
3.1.3.1.1 CD3 and CD8 Pre-AIDS results
As with the normal cases the number ofCD3 and CD8 positive cells
found per section was too great to quantify. Figure 18a and 18b demonstrates
that as with the normal brains the majority of T lymphocytes present
displayed a CD8 phenotype.
3.1.3.2 AIDS brains
Sections from all areas of the brain from each case in group 4 (AIDS
no CNS pathology), group 5 (AIDS infiltrate), group 6 (AIDS PCNSL) were
assessed for the number ofCD20 positive B lymphocytes present. In addition,
selected cases were assessed for the number ofCD79a positive B lymphocytes
present in the brain, and semi-quantitative assessment was made of the number
ofCD3 and CD8 positive T lymphocytes present in certain cases. In the AIDS
PCNSL cases, the number ofB lymphocytes was only quantified in areas of
the brain that did not contain lymphoma. There were two reasons for this,
firstly the number of cells in the neoplastic regions was too great to quantify
accurately by subjective counting. Secondly we wished to assess the setting in
which PCNSL had developed, in terms of the size of the B lymphocyte
population forming a background in the affected brain.
105





brown) in a pre-
AIDS brain
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The results for each case in each group are summarised in table 20 and
the data from each individual section given in table A4, A5 and A6 (appendix
A).


























In AIDS cases with no CNS pathology (group 4), the brain was almost
devoid of B lymphocytes, with only 1 case out of 5 containing any CD20
positive cells in the parenchyma or the perivascular spaces of the brain. In
comparison to normal controls this represented a significant decrease in the
number of B lymphocytes (p=0.009). The AIDS cases with pleomorphic
lymphocytic infiltrations (group 5) showed higher levels of B lymphocytes in
both the parenchyma and perivascular spaces of the brain. The mean number
ofparenchymal CD20 positive cells was 0.174 cells/cm compared to 0.008
cells /cm in the AIDS cases with no pathology.
All cases from group 5 contained blood vessels with infiltrations of
lymphocytes in the perivascular space. Figure 19a shows a representative
section stained using CD20 antibody. The majority of cells that were CD20
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negative were shown to be CD3 positive T lymphocytes, with the vast
majority of those being CD8 positive T lymphocytes (see figure 19b).
Focuses ofperivascular infiltrations were found throughout the brains in this
group, however there were areas in each brain devoid ofB lymphocytes.
There did not appear to be any one anatomical area of the brain in
which these infiltrations were more common. The average number of
perivascular CD20 positive cells in this group was 14.776 cells/cm2, a large
increase over that seen in all of the other groups. In comparison to the normal
cases and AIDS cases with no CNS pathology statistical significance was not
reached. This was primarily due to the low numbers of cases, but also due to
an outlier in the data. Case 26 had larger numbers ofB lymphocytes than other
cases in the group (54.027 compared to an average of 4.963 for the rest of the
group). Removal of this outlier would give a significant difference between
this group and both normal cases and AIDS cases with no CNS pathology,
p=0.008 and p=0.029 respectively.
The AIDS cases with PCNSL, assessed outwith the area of lymphoma,
were similar to the AIDS cases with no CNS pathology in terms of the
presence ofB lymphocytes. Only 2 out of 7 cases contained any B
lymphocytes in the brain parenchyma or perivascular spaces. In both the
parenchyma and perivascular spaces the overall average number ofCD20
positive cells for the group was low, with the former having 0.003 cells/cm2
and the latter 0.015 cells/cm . In terms of the number ofparenchymal B
lymphocytes this represented a significant decrease in comparison to normal
controls, p=0.022.
In addition to the cases assessed for CD20 positive cells, 3 PCNSL
cases and 1 AIDS case with no CNS pathology were assessed for brain B
lymphocytes using CD79a antibody. The results are shown in table 21, which
includes the CD20 results for each case to allow comparison.
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Figure 19: Section from AIDS case with pleomorphic







CD8 stained section CD3 stained section
The majority of cells found in pleomorphic infiltrates ofAIDS
brains are dual CD3 positive CD8 positive cells. Therefore the
number of CD3 positive CD4 positive cells is likely to be low.
CD20 B lymphocytes represent a smaller percentage of the
inflammatory cells present than CD3 T lymphocytes.
In addition most of the parenchymal CD3 T lymphocytes in
AIDS brains appeared to be dual CD3, CD8 positive cells.
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Table 21: Comparison of CD79a and CD20 results from selected cases
in AIDS groups



















38 (PCNSL) 0 0 0 0
39 (PCNSL) 0.015 0.016 0 0




0 0.039 0 0
Group
average
0.014 0.023 0 0
The data in table 21 shows that overall a slightly lower number of
CD79a positive cells were found in AIDS brains compared to CD20 positive
cells. As with the normal cases and the pre-AIDS cases the difference was not
statistically significant (p=0.437).
3.1.4 Effects of encephalitis on brain B lymphocyte population
B lymphocytes have been shown to play a crucial role in the clearance
ofmany viral infections from the CNS (Hatalski et al 1998a, 1998b, Tyor,
Moench & Griffin 1989, Dorries 2001). Since there is a high prevalence of
HIV encephalitis (HIVE) in AIDS patients, particularly in the drug using
AIDS patients in the Edinburgh cohort, we sought to determine the effects of
HIVE on the B lymphocyte population of the brain.
Brains which had pathological evidence of encephalitis (HIV related or
otherwise) were available from 3 different categories: 6 AIDS cases with
HIVE (group 6), 1 pre-AIDS case with non-HIV viral encephalitis, and 3 non-
HIV cases with viral encephalitis (group 8). Sections from all areas of the
brain were assessed for B lymphocytes using the anti-CD20 antibody. Table
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22 shows a summary of the results in each group, data from individual
sections in each case are given in table A7 and A8 (appendix A).
Table 22: Quantitation of CD20 positive cells in HIV and



















An average of 0.075 CD20 positive cells/cm2 was found in the
parenchyma ofAIDS HIVE brains. No significant difference was detected
between the average number ofB lymphocytes found in the brain parenchyma
ofAIDS patients with HIVE (group 6) and normal controls (group 1)
(p=0.414) or AIDS patients with no CNS pathology (group 4) (p=0.130).
Conversely, a significant increase was noted in the perivascular brain
compartment ofHIVE AIDS patients when compared to normal controls
(p=0.028). Compared to AIDS patients with no CNS pathology (group 4) a
large increase in the number of perivascular CD20 positive cells was noted in
HIVE cases (an average of 0.005 CD20 cells/cm2 compared to 0.306 CD20
cells/cm , p=0.07), however this did not reach statistical significance.
However in comparison to cases with non-HIV viral encephalitis in
immunocompetent patients (group 8) HIVE cases had far fewer parenchymal
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and perivascular CD20 positive cells (see figure 20a and figure 20b). No
statistical tests were performed on group 8 due to the low number of cases
available.
Case 46 was a pre-AIDS case with non-HIV viral encephalitis. In
terms ofboth parenchymal and perivascular CD20 cells, this case contained
more cells than the AIDS HIVE cases but less than non-immunocompromised
viral encephalitis (see table 22 and figures 20a and 20b). The data shown in
figures 20a and 20b suggest a rising trend in the number of both parenchymal
and perivascular B lymphocytes in the brain from AIDS cases with no CNS
pathology with the least B lymphocytes, to AIDS HIVE cases, then pre-AIDS
encephalitis cases, and finally immunocompetent encephalitis cases with the
greatest numbers ofB lymphocytes.
3.1.5 Lymphocyte proliferation markers
The proliferation index of lymphocytes infiltrating the brain was
assessed by staining sections with anti-Ki-67 and anti-PCNA (proliferating
cell nuclear antigen) antibodies. Ki-67 is a nuclear protein expressed during
all stages of the cell cycle (Gi, S, M, G2 phases) except Go, it is therefore a
marker of cells in active cell division. PCNA is also a nuclear protein
expressed during active cell division, with maximal production occurring
during S phase.
Only sections from AIDS PCNSL cases and AIDS infiltrate cases were
assessed, as the other groups had too few lymphocytes present. Sections were
stained individually with both antibodies which revealed high numbers of
proliferating lymphocytes in both infiltrate cases and in lymphomatous areas
ofPCNSL cases. However both cases contained a mixture ofB and T
lymphocytes and it was not possible to distinguish these morphologically,
therefore it could not be determined which cell types were proliferating.
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Figure 20a: Quantitation ofParenchymal CD20 cells









































































Double immunohistochemistry combining CD20 (monoclonal, B
lymphocyte marker) and Ki67 (polyclonal, proliferation marker), and CD3
(polyclonal, T lymphoyte marker) and PCNA (monoclonal, proliferation
marker), was then used to assess the proliferation of individual cell types.
Results from this technique were poor as it was difficult to distinguish the two
different stains on the same section. This was primarily due to the large
numbers of stained cells and their close proximity to each other, and the fact
that both antigens being labelled were potentially contained within the same
small cell. An additional problem with this technique was the use of anti-
PCNA antibody to mark proliferation in T lymphocytes (CD3) and anti-Ki-67
for B lymphocytes (CD20). Although both antibodies stain proliferating cells,
PCNA shows weaker staining in cells that are not in S-phase of the cell cycle
therefore making comparisons more difficult.
In general the results suggested that within lymphomatous lesions of
PCNSL cases both B and T lymphocytes were proliferating, while in
perivascular infiltrations ofAIDS infiltrate cases only the T lymphocytes were
proliferating.
In order to obtain more satisfactory results the double
immunohistochemistry technique used above was repeated using
immunoflouresence rather than traditional staining techniques. These results
showed similar findings, however the intensity of staining was poor and
although this could have been resolved with additional time it was felt that this
would not alter the results.
3.1.6 Summary of study of B lymphocytes in the brain
Figure 21a and 21b show a summary of the parenchymal and
perivascular B lymphocyte data for all 8 groups.
Examination of the brain in seven normal young subjects (Group 1)
showed that B lymphocytes were present in the parenchyma in very small
numbers but consistently so in all cases. Double staining with the Von
Willebrand antibody confirmed that these occasional parenchymal B



















































































The number ofparenchymal and perivascular B lymphocytes found in
the brains ofnon-HIV drug misusers (group 2), does not differ significantly
from that found in normal (non-drug misusing) controls (group 1).
On routine staining pre-symptomatic HIV infected patients (Group 3)
displayed mild focal lymphocytic infiltrates in the leptomeninges and around
some white matter vessels B lymphocytes appeared in the perivascular
infiltrates and were also found in increased numbers in the parenchymal
compartment. In contrast, once patients progressed to AIDS with a
corresponding fall in the CD4 and CD8 blood lymphocyte counts, there was a
decline in the brain parenchymal B lymphocytes to virtually zero, both in the
parenchymal and perivascular compartments. Surprisingly, when the brains
were examined from patients who had developed PCNSL (Group 7), the areas
of the brain outwith the neoplastic foci showed a virtual absence of
parenchymal and perivascular B lymphocytes. Group 5 included AIDS
subjects in whom the brain displayed quite widespread pleomorphic lymphoid
infiltrates which did not have the characteristics of lymphoma and which were
accompanied by similar lymphoid infiltrates in non-CNS organs. These
patients had somewhat higher CD4 and CD8 lymphocyte counts than the other
AIDS groups in this study. Quantitation ofB lymphocytes in multiple areas
from these brains showed a widespread increase in parenchymal and
perivascular B lymphocytes compared with other AIDS subjects and with pre-
symptomatic HIV positive patients. In AIDS patients with HIVE the B
lymphocyte response was greater than that seen in AIDS patients with no CNS
pathology, but far smaller than that seen in encephalitis in the brains of non-
immunocompromised patients.
Semi-quantitative assessment of the T lymphocyte presence in the
brains studied showed low level T lymphocytes in normal brains, increased
numbers in the pre-symptomatic HIV positive patients and a decline in most
AIDS subjects. These results confirm previous reports by Bell et al (1993)
and Tomlinson et al (1999) regarding T lymphocyte entry to the brain.
Pleomorphic infiltrates included a high proportion ofCD3 positive T cells. In
subjects with PCNSL, the lymphomatous areas often had significant numbers
ofCD8 lymphocytes but these were not a feature of the non-lymphomatous
areas. Proliferative activity, as confirmed by Ki-67 or PCNA positivity, was
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seen in both the pleomorphic infiltrates and in the lymphomas, but was
predominantly in T cells in the former group whereas in the latter, both T and
B lymphocytes were Ki-67 positive although proliferating B cells greatly
outnumbered T cells.
There is no evidence that B lymphocytes home to any specific region
of the brain.
Activation status of B lymphocytes in brain tissue
In order to determine the activation status ofB lymphocytes present in
the brain a novel method of staining the same sections twice was utilised.
Sections were stained using the first antibody, then both the antibody and stain
were removed from the section before re-staining the same section with a
second antibody. This method was used in preference to double
immunohistochemical labelling of the two antigens on one section at the same
time for two reasons. Firstly because the two antibodies available were both
mouse monoclonal antibodies, and use ofboth antibodies on the same section
would may have produced binding of the secondary antibodies (Rabbit anti
mouse) to both primary mouse antibodies. Secondly, the antigens of interest
co-localised to the same regions of the cell making double staining difficult to
interpret. The antibodies used in this experiment were anti-CD20 and anti-
CD23 (activated B lymphocyte marker). The anti-CD23 antibody was
optimised as described in table 23.


















FFPE sections were stained using anti-CD20 antibody (B lymphocyte
marker) with an alkaline phosphatase visualisation reagent. Sections were
then examined under a light microscope and the position marked and co¬
ordinates taken ofCD20 cells present in the parenchyma, perivascular space
and intravascular cells. CD20 positive cells were then photographed, before
the cover slips were removed and the sections placed in an antibody removal
solution. Sections were then re-stained with an anti-CD23 antibody, which
labels activated B lymphocytes. The previously noted co-ordinates were then
used to locate the cells of interest and assess whether or not they were
expressing CD23. Control sections for this experiment were from normal
tonsil. Four sets ofpositive and negative tonsil control sections were utilized;
firstly, positive and negative sections for CD20; secondly, positive and
negative sections for CD23; and thirdly, positive and negative sections stained
for CD20. These sections were then stripped of antibody and re-stained for
CD23. The final set of control tonsils were stained for CD20, then stripped of
antibody, before having the secondary antibody for CD23 applied followed by
the ABC complex and the visualisation agent applied. Failure to remove all of
the first primary antibody during the stripping process would have led to the
CD20 antibody re-staining, in addition to the CD23 antibody, when the second
round of immunohistochemistry was completed. Therefore the final control
set was important to ensure that all of the first primary antibody had been
removed from the section. Any staining seen in this final control set resulted in
the entire run being discarded. The exact methods utilised in this technique
are listed in section 2.2.1.6 page 72. The optimisation of the stripping
technique required 4 test runs with alterations in each run to the length of time
sections were immersed in the stripping solution and the strength of acid used.
The technique described in 2.X provides full removal of all antibodies and
stains present in the section, with minimal digestion/degradation of the tissue
section.
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Sections from 5 patient groups were used:
■ Non-HIV - 6 normal cases with 39 sections and 4 drug users with
11 sections in total
■ Pre-AIDS- 6 cases with 24 sections in total
■ AIDS no CNS
pathology- 3 cases with 11 sections in total
■ AIDS
infiltrate- 3 cases with 7 sections in total
■ AIDS
PCNSL - 6 cases with 18 sections in total, 9 with
lymphoma tissue present in the section.
Each stained section was assessed for CD20 positive B lymphocytes in
three locations: brain parenchyma, perivascular space, and intravascular space.
A total of 110 sections were stained for CD20 cells, of these 43 contained
CD20 positive cells whose location could be easily identified. Table 24 lists
the sections from the above cases in which CD20 positive cells were found.
Also shown in table 24 is the number of CD20 positive cells which then re-
stained for CD23 after the CD20 antibody and staining had been removed
form the section. Table B1 in appendix B lists the results of all the sections
stained for CD20.
Five CD20 positive parenchymal cells where found in the non-HIV
group, 4 ofwhich proved to be CD23 positive (see figure 22a-d). All 5
belonged to two normal cases (1 and 2), no CD20 positive parenchymal cells
were found in any of the drug user cases . Only one cell was found in the
perivascular space of the non-HIV group and this cell failed to show a CD23
positive phenotype. Eighteen CD20 cells were located in blood vessels, 9 of
which showed a CD23 positive phenotype. Thirteen of the CD20 positive
intravascular cells were found in 5 normal cases and 5 in 2 drug user cases.
In the pre-AIDS group, 4 CD20 cells were found in the brain
parenchyma and all 4 stained for CD23. Fifty one cells were found in the
perivascular space and 50 of these were CD23 positive. The majority of
perivascular cells in this group (44 of 51) were in sections from one case (case
46) which had evidence of a non-HIV encephalitis. Nine CD20 cells were
found in the blood vessels of this group, 7 ofwhich were CD23 positive.
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Table 24: Results of sections stained for CD20, then stripped of



























1 frontal 1 0 0 0 1 *
2 basal ganglia 2 2 0 0 1 0
2 temp hip 2 2 0 0 1 0
3 cerebellum 0 0 0 0 2 1
3 frontal 0 0 0 0 1 1
3 temporal
hippocampus
0 0 0 0 2 1
5 bg 0 0 0 0 1 0
6 bg 0 0 0 0 5 5
8 frontal 0 0 0 0 1 0
8 frontal 0 0 0 0 1 0




0 0 0 0 I 0
13 cerebellum 0 0 0 0 1 1
13 frontal 0 0 0 0 1 1
46 cerebellum 4 4 25 25 0 0
46 mid brain 0 0 19 19 0 0
17 cerebellum 0 0 7 6 3 3
17 parietal convex 0 0 0 0 1 0
18 temp hip 0 0 0 0 2 2
AIDS Cases with HIVE
35 cerebellum 0 0 0 0 1 0
35 mid brain 0 0 0 0 1 0
35 pc 0 0 0 0 1 0
AIDS Cases with pleomorphic infiltrates
24 cerebellum 2 2 0 0 1 0
24 occipital 0 0 14 14 0 0
25 basal ganglia 0 0 1 1 1 1
26 cerebellum 2 2 1 1 0 0
26 mid brain 0 0 56 56 1 1
26 temporal
hippocampus
2 2 17 17 0 0
AIDS cases with PCNSL
36 mid brain Lymphoma Lymphoma 0 0 0 0
38 medulla Lymphoma Lymphoma 0 0 0 0
38 frontal Lymphoma Lymphoma 0 0 0 0




0 0 0 0 0
39 basal ganglia 2 2 0 0 1 0





0 0 0 0
40 frontal Lymphoma Lymphoma 0 0 0 0
41 cerebellum Lymphoma Lymphoma 0 0 0 0
41 medulla Lymphoma Lymphoma 0 0 1 1
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In sections from AIDS cases with no CNS pathology no CD20 cells
were found in either the parenchyma or the perivascular spaces. Three cells
were found in blood vessels, none ofwhich showed positive staining for
CD23.
Six parenchymal CD20 positive cells were examined from AIDS cases
with pleomorphic infiltrates, with all 6 showing a CD23 phenotype. A total of
89 perivascular CD20 cells were assessed in this group, and again all cells
showed positive staining for CD23 (see figure 22e and f). Only three
intravascular cells were studied, none ofwhich stained for CD23.
The final group of cases included sections from AIDS cases with
PCNSL. Nine sections containing tumours were assessed from 5 different
cases. Seven of these showed strong CD23 staining throughout the tumour, a
representative picture of these seven sections is shown in figure 22g-j. Of the
other two sections with lymphoma cells, the basal ganglia of case 40 showed
only a minority of tumour cells expressing CD23, while the mid brain of case
39 had 5 parenchymal CD20 positive cells in the mid brain none ofwhich
stained for CD23. Given the rarity ofCD20 cells in PCNSL brains outside the
area of lymphoma, these 5 cells probably represent the very edge of a
lymphomatous region. In addition case39 also had 2 parenchymal cells in the
basal ganglia, both ofwhich showed a CD23 phenotype. No perivascular
CD20 positive cells were found outwith the areas of lymphoma in any of the
cases in this group. Two cells were located in blood vessels, one ofwhich
displayed a CD23 positive phenotype.
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Figure 22: Sections from normal brain stained
for CD20 then stripped of antibody
and re-stained for CD23
25jj.ni
22a




Section from figure 22a striped of
antibody and re-stained for
CD23 (brown staining). Red box




Case 1 (Normal) Temporal Section from figure 22c striped of
Hippocampus. CD20 (purple staining) antibody and re-stained for
CD23 (brown staining). Red box
identifies the same cell in each
photograph.
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Figure 22 (continued): Sections stained for CD20 then






Case 25 (AIDS Infiltrate Case) Section from figure 22e striped of
CD20 (purple staining) antibody and re-stained for
CD23 (brown staining).
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Figure 22 (continued): AIDS PCNSL sections stained
for CD20 then stripped of
antibody and re-stained for CD23
25pm
22g




Section from figure 22a striped of








Section from figure 22a striped of
antibody and re-stained for
CD23 (brown staining).
A summary of the results from table 24 is shown in table 25. From the
17 parenchymal CD20 positive cells examined, from all cases, sixteen cells
showed expression of the CD23 activation marker (94%). Of the 141
perivascular CD20 cells assessed, 139 showed a CD23 phenotype (99%). By
contrast the intravascular cells assessed showed a much lower level of CD23
expression, with 17 out of 35 cells expressing both CD20 and CD23 (49%). It
should be noted that although on average 49% of CD20 positive intravascular
cells also expressed CD23, there was a wide variation between the different
groups. The pre-AIDS cases showed quite a high level of CD23 expression,
with 7 out of 9 cells (78%) displaying a double CD20/CD23 phenotype. In
addition, 50% of the intravascular CD20 positive cells from the non-HIV
group expressed detectable CD23, while only one of eight CD20 cells from all
the AIDS cases together showed a CD23 positive phenotype (12.5%).
The this data suggests that in order for CD20 cells to enter the
perivascular and parenchymal spaces of the brain they must display an
activated CD23 phenotype, alternatively it is conceivable that all CD20
positive cells entering the brain are activated on entering the CNS rather than
before entry.
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Table 25: Summary of data from table 24













































Non-HIV 5 4 80% 1 0 0% 18 9 50%
Pre-AIDS 4 4 100% 51 50 98% 9 7 78%
AIDS HIVE 0 0 NA 0 0 0 3 0 0%

























94% 141 139 99% 35 17 49%
Of the nine areas of lymphoma, 8 had large areas of lymphoma (>100 cells), in 7 of which the CD20 cells
showed -100% CD23 expression, and one showed only a minority of cells CD23 +ve. The section which was
negative had only 5 CD20 cells present.
NA Not applicable
3.3 Determination ofEBV infection status of B lymphocytes in brain
The aim of these experiments was firstly to ascertain if B lymphocytes
present in human brain tissue were infected with EBV, and secondly to assess
the EBV viral load in brains from different patient groups. Samples consisted
of 5pm and 20pm thick FFPE sections, frozen tissue samples and CSF
samples taken at autopsy. FFPE sections were available from all of the cases
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listed in section 2.1.1 table 5, frozen tissue and CSF samples was available for
a limited number ofHIV cases and from additional non-HIV cases not
included in Section 1 (see section 2.1.1 table 6).
DNA extracted from FFPE sections was first screened using BamW
PCR to detect any EBV DNA present in sections; in-situ hybridisation for
EBERs was then used to localise EBV infected cells in sections positive for
EBV by PCR. Semi-quantitative BamW PCR was then used on DNA
extracted from frozen tissue samples and CSF to assess the viral load in brains.
3.3.1.1 BamW PCR on DNA extracted from FFPE sections
DNA was extracted from FFPE sections as described in 2.2.3.1 page
74. In order to verify that PCR amplifiable DNA had been extracted from
samples, a P-globin PCR was performed. Samples positive for p-globin were
then used in the Bam W PCR. Representative gel photographs of p-globin
PCR are shown in Figure 23 (showing 7 out of 16 samples were positive).
Most samples had to be tested at least twice in order to obtain a positive result
(gel photographs not shown). Eventually positive signals were obtained from
twenty samples. Control DNA extracted from B lymphocyte cell lines
Namalwa and BJAB were used for the PCR. Samples that were PCR positive
for p-globin were subsequently tested for EBV using BamW PCR, see Figure
24 for representative autoradiographs ofBamW PCR. Controls for this PCR
consisted of an EBV infected Burkits lymphoma cell line (Namalwa) and an
EBV negative B lymphocyte cell line (BJAB). Table 26 summarises the
results.
EBV DNA was not detected in any of the samples tested, including six
sections taken from HIV positive PCNSL brains.
The control, EBV positive, Namalwa dilution series (see 2.1.6.3 page
67) showed that approximately 102 — 103 EBV positive cells were required for
a consistently detectable positive result. Therefore given the low number ofB
lymphocytes present in the sections tested, even in the lymphoma sections, it




Sample Number Case Number Group
(brain region)
l 36 Mid brain AIDS PCNSL
2 24 Cerebellum AIDS HIVE
3 40 Frontal 2 AIDS PCNSL
4 38 Basal Ganglia AIDS PCNSL
5 17 Parietal parasagittal Pre-AIDS
6 44 thalamus Non-HIV Viral
Encephalitis
7 46 Cerebellum Pre-AIDS
8 2 Basal Ganglia Normal
9 25 Cerebellum AIDS Infiltrate
10 41 Cerebellum AIDS PCNSL
11 26 Parietal parasaggital ATDS Infiltrate
12 13 Central White Matter Pre-AIDS
13 41 Medulla AIDS PCNSL
14 43 Temporal Non-HIV Viral
Hippocampus Encephalitis
15 40 Frontal 1 AIDS PCNSL
16 45 Cerebellum Non-HIV Viral
Encephalitis
Summary of all data from this set of experiments is given in table 26.
Key for figure 23:
BJ - BJAB (EBV -ve lymphoma cell line)
H20 - Water (PCR control)
N - Namalwa (EBV +ve Burkitt's lymphoma cell line)
Figure 23: B-Globin PCR on DNA extracted from
Formalin Fixed Paraffin Embedded sections
Samples









Sample Number Case Number Group
(brain region)
l 36 Mid brain AIDS PCNSL
2 24 Cerebellum AIDS HIVE
3 40 Frontal 2 AIDS PCNSL
4 38 Basal Ganglia AIDS PCNSL
5 17 Parietal parasagittal Pre-AIDS
6 44 thalamus Non-HIV Viral
Encephalitis
7 46 Cerebellum Pre-AIDS
8 2 Basal Ganglia Normal
9 25 Cerebellum AIDS Infiltrate
10 41 Cerebellum AIDS PCNSL
11 26 Parietal parasaggital AIDS Infiltrate
12 13 Central White Matter Pre-AIDS
13 41 Medulla AIDS PCNSL
14 43 Temporal Non-HIV Viral
Hippocampus Encephalitis
15 40 Frontal 1 AIDS PCNSL
16 45 Cerebellum Non-HIV Viral
Encephalitis
Summary of all data from this set of experiments is given in table 26.
Key for figure 24:
BJ - BJAB (EBV -ve lymphoma cell line)
H20 - Water (PCR control)
N - Namalwa (EBV +ve Burkitt's lymphoma cell line)
Figure 24:









13 14 15 16 N BJ H20
298bp
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The problems in obtaining DNA from FFPE sections suitable for PCR
are well documented (Bramwell & Bums 1988). Due to the long fixation
periods required for whole brains this type of tissue is likely to suffer greatly
from the effects of formalin DNA degradation which may partially explain the
weak |3-globin bands obtained.
Table 26: Bam W PCR on DNA from FFPE sections






36 Mid brain -
41 Brain stem -






24 Basal ganglia -
25 Cerebellum -
26 Parietal parasagital -
Pre-AIDS
46 Cerebellum -
13 Central white matter -
17 Parietal parasagital -








Normal 2 Basal ganglia -
3.3.2 EBERs in-situ hybridisation
Due to the failure of the Bam W PCR to detect any EBV DNA in DNA
extracted from FFPE sections it was decided to screen sections from all case
types by in-situ hybridisation for EBV. Dako EBER PNA probe and detection
kit (see section 2.2.2 page 73) was used to detect EBV infection of cells in
FFPE sections. Sections shown to contain the highest numbers of B
lymphocytes per section by CD20 immunohistochemical staining were
selected for EBERs in-situ hybridisation staining, in order to maximise the
number of B lymphocytes assessed for EBV infection. Controls for this
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experiment included DAKO PNA positive and negative controls to show that
the detection kit was working, and FFPE sections from a SCID mouse grown
B lymphoblastoid cell line derived tumour previously shown to be EBV
positive. The results are summarised in table 27 and a full list of sections
stained and results are given in table CI appendix C.














AIDS infiltrate 22 0
All sections tested
had large infiltrates,
all of which had
been shown to have















All 13 sections from lymphoma cases which contained neoplastic cells
showed positive staining for EBERs (see figure 25). Approximately 90-100%
of lymphoma cells in these sections stained strongly for EBERs. In addition to
sections containing lymphoma tissue, 2 cases included sections with no
lymphoma cells present, as defined by CD20 immunohistochemistry and
assessment of haematoxylin and eosin sections. Case 38 included 2 sections
with no lymphoma cells present. Only 2 sections were available from case 39
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Results from these experiments are summarised in table 27.
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Twenty two sections from 5 different AIDS cases with pleomorphic
infiltrates were tested and all proved negative for EBERs, although CD20
immunohistochemical staining had shown consecutive sections to those used
for EBERs staining to contain high numbers ofB lymphocytes (see section
3.1).
Eleven sections from 3 pre-AIDS cases with mild lymphocytic
meningitis were tested and all sections were EBERs negative.
Three groups ofnon-HIV cases were also tested: normal (3 cases, 14
sections), drug users (3 cases, 9 sections), and non-HIV viral encephalitis (3
cases, 10 sections). None of the sections stained in these three groups were
positive for EBERs.
3.3.3 EBV Semi-quantitative Bam W PCR on DNA extracted from
frozen tissue and CSF samples
A semi quantitative PCR (Bam HI W) was used to determine EBV
copy number in samples from frozen tissue and CSF samples. DNA was
extracted from samples as described in 2.2.3.1. In order to verify that PCR
amplifiable DNA had been extracted from samples, a p-globin PCR was
performed. Samples positive for p-globin were then used in the Bam W PCR.
An EBV positive Burkitt's lymphoma cell line (Namalwa) was used as a
positive control and an EBV negative B lymphocyte cell line (BJAB) was used
as a negative control. A series ofNamalwa cells diluted in BJAB cells was
used to allow a semi-quantitative assessment of viral load (see section 2.1.6.3).
Figure 26 shows representative gel photographs from p-globin PCR on
both frozen samples and CSF samples, all 16 frozen tissue samples were p-
globin positive and 15 out of 19 CSF samples were p-globin positive. All 16
frozen samples and CSF samples from 8 cases were subsequently tested for
EBV. The CSF samples which were p-globin negative were also tested in
order to make certain any cell free EBV present in these samples was not
ignored. Figure 27 shows representative autoradiographs ofBamW PCR.
134
Figure 26a Legend:
Sample Case Number Group
Number (brain region)
1 42 Frontal AIDS PCNSL
2 42 Cerebellum AIDS PCNSL
3 42 Basal ganglia AIDS PCNSL
4 42 CSF 1 AIDS PCNSL
5 42 CSF 2 AIDS PCNSL
6 42 CSF 3 AIDS PCNSL
7 42 CSF 4 AIDS PCNSL
8 39 CSF (pellet) AIDS PCNSL
9 39 CSF (fluid) AIDS PCNSL
10 46 CSF (fluid) Pre-AIDS
11 22 CSF (pellet) AIDS
12 22 CSF (fluid) AIDS
13 25 CSF (pellet) AIDS Infiltrate
14 25 CSF (fluid) AIDS Infiltrate
15 20 CSF (pellet) AIDS
16 20 CSF (fluid) AIDS
17 40 CSF (pellet) AIDS PCNSL
18 40 CSF (fluid) AIDS PCNSL
19 23 CSF (pellet) AIDS
20 23 CSF (fluid) AIDS
Key:
H20 - water (-ve control)
BJ - BJAB (+ve control)
Figure 26a: B-Globin PCR on DNA extracted from frozen
tissue samples and frozen CSF
1 2 3 4 5 6 7 H20
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Figure 26b Legend:
Sample Case Number Group
Number (brain region)
1 39 Parietal AIDS PCNSL
2 46 Cerebellum Pre-AIDS
3 46 Basal Ganglia Pre-AIDS
4 22 Parietal AIDS
5 25 Occipital AIDS Infiltrate
6 26 Cerebellum AIDS Infiltrate
7 26 Brain stem AIDS Infiltrate
8 20 Parietal AIDS
9 40 Frontal AIDS PCNSL
10 41 Cerebellum AIDS PCNSL
11 41 Brain stem AIDS PCNSL
12 21 Parietal AIDS
13 52 Frontal Normal
14 39CSF AIDS PCNSL
15 46 CSF Pre-AIDS
16 22CSF AIDS
17 25 CSF AIDS Infiltrate
18 40 CSF AIDS PCNSL
19 20 CSF AIDS
20 41 CSF AIDS PCNSL
Key: H20 - water (-ve control)
NM - Namalwa (+ve control)
PB - PBMC (+ve contol)
See table 28 for a summary of data.
Figure 26b: B-Globin PCR on DNA extracted from frozen
tissue samples and frozen CSF




Key: H20 - water (-ve control)
NM - Namalwa (+ve control)
PB - PBMC (+ve contol)
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i 42 Frontal AIDS PCNSL
2 42 Cerebellum AIDS PCNSL
3 42 Basal Ganglia AIDS PCNSL
4 42 CSF 1 AIDS PCNSL
5 42 CSF 2 AIDS PCNSL
6 42 CSF 3 AIDS PCNSL
7 42 CSF 4 AIDS PCNSL
8 39 CSF (pellet) AIDS PCNSL
9 39CSF (fluid) AIDS PCNSL
10 46 CSF (fluid) AIDS PCNSL
11 22 CSF (pellet) AIDS
12 22CSF (fluid) AIDS
13 25 CSF (pellet) AIDS Infiltrate
14 25 CSF (fluid) AIDS Infiltrate
15 20 CSF (pellet) AIDS
16 20CSF (fluid) AIDS
17 40 CSF (pellet) AIDS PCNSL
18 40 CSF (fluid) AIDS PCNSL
19 23 CSF (pellet) AIDS
20 23 CSF (fluid) AIDS
21 39 Parietal AIDS PCNSL
22 46 Cerebellum Pre-AIDS
23 46 Basal Ganglia Pre-AIDS
24 22 Parietal AIDS
25 25 Occipital AIDS Infiltrate
26 26 Cerebellum AIDS Infiltrate
27 26 Brain stem AIDS Infiltrate
28 20 Parietal AIDS
29 40 Frontal AIDS PCNSL
30 41 Cerebellum AIDS PCNSL
31 41 Brain stem AIDS PCNSL
32 21 Parietal AIDS
33 52 Frontal Normal
34 39 CSF AIDS PCNSL
35 46 CSF Pre-AIDS
36 22 CSF AIDS
37 25 CSF AIDS Infiltrate
38 40 CSF AIDS PCNSL
39 20CSF AIDS
40 41 CSF AIDS PCNSL
Summary of data from figure 27 is given in table 28.
Figure 27: BamW PCR on DNA extracted from
frozen tissue and CSF samples
SAMPLES
1 2 3 4 5 6 7 8 9 10 11 12 13 BJH20
SAMPLES
i




34 35 36 37 38 39 40
Figure legend over page
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The Bam W PCR consistently detected between 103 and 102 EBV positive
Namalwa cells in a background of 106 EBV negative BJAB cells. On two
occasions, however, the BamW PCR detected 1 EBV positive cell in a
background of 106 EBV negative cells (see Figure 28). Densitometry readings
were taken from positive samples and from the Namalwa dilution series, and
the dilution series data used to plot densitometry curves (see figure 29), the
curves were then used to make semi quantitative assessment of the number of
EBV genomes per sample.
Bam W PCR was repeated twice on all samples and an average of the
two results calculated. In samples that were only positive in 1 reaction, only
the results from the positive reaction are given. The results are summarised in
Table 28.
No EBV DNA was detected in either of the normal frozen brains or in
any of the 5 normal CSF samples. Likewise, no EBV was detected in any of
the 3 pre-AIDS brains or in the 1 CSF sample in this group.
4 CSF samples and 7 frozen tissue samples were tested from the AIDS
group with no CNS pathology (see table 28). 2 CSF samples were negative, 1
showed very low levels ofEBV (2 copies/pg ofDNA), and 1 demonstrated an
intermediate level ofpositivity (12600 copies/pg ofDNA). The case which
showed higher levels ofEBV, case 23, had evidence of a systemic lymphoma
at autopsy but no evidence ofCNS involvement. 6 of the 7 frozen samples
were negative, and 1 sample very weakly positive (1 copy/pg of DNA).
3 frozen samples were tested from 1 case with HIVE, all ofwhich were
negative.
The AIDS group with pleomorphic infiltrates had 2 CSF samples and 8
frozen tissue samples available. Both CSFs showed intermediate levels of
EBV (6300 and 12600 copies/pg ofDNA). 6 of the 8 frozen samples were
negative and 2 weakly positive (110 and 160 copies/pg ofDNA).
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Figure 28: BamW PCR Namalwa dilution series
106 105 104 103 102 101 10° Number of
Namalwa
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Figure 29: Densitometry readings from control Namalwa
























0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0
(log) number of Namalwa cells
Graph plotted using densitometry readings taken from Namalwa dilution series
Key:
Indicates densitometry reading of samples
Details of each sample are given in the legend for Figure 27












EBV / |ig DNA
47 NORMAL CSF - - 0
48 NORMAL CSF - - 0
49 NORMAL CSF - - 0
50 NORMAL CSF - - 0
51 NORMAL CSF - - 0
52 NORMAL
BRAIN - - 0
BRAIN - - 0
53 NORMAL BRAIN - - 0
54 NORMAL BRAIN - - 0
15 PRE-AIDS BRAIN - - 0
17 PRE-AIDS
CEREBELLUM - - 0
FRONTAL - - 0




CSF - - 0
BASAL GANGLIA - - 0




CSF - + 2






CSF - - 0









CSF - - 0




FRONTAL + - 1
CEREBELLUM - - 0
TEMPORAL - - 0
PARIETAL - - 0
32 HIVE DRUG USER
CEREBELLUM - - 0
OCCIPITAL - - 0




CSF + + 6300
CSF 2 (BLOOD) - + 12600
CEREBELLUM - - 0
OCCIPITAL + + 110




OCCIPITAL - - 0
CEREBELLUM - - 0
PARIETAL - - 0
FRONTAL - - 0
BRAIN STEM + + 160
37 PCNSL CSF + + 283
40 PCNSL
CSF + + >I06
FRONTAL + + 7.9X105
BASAL GANGLIA + + >106
41 PCNSL
CEREBELLUM + - 7.9X105
BRAIN STEM - - 0
42 PCNSL
CSF + + 40000
FRONTAL + + 140000
BASAL GANGLIA + + >106








4 CSF samples and 8 frozen tissue samples were tested from the AIDS group
with PCNSL. All 4 CSF samples were positive; 2 low level (283 and 1300
copies/pg ofDNA) and two at higher levels (40000 and 106 copies/p.g of
DNA). 6 of the 8 frozen tissue samples showed high levels ofpositivity
(between 20000 and 106 copies/jag ofDNA), all 6 were from areas containing
tumour. 2 samples were negative, both ofwhich were from areas devoid of
tumour.
In summary, BamW PCR failed to detect EBV in any of the normal,
pre-AIDS, or HIVE cases assessed. All samples from AIDS cases with no
CNS pathology were negative or very low level positive (1-2 copies/pg of
DNA) with the exception of case 23 which showed higher levels. However
this case had a potential confounding factor with the presence of a systemic
lymphoma, and may not be representative of the rest of the group. The AIDS
infiltrate group showed evidence ofEBV in the CSF and in 2 of 8 brain tissue
samples. However the areas of the brain showing positivity were not the areas
containing the greatest numbers ofB lymphocytes. Finally, in the AIDS group
with PCNSL all CSF samples showed some PCR positivity, and all tissue
samples from tumour areas contained high EBV copy numbers, while areas
without tumour were negative. This suggests that within the brain EBV
presence is restricted to infected B lymphocytes (lymphoma cells) and is not
present as free virus throughout the brain.
3.3.4 EBV protein expression
Sections with high numbers ofB lymphocytes or sections which were
previously shown to be EBERs positive were assessed for the expression of
two EBV latent proteins; EBNA-2 (Epstein Barr nuclear antigen 2) and LMP-
1 (latent membrane protein 1). This allowed the latency state of virus in
different cases to be assessed.
FFPE sections from five lymphoma cases and three AIDS infiltrate
cases were assessed. Table 29 shows the results for both LMP-1 and EBNA-2
staining. In all sections assessed from lymphoma cases, which contained
tumour cells, some positivity was found for both EBNA-2 and LMP-1. The
number of cells staining positive for LMP-1 in each section varied greatly
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between cases. Figure 30a and 30b shows sections from cases 42 (a) and 38
(b) in which only a few lymphoma cells stained for LMP-1. By contrast
sections from cases 36 (figure 30c) and 40 (figure 30d) showed approximately
half of the lymphoma cells stained for LMP-1. EBNA-2 staining was more
consistent between cases, with all cases showing a high level ofpositivity and
the majority of tumour cells staining positive (see figure 30e-h).
Sections from the AIDS infiltrate group showed no staining with either
antibody, consistent with the negative in situ EBERs findings (3.3.2). The
results from the lymphoma cases studied suggest a latency III phenotype for
EBV in all of these lymphomas.
In summary, all PCNSL cases studied which had sections containing
tumour cells, were EBERs positive. All showed strong EBNA-2 staining and
variable LMP-1 staining, suggesting a latency III viral phenotype. Three of
these cases had frozen tissue available which showed high levels ofEBV
DNA in tumour areas. Four cases had frozen CSF's available, all four of
which showed evidence ofEBV DNA. In addition one case with a systemic
lymphoma but no CNS pathology had evidence ofEBV DNA in the CSF. No
EBERs staining was found in any other group, or in the AIDS lymphoma
group outwith the areas of lymphoma. However, both of the AIDS infiltrate
cases for which there was frozen tissue available showed evidence of low level
EBV DNA in one area of the brain. In one case CSF was available, which
also showed evidence of EBV DNA.
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Figure 30: EBNA-2 and LMP-1
immunohistochemistry staining on
AIDS PCNSL cases
A Case 42 Cerebellum B Case 37 Cerebellum
LMP-1 staining (brown) LMP-1 staining (brown)
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Results of these experiments are summarised in table 29.
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Figure 30 continued: EBNA-2 and LMP-1
immunohistochemistry staining
on AIDS PCNSL cases
E Case 42 Cerebellum F Case 38 Cerebellum
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Results from these experiments are summarised in table 29.
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Basal ganglia +++ +
42
Lymphoma













Temporal hippocampus - -
Key: - negative, + Only a few cells positive, ++ approximately half the cells positive,
+++ majority of cells positive.
3.4 Clonality of B lymphocytes in tumours and pleomorphic infiltrates
in AIDS brains
Large numbers ofB lymphocytes have been shown to be present not
only in PCNSL brains (within tumours) but also in AIDS brains with
pleomorphic lymphocytic infiltrates. We had considered the possibility that
these pleomorphic lymphocytic infiltrates might represent a pre-malignant
lesion, and therefore to provide more data on potential mechanisms of
pathogenesis of both groups, the clonality of the B lymphocytes present in the
lesions was assessed.
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Three methods were used to assess the clonality of large accumulations
of B lymphocytes in the brain:
1- In-situ hybridisation using probes for kappa and lamda light Ig chains
2- PCR amplification of the frame work (FR) 3 region of Ig heavy chain
genes (IgH)
3- PCR amplification of the FR1 region of IgH genes.
3.4.1 kappa and lamda Ig light chain in-situ hybridisation
Dako PNA probe and detection kit were used in accordance with the
manufacturer's instructions. Positive control material was FFPE tonsil
sections which had been previously shown to contain large numbers ofCD20
positive B lymphocytes. Despite numerous attempts, no staining was achieved
on positive control sections using the manufacturers' reaction conditions.
Conditions were then altered, increasing and decreasing the hybridisation
temperature of the probe; again this failed to produce a positive result. The
stringency of the probe washing was then altered, however this led to
background staining but no specific staining. Finally the temperature at which
sections were incubated in proteinase K was altered, but again no staining was
produced. It was concluded that this technique was unsuitable for the
material being tested and therefore the technique was abandoned and
alternative methods of determining B lymphocyte clonality were pursued. It
has since become apparent that a fault in the production of the proteinase K
used in the DAKO PNA detection kit may have been responsible, and the kit
has now been recalled by the manufacturer.
3.4.2 PCR amplification of the FR3 region of Ig heavy chain genes
This technique involved PCR amplification of the FR3 region of the Ig
heavy chain genes, which is re-arranged during B lymphocyte development.
PCR amplification yields a product of approximately lOObp from DNA
derived from cells with re-arranged Ig genes. In cells which do not have re¬
arranged Ig genes the primer binding points are too far apart for PCR
amplification and no product is produced. The experimental technique, PCR
reaction conditions and primer sequences have been previously published
(Trainor et al 1990, Trainor et al 1991, Steward et al 1994) but the technique
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has not been used before in our laboratory. Therefore, using the published
conditions as a starting point, the PCR was optimised for use. DNA was
extracted from 3 B lymphoma cell lines, 2 T lymphocyte cell lines, a
monocyte cell line and PBMCs from 4 healthy donors, for use as control
DNA. The B lymphoma lines chosen represent monoclonal B lymphocyte
populations, while PBMCs should have polyclonal populations present. T
lymphocyte and monocyte lines acted as negative controls, as normally only B
lymphocytes have re-arranged Ig genes.
3.4.2.1 Optimisation of FR3 PCR
The PCR reaction conditions were optimised using a Burkitt's
lymphoma cell line (Akata). Altering one variable at a time, concentrations of
the following components were optimised: MgCh, primers, dNTP, Taq
polymerase, as well as annealing temperature of primers and quantity ofDNA
used per reaction.
3.4.2.1.1 MgCh concentration
2"b •The enzyme Taq polymerase used for PCR is dependant on Mg ions
for its activity and therefore the concentration ofMgCl2 in the reaction
2+mixture is critical. High concentrations ofMg inhibit enzyme activity, while
too low concentrations result in a poor yield of PCR product (Linz 1990).
MgCl2 was vaired as follows: 1.5pi, 3pl, 4.5pl, 6pl of25mM MgC^. The best
results were achieved using 4.5pl of25mM MgCf.
3.4.2.1.2 Primer concentration
An excess ofPCR primer is required for efficient PCR amplification,
however, a large excess can lead to amplification of non-target sequences,
while too low concentrations will inhibit efficient PCR amplification. Primer
concentrations were tested as follows: 25 pmol, 50 pmol, 75 pmol, 100 pmol
per reaction. Optimum results were achieved using 50pmol/ reaction (50pl).
3.4.2.1.3 dNTP concentration
An excess of dNTPs is required for efficient PCR amplification,
although a large excess can inhibit the reaction, and too low a concentration
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leads to poor yields. dNTP concentrations were tested as follows: 0.25pl,
0.5pl, 0.75(0,1, IjlxI of 20mM dNTP per reaction. Optimum results were
achieved using 0.75pi of 20mM dNTP.
3.4.2.1.4 Taq polymerase concentration
The concentration ofTaq polymerase is important for the PCR reaction
as a low concentration leads to poor yield of product, while high
concentrations can lead to amplification of non-target sequences. Taq
concentrations were tested as follows: 1.25, 2.5, 3.75, 5 units per reaction.
Optimum results were achieved using 2.5 units per reaction.
3.4.2.1.5 Annealing temperature of primers
The annealing temperature of the primers controls the efficiency of
primer annealment to target sequences. Too high a temperature inhibits
annealment, while a temperature which is too low can lead to primers binding
to non-target sequences. Annealing temperatures were assessed using a
robocycler (Stratagene) at temperatures of 59°C, 57°C, 55°C, 53°C, 51°C,
with all other variables used at the optimum obtained above. 55°C produced
the best results.
3.4.2.1.6 Quantity ofDNA per reaction
The amount of template DNA used in a reaction is important to obtain
a good yield ofPCR product, however it is also important to optimise the
quantity ofDNA required so that precious resources of DNA from samples are
not wasted. The following DNA amounts per reaction were assessed: 0.01 pg,
0.1 pg, 0.5pg, lpg, 1.5pg, 2pg. The optimal DNA concentration was lpg of
DNA per reaction.
3.4.2.2 FR3 PCR on DNA extracted from control cells
Having optimised the FR3 PCR reaction conditions, the PCR was
tested on 3 control B lymphoma cell lines (Akata, Raji, P3HR1), 2 control T
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lymphocyte cell lines (Hut 78, MOLT 4), 1 control monocyte cell line (U937),
and PBMC samples taken from 4 healthy donors. A representative gel
photograph is shown in figure 31. All 3 B lymphoma cell lines are
monoclonal, as expected. Both T lymphocyte cell lines also showed
monoclonal bands, which was unexpected since normally only B lymphocytes
re-arrange Ig genes. There are 2 possible explanations for finding T cell lines
with re-arranged IgH genes. It is possible that the cell lines had been
contaminated with B lymphocytes. Alternatively, there is evidence in the
literature (Davey et al 1986, Szczepanski et al 1999) which suggests that some
T cell leukaemias can re-arrange their Ig genes as well as their T cell receptor
genes. We attempted to rule out contamination with B lymphocytes using
immunocytochemistry with anti-CD3 and anti-CD 19 antibody on cell
cytospins from the T lymphocyte lines. Although both cell lines were CD3
positive (T lymphocyte marker), CD19 negative (B lymphocyte marker), the
low number of cells tested means we cannot rule out low level contamination
of the T cell line.
The monocyte cell line produced no band, indicating there were no
cells present with re-arranged Ig genes. All 4 PBMC samples gave single
bands indicating monoclonal populations ofB lymphocytes were present in
each. This result was unexpected as the samples were taken from healthy
donors who are unlikely to have a single large monoclonal population ofB
lymphocytes in their blood. PBMCs would be expected to show either
multiple bands or a smear ofbands; indicating the presence ofmultiple clones.
The products produced by this PCR for different clones vary by as
little as 1 base pair. This may explain the appearance of an apparently
monoclonal band in the PBMC samples, and therefore we sought to ensure
that the gel resolution being used was high enough to distinguish between such
a small difference. An FR3 PCR was carried out on DNA from Akata and
P3HR1 cell lines mixed in a 50:50 ratio. Again only one band appeared,
suggesting that the gel resolution was too low to distinguish between bands of
similar sizes (approximately lOObp). In order to improve the resolution the
experiment was repeated and the PCR products run on 5% and 8% nu-sieve
agarose gels and 6 % polyacrylamide gel instead of 3% agarose. Neither of
these gels allowed resolution of the products.
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Figure 31: FR3 PCR optimised conditions








This technique was abandoned at this stage for 2 reasons. Firstly, the PCR
was unable to differentiate two clonal cell lines. Secondly, all the bands
produced seemed to be an identical size with no variation, suggesting that
either the PCR could only detect re-arranged Ig genes and not differentiate
between different clones, or that it was amplifying the wrong sequence. This
technique has been previously used by Trainor et al 1990, and 1991, Steward
et al 1994 who were able to demonstrate resolution of similarly sized bands.
3.4.3 PCR amplification of the FR1 region of Ig heavy chain genes
FR1 PCR requires six PCR reactions per sample, one to detect re¬
arrangement of the germ line DNA for each of the variable heavy chain Ig
family genes (VH1,2,3,4,5 and 6). The primers are designed to bind to
conserved regions within in each of the six families. As with the FR3 PCR,
non re-arranged Ig genes are not amplified as the primer binding sites are too
far apart for PCR amplification.
Control material used was DNA extracted from 7 different samples of
PBMCs from healthy donors and the clonal B cell lines Akata, Raji, P3HR1,
the T cell lines Molt 4 and HUT 78, and a monocyte line U937. All 7 PBMC
samples gave positive reactions in at least 3 different FR1 PCRs,
demonstrating their polyclonality. Akata was positive only in VH1 PCR, Raji
only in VH3 PCR and P3HR1 only in VH4 PCR, showing the monoclonality
of these cell lines. Figure 32 shows the sensitivity of the PCR (Akata dilution
series). 102-l 03 cells were required to obtain a positive PCR reaction,
therefore only relatively large clonal population will be detected by this
method. Neither Molt 4, HUT 78, or U937 gave bands in any of the VH PCR
reactions. None of the control samples showed positivity for VH5 or VH6
PCR, however given the low usage of these families by normal human B
lymphocytes, and the fact that the same PCR reaction conditions and primers
had been shown to work by Inghirami et al (1993), it was decided to proceed
with testing samples using this technique.
Test DNA was extracted from frozen brain tissue and frozen CSF
samples as described in 2.2.3.1. PCR was performed on those cases from
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Figure 32: FR1 PCR (VH1)
Akata dilution series
Number of Akata cells diluted in 106 U937 cells




U U937 (monocyte cell line)
H20 Water (control)
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which frozen tissue was available and which had previously been shown to
contain large accumulations ofB lymphocytes in the brain.
Figure 33 shows representative gel pictures from PCR for VH1,2,3,4,5
and 6. Where sufficient material was available, the 6 PCRs were repeated
three times. The results are summarised in table 30. In two of the three
PCNSL cases tested (41 and 42) only one variable immunoglobulin heavy
(IgH) chain family gene re-arrangement was detected, both VH3. In case 41
both brain areas tested showed weak positivity for VH3 in one out of two
PCRs, suggesting that this tumour may represent a clonal population but that
the number of cells present was close to the limit of detection. In case 42 both
the cerebellum and basal ganglia showed evidence ofB lymphocytes with re¬
arranged VH3 family IgH genes, as did the CSF. In the frontal lobe of this
case, no re-arranged IgH chain genes were detected. The third lymphoma
case, case 40, showed positive reactions for germ line DNA re-arrangements
of all six variable IgH family genes in the frontal lobe. In the basal ganglia of
this case only re-arrangement ofVH1 family gene was detected, however this
was only detected on one of three tests. No clonal populations with re¬
arranged variable IgH family genes were detected in the CSF of this case.
This data suggests that there are accumulations of polyclonal B lymphocytes
in the frontal lobe in this case.
Two AIDS infdtrate cases were tested. Case 26 showed re¬
arrangements of all six variable IgH family genes in the cerebellum, re¬
arrangements ofVH1,3 and 5 in the occipital lobe, re-arrangements ofVH1,2
and 3 in one sample from the parietal lobe and re-arrangements ofVH1 and 3
in a second parietal lobe sample. This suggests that the B lymphocyte
accumulations seen throughout this brain were polyclonal. Case 25 showed
re-arrangements in VH1,3,4 and 5 in the occipital lobe. In the cerebellum only
one re-arrangement ofVH5 family genes was detected. No re-arrangements
were detected in the parietal lobe, while in the CSF VH1 and 3 re¬
arrangements were detected. This again suggests that the B lymphocyte
accumulations seen throughout this brain were polyclonal.
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Figure 33 a legend:











































28 Control Hut 78




Summary of results from these experiments is given in Table 30.
Figure 33a: VH1 PCR (FR1 region of
immunoglobulin heavy chain genes)
loobp 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ioobp 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Figure 33b legend:














8 41 (AIDS Cerebellum
9 Lymphoma) Brain stem
10 Cerebellum
11



















26 Control Hut 78
27 Control Molt 4
28 Control U937
Key: Yellow box indicates location ofpositive result in this gel.
Summary of results from these experiments is given in Table 30.
Figure 33b: VH2 PCR (FR1 region of
immunoglobulin heavy chain genes)


















































27 Control Hut 78
28 Control Molt 4
Summary of results from these experiments is given in Table 30.
Figure 33c: VH3 PCR (FR1 region of
immunoglobulin heavy chain genes)
Target sequence size ~300bp
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Figure 33d legend:










































27 Control Hut 78




Summary of results from these experiments is given in Table 30.
Figure 33d: VH4 PCR (FR1 region of
immunoglobulin heavy chain genes)
300bp



















































28 Control Hut 78
29 Control Molt 4
30 Control U937
31 Control h2o
Summary of results from these experiments is given in Table 30.
Figure 33e: VH5 PCR (FR1 region of
immunoglobulin heavy chain genes)
lOObp



























































28 Control Hut 78




Key: Yellow box indicates location ofpositive sample.
Summary of results from these experiments is given in Table 30.
Figure 33f: VH6 PCR (FR1 region of
immunoglobulin heavy chain genes)
123456789 10 1112 13 14 15
lOObp
































Cerebellum - - 2/3 - - -
Basal ganglia - - 2/3 - - -
Frontal - - - - - -




Frontal 1/3 3/3 1/3 2/3 2/3 2/3
Basal ganglia 1/3 - - - - -




Cerebellum - - 1/2 - - -
Brain stem - - 1/2 - - -
26
AIDS infiltrate
Cerebellum 2/3 1/3 3/3 1/3 1/3 2/3
Occipital 1/3 - 3/3 - 1/2 -
Parietal (1) 2/3 1/3 2/3 - - -
Parietal (2) 1/3 - 3/3 - - -
25
AIDS infiltrate
Occipital 2/3 - 3/3 1/3 1/3 -
Cerebellum - - - - 1/2 -
Parietal - - - - - -




Cerebellum - - - - - -
Basal ganglia - - 2/3 - - -
CSF* - - - 3/3 - -
* Sample only tested once due to limited supply of test material
One pre-AIDS case with viral encephalitis was tested. In this case no
re-arrangements were detected in the cerebellum, while re-arrangement of the
VH3 family genes was detected in the basal ganglia, and in the CSF re¬
arrangement of the VH4 family gene was detected. These data suggest that
two monoclonal populations are present in different locations in this case, it is
difficult to make conclusive assessments from the data as
immunohistochemistry showed that this case has relatively few B lymphocytes
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present and therefore smaller clones could potentially be on the limit of
detection by this test.
3.5 Expression of B lymphocyte chemoattractants in the brain
Several brains investigated in this study contained high levels of
infiltrating B lymphocytes. Although B lymphocytes were found scattered
randomly throughout the brain parenchyma, the majority of cells were located
in the perivascular regions surrounding blood vessels. A preliminary
investigation was set up to detect possible chemoattractants that may be
expressed in these particular brains and possibly play a role in attracting B
lymphocytes into the brain.
3.5.1 SDF-1 expression in brain
Normal functions of SDF-1 include controlling movement ofB
lymphocytes in lymphoid tissues and also regulating early B lymphocyte
movement in the bone marrow. A mutant version of SDF-1 has recently been
linked to an increased incidence ofNHL in AIDS patients (Rabkin et al 1999).
In the brain the chemokine can be produced by both astrocytes and neurones
(Bajetto et al 1999).
We therefore sought to determine if SDF-1 is over expressed in brains
with PCNSL and if it therefore plays a role in the pathogenesis ofAIDS
PCNSL. In order to determine if SDF-1 is over expressed in PCNSL we also
assessed the level of brain expression in other groups (group 1,3,4,5, and 8).
The antibody was optimised as described in 3.5.1.1 and then used to
assess SDF-1 protein expression in the brain. The antibody used here binds to
SDF-1 produced by both the wild type gene and mutant gene found in some
AIDS patients.
3.5.1.1 Optimisation of stromal cell derived factor-1 (SDF-1) antibody
Table 31 shows the antibody concentrations, pre-treatments and
immunohistochemical techniques used to find the optimal staining procedure
using this antibody. In order to allow better access for antibodies to antigens
affected by formalin cross linking the sections were subjected to 2 pre-
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treatments: microwaving in either EDTA or citric acid. Full details of
immunohistochemical methods are given in 2.2.1 page 67.


































Key: +++ strong staining, ++ moderate staining, + weak staining
An antibody concentration of 1/15 in combination with citric acid
microwave pre-treatment gave the best overall result, and was therefore used
for all sections stained in 3.5.2.2 below.
3.5.1.2 SDF-1 staining of brain sections
Cases with large numbers of B lymphocytes (PCNSL, AIDS infiltrate,
non-HIV viral encephalitis) were chosen for this experiment together with
AIDS brains with no CNS pathology and normal controls. In the cases with
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large numbers of lymphocytes, areas of the brain with and without B
lymphocytes were studied. AIDS cases with no CNS pathology were included
to allow an assessment of the level of SDF-1 expression in AIDS compared to
normal controls.
Table 32 shows the sections stained for SDF-1. Representative
photomicrographs are shown in figure 34. In order to allow comparison of
different groups the staining was quantified using an Olympus BX40
microscope linked via Roper Scientific digital camera to a computer, utilising
image pro-plus software. Six individual, randomly selected, areas were
assessed per slide and the area of staining summed for each slide. Figure 35
(SDF-1 graph) shows a summary of the results from the groups assessed.
Sections from the normal group, non-HIV viral encephalitis group, and AIDS
with no CNS pathology group had minimal or no staining, and the staining
level shown in figure 35 for these groups is probably representative of the
level of background staining seen with this antibody (see figure 34 photos of
SDF-1). The AIDS infiltrate and AIDS lymphoma groups were divided into
those sections which contained large numbers of B lymphocytes and those
which contained none or very few lymphocytes. Both of these groups showed
high levels of SDF-1 in the sections containing B lymphocytes (see figure 34),
while the sections devoid of lymphocytes showed the base line level of
staining seen in the normal group. Only two sections from one pre-AIDS case
were assessed. This case had non-HIV encephalitis and contained occasional
blood vessels with small numbers ofB lymphocytes in the perivascular space.
Figure 35 shows that this case had an increased level of SDF-1 expression
over the base line level of the normal group, but a much lower level of
expression than either the AIDS infiltrate group or AIDS lymphoma group
(areas with B lymphocytes).
These data suggest an association between B cell accumulation in the
brain ofHIV patients and expression of SDF-1. Although the number of cases
studied was low there does appear to be a link between the amount of SDF-1
expressed locally in HIV brains and the accumulation of B lymphocytes in
these areas. Interestingly the non-HIV viral encephalitis group which
contained large numbers of both parenchymal and perivascular B lymphocytes
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showed no or little expression of SDF-1, suggesting other mechanisms are also
involved in the accumulation ofB cells in the brain.
Table 32: Sections stained for SDF-1
Case number Area of brain
Area of section stained































AIDS Infiltrate (sections with no or few B lymphocytes)
24 Basal ganglia 1.465












AIDS PCNSL (areas with no lymphoma)
36 Temporal hippocampus 23.775
Cerebellum 0
















Figure 34: Immunohistohemical staining
with SDF-1 antibody
34a: Control tonsil section
showing SDF-1 staining
25fj.ni
34b: SDF-1 protein localised
to the perivascular





34c: SDF-1 protein localised
to area of lymphoma in
an AIDS PCNSL brain
Data from these experiments are summarised in table 32.
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Figure 35: Graph of SDF-1 expression
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3.6 Expression of cytokines in the brain
This experiment was a preliminary study to assess cytokine gene
expression in different brains. The expression of different cytokines has an
influence on the type of immune response that develops. IL-4, IL-6 and IL-10
were chosen to be studied as these are all linked with a TH2 (humoral)
immune response. IL-2 is required for activation and proliferation ofT
lymphocytes and therefore its presence suggests a TH1 (cellular) immune
response. Finally, INFy is another TH1 derived cytokine which inhibits TH2
reponses and is known to upregulate expression ofMHC molecules. 10 frozen
brain samples from 8 different cases were assessed:
3 AIDS PCNSL cases (with tissue being taken from areas of
the brain known to contain lymphoma)
2 samples from 1 AIDS infiltrate case (case had large numbers
ofperivascular B lymphocytes)
2 AIDS cases with no CNS pathology (which had few or no B
lymphocytes)
2 normal brain which were assumed to have few B
lymphocytes.
RNAzol B was used to extract RNA from frozen tissue samples (full
procedural details for RNA extraction are given in 2.2.4.1 page 79). RNA was
then converted to cDNA using an Invitrogen superscript kit (see 2.2.4.2 page
79). A GapDH PCR was used to confirm the presence of amplifiable DNA in
samples. Samples were then analysed in separate experiments for the
expression of: IL-2, IL-4, IL-6, IL-10, INF y. Primer sequences and reaction
conditions for PCRs are described in 2.x.x. IL-10 primers had been previously
shown to bind only to human IL-10 and not EBV viral IL-10 transcripts
(Johannessen 1997). Positive control material was RNA extracted from PHA
stimulated PBMCs (see section 2.1.5), and a cDNA free reaction was included
with each run as a negative control with sterile water replacing the target
DNA. PCR products were run on agarose gels and then Southern blotted onto
nitrocellulose paper, which was then probed using cytokine specific probes
(see 2.2.4.4 for probe sequences, and hybridisation conditions). Probes were
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labelled and detected using DIG non-radioactive labelling and detection kits
(see 2.2.5.2).
Figure 36 shows representative gel images of GapDH PCR. All
samples assessed were PCR positive for GapDH.
Figure 37a shows representative probed gel blots for samples assessed
for IL-2 expression, figure 37b for IL-4, figure 37c for IL-6, figure 37d for IL-
10, and figure 37e for INFy. In each PCR reaction non-specific bands (bands
of incorrect size) appeared on the gel photographs, but these disappeared when
the gel blots were probed in all cases except INFy. The results are
summarised in table 33.
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Figure 36: Photomicrograph of GapDH PCR
products
123456789 10




2 50 Frontal Normal
3 41 Cerebellum AIDS PCNSL
4 51 Frontal Normal
5 42 Basal ganglia AIDS PCNSL
6 42 Cerebellum AIDS PCNSL
7 26 Frontal AIDS Infiltrate
8 26 Cerebellum AIDS Infiltrate
9 40 Frontal AIDS PCNSL
















7 AIDS no CNS 20 Parietal
8 pathology 21 Parietal








Data from these experiments are summarised in table 33.
Figure 37b legend:











6 42 Basal ganglia
7 AIDS no CNS 20 Parietal




Data from these experiments are summarised in table 33.
Figure 37: mRNA cytokine gene expression
(Probed Southern blots)
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Figure 37c legend: (see table 33 for summary of data from these experiments.
Sample
number











7 AIDS no CNS pathology 20 Parietal
8 21 Parietal








Figure 37d legend: (see table 33 for summary of data from these experiments.
Sample
number
Group Case Number Area of brain
1 Control h2o
2 Normal 53 Frontal
3 AIDS PCNSL 40 Frontal
4 AIDS PCNSL 41 Cerebellum
5 AIDS PCNSL 42 Cerebellum
6 AIDS PCNSL 42 Basal ganglia
7 AIDS Infiltrate 26 Frontal
8 AIDS Infiltrate 26 Cerebellum




13 AIDS no CNS pathology 21 Parietal
14 Normal 52 Frontal
Figure 37e legend: (see table 33 for summary of data from these experiments.
Sample
number
Group Case Number Area of brain













8 42 Basal ganglia








Figure 37 continued: mRNA cytokine gene expression
(Probed Southern blots)
37c: IL-6
1 2 3 4 5 6 7 8 9 10 11 12 13 14
90bp
37d: IL-10
1 2 3 4 5 6 7 8 9 10 11 12 13 14
37e: INF-gamma
1 2 3 4 5 6 7 8 9 10 11 12 13 14
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In the normal brain tissue one case showed expression of IL-10, while
the other had no detectable expression of any of the cytokines assessed here.
Both AIDS cases with no CNS pathology showed detectable expression of
IL-6, while one also expressed IL-10. The AIDS infiltrate case showed
expression of IL-4 and IL-6 in the frontal lobe, while only INFy was expressed
in the cerebellum. All of the AIDS PCNSL samples were from areas of the
brain containing tumour tissue, and all samples showed detectable expression
ofboth IL-6 and IL-10. In addition 3 of the 4 samples had detectable
expression of INFy, while IL-4 was expressed in only 1 of 4 samples. No IL-2
expression was detected in any PCNSL samples tested or in any of the other
samples assessed from other groups.
The number of cases studied is too low to make any conclusive
assessment of cytokine expression pattern in the groups studied. However it is
interesting that 7 out of 8 samples from AIDS brains had detectable expression
of IL-6 and that in the PCNSL cases all cases showed expression of both IL-6
and IL-10, with INFy expressed in 3 of 4 samples. Although cytokine
expression was detected in all but one brain sample the technique used was not
quantitative and therefore no estimation could be made regarding the level of
expression of each cytokine in individual brains or which cell types were
producing the cytokines.
Study of the competence of the blood brain barrier in normal and
AIDS brains
Damage to the BBB can allow entry to the brain of blood borne cells
and compounds which are normally excluded or have restricted access. In
order to assess the role of any BBB damage in the accumulation ofB
lymphocytes in the brain, FFPE sections were stained with an anti-fibrinogen
antibody. Fibrinogen, a normal plasma component, is normally kept within
the blood vessels of the brain by the BMVEC which constitute part of the
BBB. Disruption of the BMVECs can allow fibrinogen to leak from the
vasculature into the surrounding parenchymal tissue, which can be detected
immunohistochemically indicating BBB damage.
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A key difference between brain endothelial cells and non-brain
endothelial cells is the expression of tight junction proteins, such as ZO-1, at
the inter-endothelial junction between adjacent brain endothelial cells. Loss of
expression of these proteins can also compromise the BBB aiding access for
compounds and cells normally excluded from the brain tissue. In order to
evaluate the level of tight junction protein expression an anti-ZO-1 antibody
was used to stain FFPE sections.
3.7.1 Plasma fibrinogen leakage
Nine sections from 3 different AIDS PCNSL cases (7 with lymphoma
present, 2 without), 7 sections from 5 pre-AIDS, and 7 sections from 4 normal
cases were assessed for fibrinogen leakage into the brain tissue.
3.7.1.1 Optimisation of anti-fibrinogen antibody
The fibrinogen antibody was tested at the concentrations given in table
34 for each antigen retrieval pre-treatment method given. Sections from a
brain with several recent cerebral infarcts, and therefore disruption of the
BBB, were used for a positive control.











1/250 Strong background staining












The results achieved using the above optimisation procedure were
unsatisfactory. There was little or no difference between the different pre-
treatment methods used. Antibody concentrations of 1/250 and 1/500 produced
very strong background staining that masked any true staining present in the
section. Concentrations of 1/5000, 1/7500 and 1/10000 gave strong staining of
fibrinogen but still produced unacceptable levels of background staining. A
concentration of 1/15000 had little background staining but fibrinogen staining
was also very weak.
Using alkaline phosphatase labelled ABC (avidin biotin complex) rather than
the standard peroxidase labelled ABC generally gives weaker staining and
consequently less background staining. Therefore the optimisation procedure was
repeated using alkaline phosphatase-ABC for all three pre-treatments at
concentrations of 1/5000, 1/7500 and 1/10000, using Vector Black as the
substrate. A concentration of 1/7500 using a citric acid pre-treatment produced
the best fibrinogen staining with minimal background staining (see figure 38a).
The full procedure used is given in section 2.2.1.
3.7.1.2 Results of fibrinogen staining
Sixty one sections from 7 groups of subjects were stained for fibrinogen
and then assessed for evidence of fibrinogen leakage by scanning the entire
section at xlO magnification with a light microscope. Table 35 gives a summary
of the results of sections stained for fibrinogen, the individual data for each
section stained is given in table D1 appendix D.
None of the 7 normal sections or 7 pre-AIDS sections tested showed any
evidence of fibrinogen leakage into the parenchymal brain tissue. Two of the 8
sections from non-HIV drug users had small areas ofweak staining in the
parenchyma. Eleven sections from the AIDS HIVE group were tested, 7 of these
had strong staining in the parenchyma, 2 had weak staining and two no staining.
The areas of staining in this group were focal and were not linked to any obvious
pathology. Fifteen sections from the AIDS infiltrate group were assessed. Five of
these had strong parenchymal staining, 2 had weak
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Table 35: Summary of fibrinogen staining
Number of Number of Number of
Group sections with sections with sections with
(Total number of strong weak no
sections stained) parenchymal parenchymal parenchymal
staining staining staining




Pre-AIDS (7) 0 0 7
AIDS HIVE (11) 7 2 2
AIDS Infiltrate (15) 5 2 8




staining and 8 no staining. In some sections the staining was localised to the
regions containing lymphocytic infiltrates, however other areas of lymphocytic
infiltration showed no staining and staining was found in areas with no obvious
pathology.
Of the 9 AIDS PCNSL sections, 2 had no lymphoma present and neither of
these showed evidence of fibrinogen leakage. The 7 AIDS PCNSL sections all
showed varying degrees of fibrinogen leakage into the tissue. Figure 38b shows a
photograph of an AIDS PCNSL sections with fibrinogen leakage. In most of the
fibrinogen positive AIDS PCNSL sections the fibrinogen leakage was associated
with the presence of lymphoma. Staining of these sections for reticulin (Gordons
and Sweet method) showed separation and disruption of the reticulin fibres of the
blood vessels where lymphoma cells had infiltrated into the perivascular space.
Thus the damage to the blood vessels and hence leakage of fibrinogen into the
brain parenchyma may potentially be attributable to the expanding tumour (see
figure 38b). Despite some fibrinogen leakage correlating with the presence of
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Figure 38: Fibrinogen staining on control section




























Data from these experiments is summarised in table 35.
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lymphoma, many areas of lymphoma showed no evidence of leakage, even in
areas where the lymphoma had infdtrated the perivascular space; while
occasionally, in lymphoma cases, leakage could be found in areas with no
lymphoma cells present (see figure 38c). Four sections from 1 non-HIV case with
viral encephalitis were assessed and showed strong parenchymal staining in 1
section, weak staining in 2, and no staining in 1 section. Some of the areas of
staining were localised to regions of the brain containing large numbers of
lymphocytes, while other positive areas coincided with relatively few
lymphocytes.
Overall there was no obvious pattern to the leakage of fibrinogen found in the
brains assessed. In some cases the staining for fibrinogen localised to areas of
brain pathology, while other areas of staining were found in regions of the brain
with no obvious pathology. In addition there were areas ofpathology, particularly
lymphoma, which showed no evidence of fibrinogen leakage.
A potential complicating factor in assessing fibrinogen leakage by this method
is that only one time point is assessed. Both the pathological processes leading to
fibrinogen leakage from the blood vessels and the process of fibrinogen leakage
and eventual fibrin clot production are dynamic, and therefore only assessing one
time point in the process is a limitation of the technique which may bias the
observed results.
3.7.2 Assessment of BBB tight junction protein expression in normal
and AIDS brains
Sections were stained with anti-ZO-1 antibody to label tight junction
proteins. Consecutive sections were then stained with anti-Von Willebrand
antibody to detect endothelial cells. The total level of staining with ZO-1 and
Von Willebrand sections was then assessed using a computer-linked
microscope. A ratio of total ZO-1 staining (tight junction) to total Von
Willebrand (endothelial cell) staining was calculated for each area of the brain.
This allowed comparison of tight junction protein expression in several areas
of different brains taking into account any potential disparity in the number of
blood vessels and hence endothelial cells in each area of the brain and between
different brains. Figure 39 gives a schematic example.
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Figure 39: Schematic diagram of assessment of tight junction
protein expression
Von Willebrand's staining ZO-1 staining





Blood vessel Blood vessel
Total area stained = 90 Total area stained = 90
Therefore ratio tight junction to endothelial ceil = i
0
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KJ
Total area stained = 80 Total area stained = 40
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Therefore ratio tight junction to endothelial cell = 0.25
Endothelial cells (Von Williebrand)
Tight junction protein (ZO-l)
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3.7.2.1 Optimisation of ZO-1 antibody
The primary antibody concentrations given in table 36 were tested for
each of the pre-treatments given using standard ABC immunohistochemistry
methods. Sections from normal brain were used as positive controls with
intact tight junction proteins, while sections from a multiple sclerosis (MS)
brain with recently active plaques were used to demonstrate variable tight
junction protein expression.
Table 36: Conditions used for optimisation of anti-ZO-1 antibody
Pre-treatments assessed













No staining was seen on either normal or MS brains with any of the
pre-treatments and concentrations assessed, with the exception ofprotease
digested sections with an antibody concentration of 1/15 and 1/20, where some
very weak staining was seen in patches on the normal brain sections. In order
to improve the intensity of staining, the ABC technique was replaced by
tyramide signal amplification (TSA) (see 2.2.1). TSA staining generally gives
enhanced staining and requires approximately 100 fold less primary antibody.
Sections were digested with protease and then stained using TSA with a
primary antibody concentration of 1/20, 1/200, 1/2000. 1/20 and 1/200
dilutions gave a slight increase in staining intensity with no background
staining. To further increase staining intensity, the incubation period of the
primary antibody was increased from 30 minutes at room temperature to
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overnight at 4°C. This produced good staining in the majority of blood vessels
in normal sections (see figure 40), with only slight background staining. In
MS control sections, the majority of vessels stained strongly throughout the
section. In areas with active MS plaques, staining was absent or fragmented.
3.7.2.2 Results of staining with and- ZO-1 antibody
Sections from the cases listed in table 37 below were assessed for ZO-1
protein expression.
Table 37: Cases assessed for ZO-1 protein expression
















The sections were stained in 2 batches. On comparison of the positive
controls from each batch it became apparent the there was a considerable
difference in staining intensity between the positive control sections in each
batch (see figure 41a and 41b). The consequence of differing staining
intensity between batches was that sections in different batches could not be
compared with each other. In order to remedy this, all sections were re-
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Figure 40: ZO-1 immunhistochemical staining of







Figure 41: ZO-1 immunhistochemical staining of

















stained with particular care taken to ensure the staining procedure was
identical for each batch. The third and fourth batches produced staining
intensity which differed from both each other and from the original 2 batches.
In order to be sure that the differences were not due to human error, both
batches were re-stained for a third time. The first batch of this third run
produced results similar to the first original run, however the second batch was
not comparable with this. The results were assessed by two independent
observers, both ofwhom reached the same conclusions.
The inconsistency in staining with this antibody meant that a
meaningful comparisons of sections from different cases was not possible and
therefore the technique was abandoned. While the reason for the staining
variation could not be ascertained, there are two plausible explanations.
Firstly, the antibody is extremely temperature sensitive and its function rapidly
decreases if it is not stored below -20°C, therefore variations in room
temperature and fridge temperature during the staining procedure may affect
the antibody's functional activity. Secondly, the antibody only binds to
sections which have been protease digested prior to staining. As protease
activity is sensitive to both pH and temperature changes, minor changes in
either of these may potentially affect the staining intensity.
In addition to tight junction staining of the BBB several sections,
particularly in AIDS cases, also had strong nuclear staining in several large
neurones. Gottardi et al (1996) have demonstrated ZO-1 staining in the nuclei
of cells which are re-modelling their cytoskeleton in response to injury, so
nuclear expression of this protein is possible. ZO-1 expression has also been
noted in cells which never form tight junctions (Howarth, Hughes &
Stevenson 1992) suggesting it may have secondary functions, however there
are as yet no published descriptions of its expression in the nuclei of neurones.
3.8 Use of statistics analysis
The use of statistics in this thesis is limited to student T-tests
comparing the means of different populations of lymphocytes. While the use
of this test is valid it should be noted that in all cases the power of the test was
extremely low and in most cases the confidence interval was also low.
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Undoubtedly the reason for this is the relatively low number of cases in each
of the study groups. In many instances there were obvious subjective
differences between groups which because of the low case numbers did not
reach statistical significance. In most pathological studies the number of
samples and cases from one study are insufficient for statistical tests to be
applied which will have enough power to provide meaningful results.
However studies of this type are still of importance as several studies can be
combined to produce statistically valid results, and in many cases these types
of studies provide information on disease process within the body which can
not be obtained from animal models or in vitro experiments.
184
4 Discussion
4.1 Prevalence of B lymphocytes in normal brain tissue
In recent years the concept of the brain existing as an entirely
immunologically privileged organ has been challenged. The identification of
T lymphocytes able to enter and patrol the CNS independent of antigen
(Hickey et al 1991), the recognition that antigen presentation functions can be
induced in several resident brain cell types including astrocytes, microglia and
endothelial cells (Male, Pryce & Hughes 1987, Fabry, Raine & Hart 1994),
and the realisation that CNS antigen can drain to cervical lymphatics (Cserr &
Knopf 1992, Aloisi 2000) has led to this shift in attitude towards CNS
immunology. As yet however the presence ofB lymphocytes within the brain
has only been studied in disease states and no studies have examined the
prevalence in normal human brains. The deficit of studies in this area appears
to stem from the failure ofB lymphocytes to migrate across in vitro models of
the BBB (Male et al 1992), which has led to a general assumption that they
therefore do not cross the BBB in vivo in healthy brains (Williams & Hickey
1995, De Angelis 1999, Hickey 2001). However, while these models are
undoubtedly ofuse in determining interactions between endothelial cells and
lymphocytes, they can never entirely replicate the in vivo functioning of the
BBB and therefore assumptions based on these models may be flawed.
Our results show for the first time that B lymphocytes do enter the
parenchyma of normal brain albeit in extremely low numbers. We examined
multiple areas of 7 normal brains and were able to find B lymphocytes in the
parenchyma of 6 of the 7 brains, with an average of 0.112 cells/cm2 (or 1 cell
per 8.9cm ofbrain). This finding indicates the potential for humoral as well
as cellular immune responses within the CNS and further questions the
concept of the brain as an immunologically privileged site (Anthony,
Crawford & Bell, submitted). Although it is not possible from
immunopathological studies alone to assess the trafficking pathways of
lymphocytes to and from the CNS, B lymphocytes appear to move directly
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into the parenchyma since, unlike T lymphocytes, they are not generally
present in the perivascular space in the normal brain. Since no obvious
stimulus for immune activation was detected in the normal brains studied, the
presence of B lymphocytes in brain parenchyma presumably represents
normal trafficking, although at a lower level than for T lymphocytes. A
comparison of the prevalence of T and B lymphocytes within the brain was
made, with T lymphocytes estimated to be approximately 50 times more
common than B lymphocytes. However the functional role ofB lymphocytes
in the CNS under normal conditions remains unclear, and it is not known
whether they leave the CNS via the blood circulation, drain via the CSF into
the cervical lymph nodes or whether they are destined to die there. While the
present data cannot provide an explanation for the presence of these rare B
lymphocytes in the brain it is tempting to speculate on their function. In
addition to the low numbers of randomly distributed B lymphocytes found in
the brain, T lymphocytes can also be found in greater numbers in the normal
brain as well as microglia which are distributed throughout the brain.
Although all three cell types have been shown to be capable ofparticipating in
immune reactions within the brain, the relatively low numbers of cells and
lack of focal accumulations suggests that these cells are not present in the
brain responding to an ongoing acute or chronic inflammatory stimulus. A
plausible explanation may be that perhaps many antigen/pathogens commonly
encountered by humans are occasionally capable of breaching the BBB. If
this were the case then the re-infection with many pathogens in the periphery
may result in re-activation and homing ofmemory B lymphocytes to the CNS
as well as other peripheral organs in antigen surveillance function.
We have also considered the possibility that the number ofB
lymphocytes within the brain may simply be a reflection of the number of
circulating B lymphocytes in the blood. However, in the circulating blood of a
healthy donor there are approximately 0.3xl09 B lymphocytes and l-2.5xl09 T
lymphocytes, giving an approximate 8 fold greater number of T than B
lymphocytes. Our survey of the brain revealed a 50 fold higher incidence of T
than B lymphocytes, suggesting that the number of lymphocytes within the
brain is not simply a reflection of the number in the blood. Furthermore it
suggests either that T lymphocytes are preferentially recruited into the normal
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brain or that B lymphocytes are restricted in entry in comparison to T
lymphocytes.
Our data further indicate that, as for T lymphocytes, only B
lymphocytes that display an activated phenotype, defined by expression of
CD23, are able to cross the BBB and enter the CNS. If activation is a
prerequisite for B lymphocyte entry into the CNS, then facilitation by T
lymphocytes would generally be required as an initial step in the process as
CD4 T lymphocytes are required to activate most B lymphocytes.
The data produced in this study adds to a growing body of evidence
which suggests that the status of the brain as an immunologically privileged
site should perhaps be revised. While its is apparent that immune reactions are
more restricted in the CNS than at most other peripheral sites, immune
reactions can and do still occur within the CNS.
4.2 Prevalence of B lymphocytes in brains of HIV
infected individuals
The dominant characteristic ofHIV is a decrease in the number of CD4
T lymphocytes in the body (reviewed in McCune 2001). However immuno-
dysregulation seen in HIV infection affects other cell lineages including B
lymphocytes. B lymphocyte abnormalities includes a chronic, T lymphocyte
independent, B lymphocyte activation (Lane et al 1983) and resultant
hypergammaglobulinemia (Nath et al 1987). We therefore sought to establish
whether HIV infection might alter the normal migration patterns of B
lymphocytes within the CNS, leading to increased accumulation.
Our results show that in pre-symptomatic HIV patients there is an
increase in the number ofboth parenchymal and perivascular B lymphocytes
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within the brain. An average of 0.417 CD20 cells/cm (or 1 cell per 2.4cm of
brain tissue) was found in the pre-symptomatic HIV brains compared to 0.112
cells/cm2 (or 1 cell per 8.9cm2 ofbrain tissue) in normal brain parenchyma,
although the difference was not statistically significant. In the perivascular
2 .
space a significant increase was noted, with 0.452 cells/cm in the pre-
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symptomatic cases compared to no cells in the normal cases. This finding of
increased number ofB lymphocytes within the brain of pre-symptomatic
patients is in line with the increased numbers ofT lymphocytes found in pre-
symptomatic brains ofHIV infected individuals (Tomlinson et al 1999).
Brains from the majority ofAIDS subjects, including those with
PCNSL (outwith the site ofmalignancy) contained fewer B lymphocytes than
normal brains. The exception was the group ofAIDS brains with pleomorphic
infiltrates which will be discussed separately. The AIDS brains with no CNS
pathology were almost devoid ofB lymphocytes, with CD20 parenchymal and
perivascular cells each found in only 1 of 5 cases. There was an average of
0.008 cells/cm2 in the parenchyma (or 1 cell per 125cm2 ofbrain), which
represented a significant decrease in comparison to controls 0.112 cells/cm2
(p=0.009) and a non-significant decrease in comparison to pre-symptomatic
HIV brains 0.417cells/cm2. Common sense may predict that if the number of
cells found in the pre-AIDS group is greater than that found in the normal
group, and the normal group is statistically significantly different from the
AIDS group then the pre-AIDS group should also be significantly different.
However, the results form the normal group were very homogeneous in
comparison to the more widely distributed results from the individual cases in
the pre-AIDS group, hence combined with the low number of cases per group
significance was not reached.
In the perivascular spaces there was no significant difference between
the number of cells found in AIDS brains with no CNS pathology (average of
0.0046 cells/cm2) compared to normal controls, however there was a decrease
in comparison to pre-symptomatic HIV brains (0.452 cells/cm ) (p=0.051).
Similar results were found in the PCNSL brains, outwith the area of
lymphoma. An average of 0.003 cells/cm was found in the parenchyma and
0.015 cells/cm2 in the perivascular space, neither ofwhich differed
significantly from the AIDS group which lacked CNS pathology. These
results demonstrate that after an initial increase in both the parenchymal and
perivascular brain B lymphocyte populations in pre-symptomatic HIV infected
individuals compared to normal controls, there is a subsequent decrease in
both populations at the onset ofAIDS. Furthermore, as PCNSL is a late
manifestation in AIDS, these results show that PCNSL lymphoma does not
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develop in a background of increased B lymphocyte numbers in the brain.
Therefore a generalised increased in B lymphocyte trafficking into the brain
during HIV infection is not a predisposing factor for development ofPCNSL.
The increase in number of lymphocytes found within the brain in pre-
symptomatic HIV infected individuals may represent an increased surveillance
of the brain and/or increased immune reactivity within the brain during the
early stages of infection. Some of these lymphocytes are likely to be HIV
specific as HIV is thought to enter the brain early in the infection process.
Although this demonstrates the potential for immune reactivity within the
CNS, the level of reactivity is likely to be lower than that seen in other organs
due to the presence of the BBB and production of anti-inflammatory cytokines
within the brain. The subsequent decrease in lymphocytes, below the level of
the normal pathogen free brain, seen in most AIDS brains may therefore
represent a decrease in the immune surveillance of the CNS, and hence
decreased potential for immune reactivity within the CNS. Before the advent
of effective treatment (HAART) this may have predisposed the CNS to
opportunistic infections such as CMV infection. However with effective
treatment CMV and other opportunistic pathogens are less common (Baril et
al 2000). Conversely HAART has been shown to have no effect on the level
ofEBV DNA in HIV infected individuals (Stevens et al 2002), however its
use does produce an increase in immune function which may be important in
the control ofEBV infection and prevention of development ofEBV driven
tumours. EBV driven lymphoproliferations are however still a major cause of
mortality in HIV infected individuals.
4.3 Effects of encephalitis on the brain B lymphocyte
population
Having shown that the brain B lymphocyte population increases in pre-
AIDS and then decreases below normal levels as patients progress towards
AIDS, we sought to determine the effects of productive HIV infection in the
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CNS on the B lymphocyte population. We postulated that a B cell response
would be present in the CNS ofHIVE AIDS patients for three reasons:
1- Unlike T lymphocyte responses, B lymphocyte responses are preserved
until the very late stages ofAIDS. In addition B lymphocytes from
HIV patients have been shown to produce high levels of anti-HIV
antibodies (Amadori et al 1988)
2- B lymphocytes have been shown to enter the CNS in response to
antigen, and can be found in large numbers in viral encephalitis in the
non-immunocompromised patient and in animal models of encephalitis
(Hatalski et al 1998a and 1998b, Tyor, Moench & Griffin 1989)
3- HIV antigens, which B lymphocytes are capable of recognising, can be
found in the parenchyma ofHIVE brains (Budha et al 1987, Chiodi et
al 1988, Weber et al 1989).
In addition to studying cases with HIVE, a control group of 3 cases
with viral encephalitis in non-immunocompromised patients was included. A
single pre-AIDS case with a non-HIV viral encephalitis was also included.
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The HIVE cases had an average of 0.075 cells/cm (or 1 cell per 13.3 cm of
brain tissue) in the parenchyma which although greater than that found in
AIDS cases with no pathology (0.008 cells/cm2) was not significantly different
(p=0.130). In the perivascular space a larger increase was noted, 0.306
cells/cm2 (or 1 cell per 3.3cm2) in HIVE compared to 0.005 cells/cm2 in AIDS
brains with no CNS pathology (p=0.07). Although neither difference was
statistically significant, there were clear differences between the brains
particularly in the perivascular spaces and the lack of statistical significance is
most likely a reflection of the low numbers of cases studied rather than there
being no difference.
Brains from non-immunocompromised cases affected by viral
encephalitis showed a large increase in the presence of B lymphocytes in both
the parenchyma and perivascular space in comparison to HIVE cases: 6.47
cells/cm2 in the parenchyma of the non-immunocompromised brains compared
to just 0.075 cells/cm2 in the HIVE brains, and 64.32 cells/cm2 in the
perivascular spaces of non-immunocompromised brains compared to 0.306
cells/cm2 in HIVE. No statistical tests were performed on this data as only 3
cases of non-immunocompromised encephalitis were examined. The single
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pre-AIDS brain with non-HIV encephalitis gave results which fell between
those ofHIVE and non-immunocompromised encephalitis, with 1.93 cells/cm2
in the parenchyma and 39.109 cells/cm in the perivascular spaces.
We have demonstrated that a moderate increase in brain B
lymphocytes is seen in HIVE compared to other AIDS brains, however this
increase is less than that seen in viral encephalitis in non-
immunocompromised patients. A possible explanation for the decreased B
lymphocyte response seen in HIVE is that CD4 T lymphocytes may be
required to aid B lymphocyte entry to the CNS.
Tyor et al (1989) have suggested that, in mice, T lymphocytes are
required for recruitment ofB lymphocyte into the CNS in response to viral
infection. Their assumption is based on data showing similar B lymphocyte
responses to Sinbis virus encephalitis in BALB/c mice and athymic (nu/nu)
mice upto day 7 of the infection. At this point B lymphocytes in the normal
mouse represent approximately 10% of the inflammatory infdtrate and are
composed mostly of IgM positive cells. The composition of inflammatory
infiltrates in athymic mice at this point was comparable: however there was a
tenfold decrease in the number of cells present. Beyond this point there is an
isotype switch to IgG and IgA producing cells and a further increase in the
number of B lymphocytes in the normal mice, all ofwhich fails to occur in
athymic mice. At no point in the infection was the percentage of B
lymphocytes seen in the inflammatory response in the athymic mice greater
than that seen in the normal mice. They suggest that if B lymphocyte entry to
the inflammatory response was independent ofT lymphocytes present, then B
lymphocytes would be expected to be found in larger numbers in the
inflammatory reactions in the athymic mice. Therefore T lymphocytes are
required to facilitate B lymphocyte entry to the CNS.
However our data demonstrate that B lymphocytes are required to be
activated in order to enter the CNS. The majority ofB lymphocytes require
signals from CD4 T lymphocytes for activation and therefore if this holds true
in athymic mice the number of activated B lymphocytes would be lower.
Fewer cells would consequently have the potential to enter the CNS, which is
reflected in the decreased number of cells seen in the brains of athymic mice.
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Therefore, CD4 T lymphocytes are indirectly required for B lymphocyte entry
to the CNS through their role in B lymphocytes activation in the periphery.
Figure 42 shows that in the HIVE cases studied here there is a general
trend for the overall number of B lymphocytes in an HIVE brain (both
parenchymal and perivascular B lymphocytes combined) to be higher in cases
with higher final peripheral blood CD4 counts. In addition case 46, a pre-
AIDS case with non-HIV viral encephalitis, showed greater numbers ofB
lymphocytes than the HIVE cases with overall numbers approaching the
response seen in the non-immunocompromised encephalitis patients (figure
42). This case had a final CD4 count of 240 cells/pl, which was far greater
than that seen in the AIDS HIVE cases, and adds strength to the argument that
CD4 T lymphocytes have a role in B lymphocyte entry to the brain. These
data cannot differentiate between the need for CD4 T lymphocytes for
activation ofB lymphocytes and a potential additional function ofCD4 T
lymphocytes within the brain recruiting B lymphocytes to the CNS. The
situation is further confused in HIV infection as there is often hyper-activation
ofB lymphocytes in the periphery which is reported to be independent of T
lymphocytes (Martinez-Maza et al 1987, Yarchoan et al 1986).
4.4 AIDS brains with pleomorphic lymphocytic
Infiltrates
In a subset of AIDS brains, previously identified during routine
neuropathological examination as having heavy pleomorphic lymphoid
infiltrates in the perivascular spaces, there were greatly increased numbers of
B lymphocytes in the brain tissue. The parenchyma of the AIDS infiltrate
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group contained an average of 0.174 cells/cm (or 1 cell per 5.7cm of brain
tissue) in comparison to just 0.008 cells/cm2 (or 1 cell per 125 cm2 of brain
tissue) in the AIDS group with no CNS pathology. In the perivascular spaces
the difference was even greater, with an average of 14.776 cells/cm2 in the
infiltrate group compared to 0.009 cells/cm in the AIDS group with no CNS
pathology. Neither of these results reached statistical significance for reasons
192
Figure 42i


















100 200 300 400
CD4 counts (cells/jLiI blood)
Normal healthy
range



































i i i 7 / i i
orin Normal healthy200 300 400 range
CD4 counts (cells/jul blood)
193
discussed in section 3.2.3.2. The infiltrating pleomorphic lymphoid cells did
not localise to any specific area of the brain and were found in several regions
of each brain. The composition of the infiltrates was mostly CD8 T
lymphocytes with B lymphocytes accounting for between approximately 5 and
25% of the total cellular infiltrate. There was no obvious neuropathological
stimuli for the accumulation of these cells within the brain.
A possible explanation for the existence of these infiltrates is that they
merely represent an extension of the lymphocytic infiltration seen in the pre-
AIDS brains. However in the infiltrate group, the number ofperivascular
lymphocytes is significantly higher than in the pre-AIDS group despite
declining peripheral blood lymphocyte counts in the former. While the pre-
symptomatic infiltrates consisted of small T lymphocytes (Tomlinson et al
1999) the pleomorphic infiltrates contained an admixture of larger
lymphocytes, some ofplasmacytoid appearance. Further differences were
noted between the location of infiltrating cells in the pre-AIDS cases and
infiltrate cases. Lymphocytes in the pre-AIDS cases were more frequently
located in the meninges or blood vessels close to the surface of the brain, in
comparison to the infiltrate cases where lymphocytes were located around
deeper, more centrally located blood vessels. Analysis of these pleomorphic
lymphoid infiltrates strengthens our impression that they do not represent
merely an extension of the lymphoid infiltrate seen in pre-symptomatic
patients but constitute a separate pathology.
The finding that the pleomorphic lymphocytic infiltrates contained
substantial numbers ofB lymphocytes raised the possibility that they
represented a pre-malignant PCNSL state.
4.5 BBB studies
Abnormalities in the BBB may be important in mediating or permitting
damage to the brain tissue during HIV infection, as well as facilitating viral
entry to the CNS (Petito & Cash 1992). Several studies have addressed the
issue ofBBB disruption in HIV. Measurement of serum and CSF albumin
ratios has demonstrated increased BBB permeability in 15% or pre-
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symptomatic HIV infected individuals (Andersson et al 2001). In AIDS
patients at post-mortem, fibrinogen extravasation from serum to brain tissue
has been used as a marker ofBBB damage/compromise. Fibrinogen
extravasation has been shown in both HIVE AIDS brains and non-HIVE
AIDS brains; including those with lymphoma and opportunistic infection
(Petito & Cash 1992). Disruption of the tight junctions (TJ) of the BBB is a
characteristic of several CNS pathologies including multiple sclerosis, stroke,
Alzheimer's disease and HIVE (reviewed in Huber, Egleton & Davis 2001).
BBB damage has been shown to be at least partially attributable to the
production of (3-chemokines by HIV infected mononuclear phagocytic cells
(for example microglia) and astrocytes. HIV infected mononuclear phagocytic
cells have been shown to down regulate TJ proteins and transport systems on
brain microvascular endothelial cells in both autopsy human brain tissue and
in mouse models ofHIVE (Persidsky et al 2000). Sporer et al (2000) have
suggested that additional BBB damage may be caused by the induction of
matrix metaloprotease (MMP)-9 by HIV nef protein. Intracisternal injection
ofnefprotein into rats led to increased MMP-9 activity in the CSF in addition
to breaching of the BBB. The BBB damage could be inhibited by pre-
treatment with the MMP inhibitor batimastat. The source ofMMP-9 was not
clear, with only slight induction in vitro in PBMCs and macrophages treated
with nef, but no induction in endothelial cells or astrocytes (Sporer et al 2000).
Damage to the BBB during HIV infection has been shown to be
associated with the accumulation ofmonocytes in the brain of patients with
HIVE (Dallasta et al 1999). We therefore sought to determine if damage to
the BBB was also associated with the accumulation of B lymphocytes in the
brain. We hypothesised that B lymphocytes may be present in increased
numbers at sites ofBBB damage as these sites may be more readily penetrated
than sites with intact BBB. There were 2 parts to the study:
1 - Assessment of the tight junction protein ZO-1
2- Assessment of plasma fibrinogen leakage from blood vessels into the
brain tissue.
The protein ZO-1 is an integral part of the tight junctions found within
the BBB, and their presence or absence has been used in previous studies to
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define BBB integrity (Dallasta et al 1999, Luabeya et al 2000). As discussed
in the section 3.7.2, the results obtained using anti-ZO-1 antibodies to
visualise the tight junctions of the BBB were inconsistent and therefore no
valid data could be reliably extracted using the technique. Dallasta et al
(1999) using the same technique found that ZO-1 immunostaining was
disrupted or absent in HIVE brains and that monocytes were found in
increased numbers in these sites. It is not clear however from these studies if
monocytes accumulate in these areas and mediate the BBB damage or if they
accumulate as a result of the BBB damage.
Plasma fibrinogen is normally contained within blood vessels and is
not found within the brain tissue unless there is disruption of the BBB (Petito
& Cash 1992). Our data from the study ofplasma fibrinogen leakage showed
no correlation between the accumulation of B lymphocytes in the brain and
damage to the BBB as demonstrated by fibrinogen leakage. Fibrinogen
staining ofbrain tissue was only noted in AIDS PCNSL cases, in which some
of the fibrinogen positive areas coincided with the presence of tumour. The
study of 6 individual cases ofPCNSL revealed differences in the extent of the
disruption of endothelial cells lining blood vessels by the tumours. In all
tumours the malignant cells were found in concentric rings around the blood
vessels, with most tumours showing no disruption of the endothelial cells of
the blood vessels (see figure 43a). However in certain areas of several cases
(particularly cases 36 and 41) the endothelial cells appeared to have been
disrupted or destroyed by the tumour (see figure 43c). Intermediate stages
were also observed were the endothelium was partially disrupted/destroyed (se
figure 43b). While fibrinogen leakage was observed in all areas with
endothelium disruption, it was variably associated with tumours which had not
disrupted the endothelium. It is not clear whether the disruption of
endothelium seen in some cases is due to tumours being observed at more
advanced stage, or if these tumours are displaying more aggressive invasive
properties. Interestingly the case with greatest spread of lymphoma
throughout the brain (case 42) showed no evidence of disruption ofblood
vessel endothelium.
The absence of fibrinogen leakage in all brains assessed, with
exception ofPCNSL, suggests that B lymphocytes are able to penetrate the
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Figure 43: Disruption of endothelial cells by PCNSL


















BBB without disruption of the endothelial cells, providing further evidence to
suggest that B lymphocyte transmigration into the brain is a normal
physiological process.
4.6 Activation status of B lymphocytes within the brain
In accordance with the results discussed earlier showing that B
lymphocytes in normal brains all demonstrate an activated phenotype, the vast
majority of B lymphocytes found in the parenchyma ofHIV brains also
showed an activated phenotype. This further strengthens the argument that
activation ofB lymphocytes is required for entry to the brain. The large
numbers ofperivascular cells found in AIDS infdtrate cases also demonstrated
an activated phenotype. These data suggest that not only is activation required
for entry into the parenchyma, but also for penetration of the BBB and
subsequent entry to the perivascular spaces.
Eight of nine large areas of lymphoma from 4 cases ofPCNSL showed
the majority of tumour cells displaying an activated phenotype. There are two
possible explanations for this finding. Firstly, if the original cell from which
the tumour was derived migrated into the brain from the periphery then the
proceeding data would suggest that it must be activated to gain entry to the
CNS. For this reason all PCNSL cells would be expected to display an
activated phenotype. Alternatively, the tumour cells could be activated as part
of the tumourogenesis process, particularly those infected with EBV which
can activate cells via expression of viral proteins EBNA-2 and LMP-1.
We also compared the number of activated B lymphocytes found
within the blood vessels of brains studied. In the normal brains far fewer B
lymphoctes were activated within the blood vessels than within the brain
tissue (50% intravascular, 80% parenchymal). In the pre-AIDS brains the
percentage of activated cells found in the blood vessels increased to 78%. The
number of cells studied in individual AIDS groups was too low to yield valid
data. This data suggests that an increase occurs in terms of circulating
activated B lymphocytes during the early stages ofHIV infection, which is in
accordance with previously published data (Martinez-Maza et al 1987, Lane et
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al 1983) which demonstrate polyclonal B cell proliferation during early HIV
infection. It should be noted however that the results presented here may be
strongly influenced by post mortem effects such as drainage of blood from the
tissues. Activated B lymphocytes display adhesion molecules (Bonnefoy et al
1995) and are therefore more likely to adhere to endothelium and may be less
affected by drainage ofblood from tissues than non-activated cells. It would
interesting to perform similar studies, perhaps using FACS analysis, on blood
samples from these cases to determine the extent of the post mortem effects.
Post mortem blood may not be suitable for such a study in which case blood
samples taken preceding death may be required.
4.7 Effects of drug use on the B lymphocyte population of the brain
A significant proportion of individuals infected with HIV in
Edinburgh, are known drug abusers. Previous work by Tomlinson et al (1999)
has demonstrated an increase in the number of activated microglial cells in the
CNS of both HIV IDU and non-HIV IDU. Gan et al (1999) showed an
upregulation of adhesion molecules at the BBB with exposure to cocaine.
Activation ofmicroglia may lead to expression of chemoattractants within the
CNS and in combination with upregulation of adhesion molecules could
potentially facilitate increased transmigration of lymphocytes into the CNS.
Although Tomlinson et al (1999) showed no increase in the number of T
lymphocytes present in the brain of drug users, it is possible that the number
of B lymphocytes may be increased by these mechanisms and therefore it was
important to establish if the abuse of drugs had an influence of the B
lymphocyte population of the brain.
Our results demonstrated no significant increase in the number of
parenchymal or perivascular B lymphocytes in non-HIV infected drug users in
comparison to normal controls. We have demonstrated that the abuse of
intravenous drugs has no significant effect on the B lymphocyte population of
the CNS when compared to normal non-drug abusers. In addition there is no
significant difference between the numbers of parenchymal B lymphocytes in
the brains of pre-AIDS drug users as compared to non-HIV IDU. However
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there is an increase in the number ofB lymphocytes found in the perivascular
space in pre-AIDS IDU which is not seen in non-HIV IDU. This increase in
perivascular cells is therefore unlikely to be due to the effects of drug use
alone, although a synergistic effect between drug use and HIV infection
cannot be ruled out. Alternatively the B lymphocytes may be responding to
the initial stages ofHIV entry to the brain. This may explain the localisation
of the B lymphocytes in the perivascular spaces rather than in the parenchyma,
as the most likely entry point ofHIV to the brain is via blood borne
inflammatory cells which migrate across the BBB into these areas (Nottet et al
1996). Tomlinson et al (1999) have shown that an increase in activated
microglia occurs in both non-HIV and HIV infected drug users, which they
suggest may predispose drug users to HIV infection of the brain. In
accordance with this Bell et al (1998b) demonstrated an increased incidence of
HIVE and generally higher CNS viral load in drug users than homosexuals
with HIV.
4.8 EBV in the CNS
During HIV infection the number of circulating EBV latently infected
B lymphocytes increases in comparison to healthy controls (Birx, Redfield,
Tosato 1986, Stevens et al 2002). In addition lytic gene expression, which is
not detectable in healthy carriers, has been detected in HIV infected
individuals. Expression of the lytic gene BZLF-1 is detectable in 36% ofHIV
large-cell/immunoblastic lymphomas (Rea et al 1994). While in the serum
anti-ZEBRA (lytic gene) antibodies were detected in both asymptomatic-HIV
and AIDS patients (Joab et al 1991). Thus during HIV there is an increase in
EBV latently infected cells and in some individuals lytic viral replication.
Given the potential ofEBV to drive B lymphocyte proliferations this increase
in circulating EBV may have consequences for the subsequent development of
EBV related tumours in HIV.
Almost all AIDS related PCNSL are EBV-driven lymphoproliferations
and show expression of the EBV oncogenes EBNA-2 and LMP-1 (MacMahon
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et al 1992, Auperin et al 1994). We were therefore interested to determine
whether the increased number ofB lymphocytes detected in the CNS in pre-
AIDS and/or AIDS pleomorphic infiltrates contained EBV and therefore
predisposed individuals to development of PCNSL. We hypothesised two
mechanisms that could cause increased numbers ofEBV infected B
lymphocytes to enter the brains ofHIV infected individuals:
1 - The number of circulating latently infected B lymphocytes, which is
between 5 and 500 per 107 B lymphocytes in a healthy carrier
(Miyashita et al 1995), is significantly increased in HIV infection
(Birx, Redfield, Tosato 1986). Therefore ifB lymphocyte entry to the
CNS is random process then there is an increased chance ofEBV
infected cells entering the brain. Even if the process ofB lymphocyte
entry is not random and only antigen specific B lymphocytes are able
to enter the brain, then as EBV is present in the memory B lymphocyte
population and is stably inherited in daughter cells (Babcock et al
1999, Thorley-Lawson & Babcock 1999), it is plausible that an EBV
infected cell may be recruited to the CNS.
2- Like HIV, EBV is a potent T lymphocyte-independent polyclonal
activator ofB lymphocytes, and, although EBV gene expression is
tightly controlled in healthy carriers (Miyashita et al 1997), expression
of the B lymphocyte activating genes, EBNA-2 and LMP-1, has been
detected in the immunocompromised host (Hopwood et al 2002). Our
previous data indicate that activation is a pre-requisite for B
lymphocyte entry into the brain and therefore activation by EBV is
likely to facilitate the entry ofEBV infected B lymphocytes to the
brain.
We therefore sought evidence ofEBV infection initially by screening
for EBV DNA by PCR and then by in situ hybridisation to detect EBV RNA
(EBERs) in tissue sections. The advantage of screening samples by PCR is
that it allows rapid assessment ofmany samples for the presence of the virus,
the disadvantage in using PCR is that it does not permit identification ofwhich
cells in a sample are infected. PCR may also detect cells present within the
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blood vessels of the tissue which may give a false impression of the actual
quantity ofEBV within the tissue. In contrast in situ hybridisation allows
determination of the cells infected with the virus, however the process is
laborious and the screening of sections time consuming and subjective. In
addition only small sample areas can be studied using in situ hybridisation. It
is therefore important to use both techniques in order to obtain reliable data.
Despite an extensive search ofboth normal healthy brains and HIV
infected brains by in situ hybridisation, EBV infected B lymphocytes were
only found in the cells of PCNSL tumours. PCR detected high copy numbers
ofEBV DNA in all PCNSL samples and low copy numbers in occasional
samples from infiltrate cases.
Entry ofB lymphocytes in general to the brain is a comparatively rare
event and our failure to locate any EBV infected cells within the brain B
lymphocyte population (other than tumour cells) suggests that entry ofEBV
infected B lymphocytes is also a rare event. The failure to find any EBV
infected cells (other than in tumours) is not unexpected given the relatively
low number of circulating B lymphocytes infected with the virus, even in HIV.
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Given that in the peripheral blood EBV infects between 5 in 10 and 5 in 10
cells, and assuming random entry ofB lymphocytes to the brain, it is predicted
that at least 20,000 brain B lymphocytes within the brain would have to be
studied to locate 1 EBV positive cell. Only ifEBV infection of B
lymphocytes induced a strong or absolute homing of cells to the brain would it
be possible to locate EBV infected B lymphocytes in the brain by this
technique. Despite the propensity for EBV related tumours to develop in the
brain, there is as yet no evidence in the literature to suggest that EBV infected
cells preferentially home to the brain, and our evidence does not contradict
this. Whether EBV infected cells do specifically home to the brain or are
occasionally randomly drawn into the brain, remains to be elucidated.
The fact that EBV driven tumours rarely develop in the brain of
immunocompetent individuals (Jellinger & Paulus 1995) suggests however
that the normal immune surveillance level in the brain is sufficient to prevent
EBV driven proliferations occurring at this site. That EBV driven tumours
develop in this site in immunosuppressed individuals, both in AIDS and post-
transplant settings, suggests that either the CNS may suffer an earlier or larger
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decline in immune surveillance than other organs in both these settings, or that
the extracellular milieu within the CNS in these diseases is more favourable
for EBV tumour development than at other sites. Most likely a combination of
both occurs in HIV PCNSL.
All PCNSL assessed in this study were EBV positive, as determined by
both in situ hybridisation for EBERs expression and PCR for EBV DNA,
which is in accordance with most previous studies showing an almost
complete association of EBV with PCNSL (MacMahon et al 1992, Auperin et
al 1994). Furthermore, all tumours displayed strong EBNA-2 staining and
some LMP-1 positivity, which is again in line with the majority of published
data (Auperin et al 1994) and indicates that EBV infected PCNSL display an
EBV latency III phenotype. In addition it suggests an aetiological association
between EBV and PCNSL, since both EBNA-2 and LMP-1 are major viral
oncogenes.
As well as studying the presence ofEBV in brain tissue samples we
also studied several CSF samples. Detection ofEBV in the CSF ofAIDS
patients is considered diagnostic of PCNSL (Cingolani et al 1998) in the
presence of other indicative clinical features. We therefore wished to assess
the presence ofEBV in CSF samples from AIDS PCNSL cases and AIDS
infiltrate case in order to further determine similarities or differences between
these two groups. The finding of low levels ofEBV in the CSF and some
tissue samples from the AIDS infiltrate group is interesting. All CSF samples
from PCNSL cases were PCR positive for EBV (range 283 to >106 EBV
genomes/pg DNA) as were all tissue samples which contained lymphoma
(range 2xl04 to >106 EBV genomes/pg DNA). In contrast only 2 of 8 tissue
samples from the AIDS infiltrate group were EBV PCR positive (range 110 to
160 EBV genomes/pg DNA). However the CSF of case 25 showed higher
levels ofEBV (range 6,300 to 12,600 EBV genomes/pg DNA). It should
however be considered that the CSF results may be misleading as these are
post mortem samples and therefore may potentially be contaminated with
blood (although visually only 1 sample appeared to be).
The discrepancy between results from the 2 techniques for tissue
samples from AIDS cases with pleomorphic infiltrates may be due to detection
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ofEBV infected cells in the blood vessels of the brain tissue samples and may
reflect an increased level of circulating EBV infected cells in these patients.
Or, alternatively, given the low EBV copy number detected in these cases the
differences may reflect the small area sampled by in situ hybridisation.
It is intriguing to speculate that these pleomorphic proliferations may
actually represent pre-malignant lesions demonstrating a step in the process of
PCNSL tumourigenesis. If in fact they do represent a pre-malignant PCNSL
state, then there are two plausible routes ofpathogenesis:
1 - As part of the normal inflammatory responses to antigen with the CNS
large numbers ofB lymphocytes are attracted into the CNS. In the
cases studied here the stimulus was not identified, however it is not
likely to be productive HIV infection as all sections were negative for
HIV p24 immunohistochemical staining. It is conceivable that as part
of this B lymphocyte infiltration an occasional EBV infected cell may
be recruited to the brain. Production ofTH-2 type cytokines which
occurs during HIV infection within the brain and in the periphery
(Klein et al 1997) may stimulate proliferation B lymphocytes
(including any EBV infected cells). The disruption of the immune
system seen in HIV, may affect the CNS more than other organs as its
immunity is already limited, and may lead to uncontrolled proliferation
of these B lymphocytes. This could allow survival of any EBV
infected cells utilising the latency III program which includes
expression of the major EBV oncogenes EBNA-2 and LMP-1, which
in turn would lead to uncontrolled proliferation of that clone.
Unchecked, this proliferation might lead to outgrowth of a monoclonal
tumour and hence to PCNSL.
2- Alternatively production ofEBV within the CNS or entry of free virus
from the peripheral blood, possibly via a disrupted BBB, may lead to
infection ofB lymphocytes already within the CNS which again may
cause clonal outgrowth and PCNSL as outlined in point 1 above. A
possible source of free EBV is from EBV infected B lymphocytes
which have terminally differentiated to plasma cells, a process which
induces lytic EBV replication (Crawford & Ando 1986), resulting in
release of free virus.
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Intriguing as it is to speculate on the pre-malignant nature of these
infiltrates, there is no conclusive evidence to prove or refute this suggestion.
Although the evidence accumulated in this study suggests that the
pleomorphic infiltrates seen in some AIDS brains are not pre-malignant, the
data are not conclusive and as discussed above there are possible mechanisms
of tumourigenesis which could lead to malignancy arising from these
infiltrates. In our study, despite obtaining positive EBV PCR signals, we
found no evidence by in situ hybridisation ofEBY infection ofB lymphocytes
within these infiltrates. However due to our samples size which is small
compared to the overall size of a brain, the need for only 1 or few EBV
positive cells to initiate a tumour, and the rarity ofEBV infected B
lymphocytes in the blood (1 per 105 B lymphocytes in HIV), it is highly
improbable that our survey would have detected these very rare cells. To
support the notion that occasional EBV infected B lymphocytes do enter the
brain Bell et al (1997) have previously demonstrated occasional EBV positive
cells in an infiltrate from 1 of the cases used in this study. Although the case
in question (case 28) was an African child aged approximately 6 months and it
should be considered that the child may have been experiencing a primary
EBV infection and therefore have high numbers ofEBV infected B
lymphocytes circulating in the blood expressing all viral latent genes. (Given
the prevalence ofEBV in the adult population (over 90% world wide) it is
unlikely that any of the adult cases ofAIDS infiltrates were experiencing
primary EBV infection and therefore they would have lower levels ofEBV
infected cells). Regardless of the source of the EBV, this case demonstrates
that EBV infected cells can occasionally be found within the brain, which has
implications for the pathogenesis ofPCNSL.
We conclude that the PCR test used in this study (sensitivity of 1-10
EBV positive cell in 106 EBV negative cells) detected the occasional EBV
infected B lymphocyte either in the brain tissue or blood vessels, but that EBV
infection is not the primary cause of pleomorphic B lymphocyte infiltrates.
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4.9 Comparison of AIDS pleomorphic infiltrate brains and
AID PCNSL brains.
There are further differences between PCNSL and AIDS infiltrates
which could have arisen because there is no link between PCNSL and the
infiltrates, or, alternatively because PCNSL formation is a multi-step process
ofwhich we are only viewing two points. These differences include:
1- The ratio ofB:T cells within the lesions
2- The cells proliferating within the lesion
3- The background level ofB lymphocytes within the brain.
4- The location ofB lymphocytes within the brain
5- EBV infection ofB lymphocytes (discussed above, section 4.8).
6- Clonality ofB cell lymphoproliferations (discussed below, section
4.10)
In terms of the ratio ofB:T cells; the cells in PCNSL lesions are almost
entirely B lymphocytes with a few infiltrating CD8 T lymphocytes, in contrast
within the pleomorphic infiltrates B lymphocytes represent between
approximately 10 and 40% of cells. The fact that infiltrates and PCNSL differ
markedly in their B:T cell composition may suggest a difference in
pathogenesis between the two. However, there is evidence from SCID mouse
models ofEBV driven B cell lymphoma in immunocompromised settings, that
CD4 T lymphocytes are required for the initial stages of tumour development
(Johannessen, Ashgar & Crawford 2000). While we were unable to look
directly for CD4 T lymphocytes, the evidence obtained using CD3 (pan T
lymphocyte marker) and CD8 markers would suggests that the majority of T
lymphocytes present showed dual positivity for both CD3 and CD 8 markers,
therefore very few CD4 T lymphocytes are present in the pleomorphic
infiltrates.
The two lesions also differ with respect to proliferation of cells. In
PCNSL both B and T lymphocytes show expression of proliferation markers
Ki67 and PCNA, in contrast only the T lymphocytes in infiltrate cases appear
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to be proliferating. Again these differences could reflect genuine differences
between the two lesions or alternatively the pleomorphic infiltrates could
represent an initial early stage in the tumourogenesis process (before the B
lymphocytes have begun to proliferate).
The background level ofB lymphocytes within the brains also differs.
PCNSL brains contained virtually no B lymphocytes other than the localised
tumour cells, while brains containing pleomorphic infiltrates tended to show
the presence of high numbers of B lymphocytes throughout the brain. Again
this could reflect genuine differences in the pathogenesis of the lesions or it
could be due to the fact that only one time point has been studied.
Finally, in PCNSL the neoplastic infiltrates were generally focal, being
located in 1 or 2 regions of the brain. In contrast the pleomorphic infiltrates
were diffusely spread and found in most regions of the brain. This could be
accounted for if the infiltrates began as a polyclonal proliferation and develop
into a single monoclonal tumour with eventual loss of the non-malignant
polyclonal cells, or alternatively it may reflect true differences between the
pathology of these lesions.
None of our data suggests that a link exists between the pleomorphic
infiltrates seen in some AIDS brains and the development of AIDS PCNSL.
However as stated throughout the discussion the limitations of this type of
study, which allows only one time point in a pathological process to be
viewed, means that a link cannot be entirely ruled out by our data.
4.10 Clonality of tumours
Several larger studies have previously addressed the issue of clonality in
AIDS PCNSL (Meeker et al 1991, Bashir et al 1993, Julien et al 1999) with
the consensus reached that the majority of these tumours are monoclonal as
determined by Ig gene re-arrangements or kA, light chain usuage. There is no
reported preferential usage of any one VH gene family in AIDS PCNSL,
however it is noteworthy that alterations in the usage ofVH gene families are
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observed in B lymphocytes present in the peripheral blood ofHIV infected
individuals.
Of the 3 PCNSL cases assessed for clonality in this study, 2 were
monoclonal with VH3 family receptor gene usuage while the third was a
polyclonal tumour. The first 2 results (monoclonal tumours) fit well with
results from previous larger studies which show the majority ofPCNSL are
monoclonal in terms of Ig gene re-arrangements (Meeker et al 1991, Bashir et
al 1993, Julien et al 1999). As these tumours are predominantly monoclonal
and always EBV positive they most likely develop from a single EBV infected
B lymphocyte that undergoes the final stages of transformation within the
CNS. However the polyclonal tumour found in our study does not fit this
model. Formation of a polyclonal EBV driven tumour could occur in two
ways. Either free EBV could infect several cells in a polyclonal B cell
proliferation, with virus possibly being produced by terminally differentiated
EBV infected plasma cells entering the lytic viral replication cycle. Or
alternatively, more than one EBV infected cell could enter the CNS and
undergo transformation. Neither hypothesis ofpolyclonal tumour formation
can be proven from our data.
The use ofVH3 family gene receptors by 2 of 3 PCNSLs was
interesting given the evidence that HIV gpl20 can act as a superantigen for
VH3 expressing B lymphocytes (Muller & Kohler 1997, Karray & Zouali
1997) and that VH3 B lymphocytes undergo clonal deletion during the later
stages of AIDS when PCNSL is most likely to develop (David et al 1995,
David et al 1996, Wisnewski, Cavacini & Posner 1996). Although the data
from our study suggest a high incidence ofVH3 gene usage in PCNSL, too
few cases were studied to enable any analysis of gene usage.
4.11 B lymphocyte Chemoattractants in the CNS
The mononuclear cell chemoattractant SDF-1 can be produced in the
brain by neurones and astrocytes (Bajetto et al 1999). It acts on lymphocytes
and monocytes, but not neutrophils, to promote cell migration in vitro. It is a
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highly potent attractant in vivo and functions via binding to the chemokine
receptor CXCR4 (Bleul et al 1996). With respect to B lymphocytes, it has
been demonstrated in tonsil tissue that SDF-1 is a specific attractant for
memory B lymphocytes (Casamayor-Palleja et al 2001). Expression of SDF-1
is not upregulated in inflammatory conditions in which B lymphocytes are
present, which has led Bleul et al (1996) to propose that it may be involved in
immune surveillance rather than inflammation.
Our preliminary study suggests an association between the
accumulation ofB lymphocytes in AIDS brains and SDF-1 expression, with
both PCNSL brains in the regions ofbrain containing lymphoma and infiltrate
brains with areas containing pleomorphic lymphocytes showing high levels of
this chemokine. Interestingly increased expression of SDF-1 was only noted
in areas that actually contained high numbers ofB lymphocytes and not other
areas of the same brain. Furthermore non-HIV encephalitic brains which also
contained high numbers ofB lymphocytes showed little or no expression of
SDF-1, suggesting a different mechanism for lymphocyte recruitment may be
involved here. As SDF-1 expression was only found at low levels in all brain
groups other than AIDS PCNSL and AIDS infiltrate, there is a tendency to
assume that these B lymphocytes are accumulating as a result of aberrant
chemokine expression, possibly induced by HIV infection of resident brain
cells. It is however conceivable that the chemokine expression is due to the
presence of the B lymphocytes in these tissues rather than being the cause of
the B lymphocyte accumulations, although if this were the case then the non-
HIV encephalitis cases which contained high numbers ofB lymphocytes
would also be expected to demonstrate high levels of SDF-1 expression.
One of the limitations of immunohistochemistry is that it allows
determination of the position of a given protein but cannot determine with
certainty which cells are actually producing the protein if the protein is
extracellular. The majority of staining found in this study was extracellular.
An interesting follow up to this study would be to use in situ hybridisation
techniques to locate the cells expressing SDF-1 mRNA. Given that astrocytes
are a potential source of the chemokine and can be infected with HIV, it may
be of further interest to determine if any link exists between astrocyte infection
by HIV and expression of SDF-1.
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Of interest are reports that a mutant version of the SDF-1 gene is
associated with an increased incidence ofNHL in HIV. Rabkin et al (1999) in
a study of 746 HIV infected individuals reported an increased incidence of
NHL in patients with a transition mutation in the 3' untranslated region of the
SDF-1 gene. 19% ofhomozygotes for the mutation developed NHL,
compared to 10% ofheterozygous and 5 % with the wild type geneotype. The
physiological effects of this mutation are as yet undetermined.
4.12 Cytokines in the CNS
Our limited study of cytokine expression in the brain, using RT-PCR,
showed detectable expression of several cytokines in AIDS brains, but only
IL-4 in 1 of 2 normal brains. In particular the TH2 cytokines IL-6 (B
lymphocyte growth factor (Tosato et al 1986, Emilie et al 1992)) and IL-10
(induces B lymphocyte proliferation) were detected in 4 of 4 PCNSL samples.
The presence of these factors would be expected to enhance tumour growth.
The present study did not allow us to determine which cells within the brain
were expressing these cytokines. However monocytes have been shown to be
a source of additional IL-6 during HIV infection (Clouse et al 1991, Nakajima
et al 1989) and monocyte entry to the CNS has been demonstrated in HIV
(Dallasta et al 1999). In addition to monocytes IL-6 and IL-10 can be
produced by HIV infected astrocytes and microglia (Yeung et al 1995, Fiala et
al 1996, Speth et al 2000). It should be noted that EBV positive tumours
produce viral IL-10 (Benjamin, Knobloch & Dayton 1992) which acts in an
autocrine manner to stimulate further tumour growth, however the PCR
primers used in our assays had been designed to detect only human IL-10 and
not the viral protein.
IL-6 expression was detected in 7 of 8 AIDS brain samples including 2
brains with no CNS pathology and 3 of 4 PCNSL, but was not detected in
either of the normal brain samples. Although the number of samples studied
was too low to draw firm conclusions, this data suggest that a consequence of
HIV infection may be the expression of IL-6 within the brain. IL-6 has been
shown in non-CNS B cell lymphomas to act as a growth factor for high grade
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B cell lymphomas (Emille et al 1992), with production occurring mostly in
non-malignant cells such as macrophages and endothelial cells. IL-6
production by these cell types can be induced by INF-y (Leeuwenberg et al
1990, Sanceau et al 1991) and INF-y production was detected in 3 of the 4
PCNSL samples assessed. As IL-6 promotes B lymphocyte proliferation and
its production is increased in HIV particularly by monocyte derived cells
(Klein et al 1997), this may be a predisposing factor to the development of
PCNSL.
4.13 Pathogenesis of AIDS PCNSL
The exact pathogenesis ofAIDS PCNSL is still unclear. However the
100% association ofEBV with these tumours (MacMahon et al 1992) suggest
EBV plays a significant part in the process of tumour formation. EBV
infection ofAIDS PCNSL shows a latency III phenotype, which includes
expression of LMP-1, and EBNA-2. EBNA-2 transactivates cellular genes
involved in proliferation and upregulates LMP-1. LMP-1 has profound effects
on B lymphocyte growth, inducing activation and differentiation (Izumi et al
1999), it is also induces upregulation of the anti-apoptotic BCL-2 gene (Rowe
et al 1994). The expression of oncogenic proteins by EBV within B
lymphocytes is likely to provide at least some of the stimuli required in the
multi-step process to tumour formation. In addition to the oncogenic
properties of the EBV proteins expressed in tumour cells, there is evidence
that during HIV infection anti-EBV CTLs become progressively less
responsive to EBV antigens as AIDS develops and the CD4 count decreases
(Van Baarle et al 2001). Thus EBV driven proliferation will be poorly
controlled in late stages ofAIDS, predisposing to B cell malignancies.
While it cannot be disputed that EBV plays an important role in the
formation of these tumours, the fact that the majority are solitary monoclonal
tumours suggests that EBV alone is not sufficient for transformation, even in
an immunocompromised setting. If it were sufficient then given the increased
number ofEBV infected cells in HIV infected patients (Laroche et al 1995) it
would be anticipated that more than one cell might be transformed.
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A significant side effect ofHIV infection is the aberrant expression of
several cytokines. In particular, expression of the TH2 cytokines IL-4, IL-6
and IL-10 are increased during HIV (Martinez-Maza et al 1987, Klein et al
1997). The effects of this are to increase B lymphocyte proliferation, which
combined with the loss ofB cell apoptotic signals normally supplied by T
helper 1 lymphocytes expressing Fas ligand and FDC, again predisposes to B
cell tumour formation. Furthermore both HIV and EBV antigens are capable
of acting as B lymphocyte superantigens, again increasing B lymphocyte
proliferation (Muller & Kohler 1997, Karray & Zouali 1997).
It would seem therefore that HIV infection produces an environment
favourable for uncontrolled EBV proliferation and subsequent tumour
formation, in terms ofboth stimuli for proliferation and loss of viral control
mechanisms. Figure 44 shows a schematic diagram of a model for the
pathogenesis of PCNSL suggested by the results presented here.
The reason for the high incidence of B cell lymphoma formation in the
CNS (20% of all NHL in AIDS) is still unclear. It is possible that EBV
infection induces CNS homing signals in B lymphocytes, however there is as
yet no evidence of this. Alternatively the extracellularmilieu of the CNS in
HIV may simply be more favourable for EBV driven B lymphoproliferations
than other sites in the body. Furthermore HIV infection of the CNS may in
some cases induce expression of chemoattractants, for example SDF-1, which
recruit an increased number ofB lymphocytes to the brain or preferentially
recruit EBV infected B lymphocytes to the brain. Again however there are no
strong data as yet to support this hypothesis.
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In summary we have demonstrated for the first time that B
lymphocytes infiltrate the normal human brain, albeit in low numbers. The
rarity of these cells within the normal brain, combined with the time
consuming microscopy required to detect significant numbers has possibly
resulted in these cells being overlooked or missed by previous studies. B
lymphocytes in the normal brain are found only in the parenchyma and not in
the perivascular spaces, which suggests that there is no impediment to
movement ofB lymphocytes from the perivascular to the parenchymal
compartment of the brain. No evidence was found ofBBB disruption in the
normal brain, signifying that B lymphocytes are able to penetrate an intact
BBB.
During pre-symptomatic HIV infection the B lymphocyte population
of the brain increases in comparison to normal controls and a significant
number of cells accumulate in the perivascular spaces in addition to the
parenchyma. The progression to AIDS in most individuals leads to a decrease
in the brain B lymphocyte population below that seen in the normal healthy
brain for most patients.
Tumours involving B lymphocyte lineage cells are prevalent in HIV
and are often associated with EBV. The development of these tumours is
probably attributable to the disruption of the immune system caused by HIV
and the shift in production of cytokines from TH1 to TH2, which promotes B
lymphocyte proliferation. Disruption of the immune system permits survival
of increased numbers ofEBV infected B lymphocytes and in some cases lytic
EBV infection. Increased numbers ofEBV infected cells, present in an
immunocompromised setting may predispose to EBV related malignancies.
However, the lack ofB lymphocytes found in most AIDS brains, in particular
in PCNSL brains outwith the areas ofmalignancy, suggests that increased B
lymphocyte infiltration of the CNS is not a predisposing factor for PCNSL
development. Although in some pre-AIDS and AIDS subjects there is an
unusual accumulation of B lymphocytes in the perivascular space, these cells
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Appendix A: Data from individual immuno stained slides
Table A1: Normal cases (Group 1)

















1 frontal 0 0 4.69 0 0
1 medulla 0 0 1.56 0 0
1 parietal convex 0




0 4.19 0 0
1 mid brain 0 0 2.5 0 0
2 cerebellum 1
0 4.75 0.210526316 0
2 basal ganglia 1 0 5.44 0.183823529 0
2 frontal 1 0 5.5 0.181818182 0
2 parietal convex 0




0 4.13 0 0
2 mid brain 0 0 4.13 0 0




0 4 0.25 0
3 parietal convexity 0 0 3.63 0 0
3 frontal 0 0 4.88 0 0
3 cerebellum 1
0 5.75 0.173913043 0
4 basal ganglia 1 0 5.81 0.17211704 0
4 cerebellum 1 0 6.44 0.155279503 0
4 frontal 0 0 4.19 0 0
4 medulla 0 0 1.94 0 0
4 mid brain 0 0 3.5 0 0
4 occ 0 0 5.19 0 0
4 parietal convexity 1 0 4.44 0.225225225 0
4 pons 0 0 4.1 0 0




0 3.69 0 0
5 frontal 1 0 5.19 0.192678227 0
5 basal ganglia 0 0 5.19 0 0
5 cerebellum 1
0 4.44 0.225225225 0
5 parietal convex 1
0 3.44 0.290697674 0
5 occipital 0 0 5 0 0
5 mid brain 1 0 2.94 0.340136054 0
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6 cerebellum 1
0 4.06 0.246305419 0




0 3.25 0 0
6 parietal convex 1
0 2.56 0.390625 0
6 pons 0 0 3.63 0 0
6 mid brain 0 0 3 0 0
6 frontal 0 0 4.75 0 0
7 parietal para 0
0 7.5 0 0
7 parietal convex 1
0 4.69 0.213219616 0
7 occipital 2 0 4.44 0.45045045 0
7 mid brain 0 0 4.07 0 0
7 thalamus 1 0 3.69 0.27100271 0
7 medulla 1 0 1.94 0.515463918 0
7 basal ganglia 0 0 6.13 0 0
7 pons 4 0 5.31 0.753295669 0
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Table A2: Drug users (non-HlV) (Group 2)


















8 central white 1 0
5.63 0.177619893 0
8 pons 1 0 4.56 0.219298246 0
8 cerebellum 1 0
5.81 0.17211704 0
8 medulla 29 0 2.13 13.61502347 0
8 basal ganglia 1 0 4.81 0.207900208 0





8 parietal 1 0
convex 4.44 0.225225225 0
8 frontal 0 4.5 1.111111111 0
8 occipital 1 0 3.13 0.319488818 0
9 medulla 1 0 3.44 0.290697674 0
9 occipital 0 0 4.63 0 0
9 basal ganglia 5 0 6.56 0.762195122 0
9 mid brain 4 0 4.12 0.970873786 0
central white 0 0
9 5.19 0 0







9 convex 6.19 0.323101777 0
9 frontal 0 0 5.06 0 0
cerebellum 0 0
9 7.18 0 0
10 basal ganglia 0 0 5.44 0 0
10 frontal 0 0 4.25 0 0
10 medulla 0 0 2.62 0 0
10 cerebellum 0 0
6.06 0 0
10 central white 0 0
6.06 0 0
10 thalamus 1 0 5 0.2 0
10 parietal 0 0





11 basal ganglia 0 0 5 0 0
11 parietal 0 0
convex 3.62 0 0
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11 occipital 0 0 4.56 0 0
11 medulla 0 0 1.81 0 0






11 thalamus 2 0 4.31 0.464037123 0
11 frontal 0 0 5.81 0 0
11 central white 0 0
5.06 0 0
12 medulla 0 0 1.94 0 0
12 occipital 2 0 4.62 0.432900433 0
12 cerebellum 0 0
6.5 0 0





12 mid brain 0 2 3.56 0 0.561797753
12 frontal 0 0 3.44 0 0
12 basal ganglia 3 1 4.94 0.607287449 0.20242915
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13 pons 5 4 4.44 1.126126126 0.900900901
13 central white 4 2
7.56 0.529100529 0.264550265





13 parietal para 2 0
6.19 0.323101777 0






14 occipital 0 20 4.44 0 4.504504505
14 medulla 0 0 2.13 0 0
14 parietal para 1 1
6.44 0.155279503 0.155279503
14 frontal 0 6 4.94 0 1.214574899
14 parietal convex 0 0
4.35 0 0
14 pons 0 0 5.19 0 0
14 mid brain 65 1 3.18 20.44025157 0.314465409
14 cerebellum 0 2
7.34 0 0.272479564
14 basal ganglia 0 0 4.81 0 0
15 cerebellum 1 13
5.5 0.181818182 2.363636364
15 parietal convex 1 4
5 0.2 0.8
15 medulla 0 0 2 0 0
15 mid brain 4 0 3.44 1.162790698 0





15 central white 2 7
6.63 0.301659125 1.055806938
15 pons 3 0 3.81 0.787401575 0
15 parietal para 0 0
4.69 0 0
15 Frontal 1 1 3.88 0.257731959 0.257731959
15 basal ganglia 0 5 4.63 0 1.079913607
16 basal ganglia 0 5 5.75 0 0.869565217
16 mid brain 0 4 3.38 0 1.183431953
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16 parietal convex 1 2
4.19 0.238663484 0.477326969






16 frontal 0 6 3.19 0 1.880877743
16 cerebellum 1 0
6.94 0.144092219 0
16 occipital 1 4 4.31 0.232018561 0.928074246
16 central white 1 6
5.94 0.168350168 1.01010101
16 medulla 0 7 2.38 0 2.941176471
17 occipital 1 0 3.81 0.262467192 0
17 mid brain 0 0 4.63 0 0
17 parietal para 1 0
4.31 0.232018561 0
17 pons 0 0 4.75 0 0
17 basal ganglia 0 0 4.88 0 0
17 frontal 0 0 6.31 0 0






18 basal ganglia 1 0 10.13 0.098716683 0
18 central white matter 1 0 9.31 0.107411386 0
18 cerebellum 1 0 8.94 0.111856823 0
18 frontal 0 6.13 0 0
18 medulla 1 0 1.94 0.515463918 0
18 mid brain 1 0 3.5 0.285714286 0
18 occ 1 1 7.38 0.135501355 0.135501355
18 parietal convexity 1 0 6.81 0.146842878 0
18 PP 1 0 6.75 0.148148148 0
18 pons 2 0 4.94 0.4048583 0
18 th 1 1 7.06 0.141643059 0.141643059
18 thai 0 0 6.63 0 0
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19 medulla 0 0 2.06 0 0
20 cerebellum 0 0
6.44
0 0
20 pons 0 0 5 0 0

















20 mid brain 0 0 3.5 0 0

















21 pons 0 0 4.13 0 0
21 mid brain 0 0 4.56 0 0












0 5.06 0 0




0 5.63 0 0
22 pons 0 0 4.5 0 0
22 basal 0 0 6.34 0 0
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ganglia
22 mid brain 0 3.69 0 0
22 cerebellum 0
0 5.5 0 0




0 3.38 0 0
23 cerebellum 0
0 6.44 0 0
23 mid brain 0 0 4.13 0 0
23 pons 0 0 3.69 0 0








0 4.5 0 0
23 occipital 0 0 4 0 0








0 5.19 0.192678227 0
23 thalamus 0 0 3.5 0 0
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24 temporal hipocampus 0 52 4.69 0 11.08742004
24 mid brain 0 3 5.13 0 0.584795322
24 cerebellum 0 15
7.69 0 1.950585176
24 basal ganglia 0 39 5.81 0 6.712564544
24 parietal para 0 1
6.31 0 0.158478605
24 occipital 0 46 5.13 0 8.966861598
24 central white 0 3
7.5 0 0.4
24 medulla 0 29 3.5 0 8.285714286
25 cerebellum 1 131
4.5 0.222222222 29.11111111
25 mid brain 1 266 2.62 0.381679389 101.5267176
25 temporal hipocampus 0 325 3.66 0 88.79781421
25 medulla 0 181 1.69 0 107.1005917
25 parietal para 1 26
4.57 0.218818381 5.689277899
25 basal ganglia 0 245 4.69 0 52.23880597
26 parietal covexity 0 20
4.75 0 4.210526316
26 cerebellum 4 5
5.94 0.673400673 0.841750842
26 medulla 2 91 2.19 0.913242009 41.55251142
26 occipital 2 58 4.63 0.431965443 12.52699784
26 temporal hipocampus 1 147 4.45 0.224719101 33.03370787
26 basal ganglia 1 16 6.19 0.161550889 2.584814216
26 pons 0 3 4.31 0 0.696055684
27 temporal hipocampus 1 0 3.81 0.262467192 0
27 thalamus 0 4 4.88 0 0.819672131
27 basal ganglia 5 143 5.19 0.963391137 27.55298651
27 cerebellum 0 9
5.5 0 1.636363636
27 mid brain 0 1 3.13 0 0.319488818
27 parietal convex 0 1
4.94 0 0.20242915
27 medulla 0 0 1.75 0 0
27 central white 1 1
4.13 0.242130751 0.242130751
28 basal ganglia 1 2 4 0.25 0.5
28 cerebellum 0 1 4.13 0 0.242130751
Group 5)
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28 frontal 2 2 3.19 0.626959248 0.626959248
28 mid brain 0 0 2.94 0 0
28 parietal convexity 1 2 3.63 0.275482094 0.550964187
28 pons 1 2 3.25 0.307692308 0.615384615
28 Temporal hipocampus 1 4 3.96 0.252525253 1.01010101
28 thalamus 0 1 2.94 0 0.340136054
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36 mid brain 0 0 3.94 0 0









36 cerebellum 0 0 5.56 0 0









0 4 0 0
37 cerebellum 0
2 5.63 0 0.355239787




0 5.75 0 0




0 4.75 0 0
38 mid brain 0 0 3.69 0 0
38 temporal
hipocampus 0 0 4.63 0 0
38 basal
ganglia 0 0 5.63 0 0
38 medulla 0 0 1.69 0 0
38 occipital 0 0 6.81 0 0
38 frontal 0 0 3.75 0 0
38 parietal
convexity 0 0 3.81 0 0
38 cerebellum
0 0 5.81 0 0
38 thalamus 0 0 5.13 0 0
39 mid brain 1 0 5.78 0.173010381 0
39 temporal
hipocampus 0 0 5.63 0 0
39 parietal
convex 0 0 5.94 0 0
39 medulla 0 0 2.81 0 0
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39 basal
ganglia 0 0 8.13 0 0
39 frontal 0 0 4.75 0 0
39 cerebellum
0 0 7.13 0 0
39 central
white 0 0 6 0 0
39 parietal
para 0 0 5.94 0 0
39 pons 0 0 6.13 0 0
39 occipital 0 0 6.31 0 0
40 basal
ganglia 0 0 4 0 0
40 occipital 0 0 5 0 0
40 central
white 0 0 5.94 0 0
40 pons 0 0 4.94 0 0
40 temporal
hipocampus 0 0 4.56 0 0
40 cerebellum 0 0 6.31 0 0
40 frontal 0 0 3.19 0 0
40 medulla 0 0 2.44 0 0
42 basal
ganglia 0 0 5.25 0 0
42 cerebellum
0 0 11.81 0 0
42 central
white
matter 0 0 6.06 0 0
42 frontal 0 0 4.31 0 0
42 mid
brain/pons 0 0 4.31 0 0
42 occipital 0 0 6.31 0 0
42 parietal
convex 0 0 5.63 0 0
42 pons 0 0 6 0 0
42 temporal
hipocampus 0 0 4.69 0 0
42 thalamus 0 0 5.56 0 0
253




















29 pons 7 10 6.81 1.027900147 1.468428781
29 parietal para 1 1
5.88 0.170068027 0.170068027
29 temporal hipocampus 1 1 5.31 0.188323917 0.188323917
29 mid brain 2 2 4.19 0.477326969 0.477326969
29 medulla 1 19 2.13 0.469483568 8.920187793
29 parietal convex 0 0
4.69 0 0
29 cerebellum 0 0
6.88 0 0
29 central white matter 0 2 6.5 0 0.307692308
29 thalamus 0 5 5.88 0 0.850340136




30 mid brain 1 0 3.69 0.27100271 0
30 medulla 0 0 1.94 0 0
30
parietal convex 0 0
5.69 0 0
30 pons 0 0 4.43 0 0
30
parietal para 0 0
5.81 0 0
31 occipital 0 0 3.93 0 0
31 basal ganglia 0 0 4.62 0 0
31 parietal convex 0
0 3.88 0 0
31 medulla 0
2 2.5 0 0.8
31 cerebellum 0
0 4.88 0 0
31 thalamus 0 0 4 0 0
31 central white 0
0 5.81 0 0
31 mid brain 0 0 3.75 0 0
32 medulla 1 7 1.93 0.518134715 3.626943005
32 parietal para 0 2 5.81 0 0.344234079
32 temporal hipocampus 1 1 4.5 0.222222222 0.222222222
32 Mid brain 0 0 3.93 0 0
32 BASAL GANGLIA 1 0 6.22 0.160771704 0
32 pons 0 4 4.12 0 0.970873786
32 cerebellum 0 0 6.13 0 0
32 parietal convex 0 0 4 0 0
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32 occipital 0 6 3.19 0 1.880877743
33 cerebellum 1 1
7.06 0.141643059 0.141643059
33 basal ganglia 0 0 5.5 0 0
33 thalamus 0 0 3.88 0 0
33 frontal 0 0 5.5 0 0
33 mid brain 1 0 4.38 0.228310502 0
33 temporal hipocampus 0 0 4.31 0 0
33 pons 1 0 4.13 0.242130751 0
33 occipital 0 0 4.5 0 0
33 parietal convex 0 1
5.25 0 0.19047619
33 medulla 0 0 2.37 0 0
34 medulla 0 0 2 0 0
34 mid brain 1 5 3.5 0.285714286 1.428571429
34 temporal hipocampus 0 0 5 0 0
34 cerebellum 0 1
6.31 0 0.158478605
34 parietal convex 0 0
4.44 0 0
34 pons 1 5 4.06 0.246305419 1.231527094
34 occipital 0 0 5.25 0 0
34 basal ganglia 0 0 6.13 0 0
255





















43 pons 34 13 4.75 7.157894737 2.736842105
43 mid brain 12 9 3.94 3.045685279 2.284263959
parietal 2 4







43 ganglia 5.5 2.545454545 35.09090909
44 parietal 3 92
convex 5.94 0.505050505 15.48821549
44 medulla 10 114 2.25 4.444444444 50.66666667
44 central 0 26
white 5.81 0 4.475043029
44 thalamus 7 228 3.81 1.837270341 59.84251969
44 mid brain 5 105 4.63 1.079913607 22.67818575
44 pons 13 115 5.13 2.53411306 22.417154
45 cerebellum 12 246 4.69 2.558635394 52.45202559
45 medulla 44 691 2.69 16.35687732 256.8773234
45 central 91 1019
white 5.31 17.13747646 191.9020716
45 basal 155 1626





45 pons 27 177 5.81 4.647160069 30.46471601
45 frontal 180 1600 5.18 34.74903475 308.8803089
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Appendix B: Sections stained for CD20, then stripped of



























90/101 frontal 1 0 0 0 1 *
90/101 mid brain 0 0 0 0 0 0
90/101 parietal convex 0 0 0 0 0 0
90/101 temporal
hipocampus
0 0 0 0 0 0
90/23 basal ganglia 2 2 0 0 1 0
90/23 cerebellum 0 0 0 0 0 0
90/23 mid brain 0 0 0 0 0 0
90/23 parietal convexity 0 0 0 0 0 0
90/23 basal ganglia 0 0 0 0 0 0
90/23 mid brain 0 0 0 0 0 0
90/23 temporal
hipocampus
2 2 0 0 1 0
90/23 parietal convexity 0 0 0 0 0 0
90/23 frontal 0 0 0 0 0 0
90/23 cerebellum 0 0 0 0 0 0
90/23 frontal 0 0 0 0 0 0
90/23 temporal
hippocampus
0 0 0 0 0 0
90/24 cerebellum 0 0 0 0 2 1
90/24 frontal 0 0 0 0 0 0
90/24 mid brain 0 0 0 0 0 0
90/24 occipital 0 0 0 0 0 0
90/24 cerebellum 0 0 0 0 0 0
90/24 frontal 0 0 0 0 1 1
90/24 frontal 0 0 0 0 0 0
90/24 temporal
hippocampus
0 0 0 0 2 1
90/24 temporal
hipocampus
0 0 0 0 0 0
90/286 frontal 0 0 1 0 0 0
90/286 cerebellum 0 0 0 0 0 0
90/286 parietal convex 0 0 0 0 0 0
90/286 basal ganglia 0 0 0 0 1 0
90/99 frontal 0 0 0 0 0 0
90/99 parietal convex 0 0 0 0 0 0
90/99 basal ganglia 0 0 0 0 5 5
92/290 thalamus 0 0 0 0 0 0
92/290 occipital 0 0 0 0 0 0
92/290 pons 0 0 0 0 0 0
92/290 parietal convexity 0 0 0 0 0 0
92/290 parietal convexity 0 0 0 0 0 0
94/300 cerebellum 0 0 0 0 0 0
94/300 frontal 0 0 0 0 1 0
94/300 medulla 0 0 0 0 0 0
94/300 cerebellum 0 0 0 0 0 0
94/300 frontal 0 0 0 0 1 0
98/423 thalamus 0 0 0 0 3 1
98/423 medulla 0 0 0 0 0 0
98/423 basal ganglia 0 0 0 0 0 0
98/424 basal ganglia 0 0 0 0 0 0
98/430 frontal 0 0 0 0 0 0
98/430 parietal convexity 0 0 0 0 0 0
Pre-AIDS Cases
91/283 parietal para 0 0 0 0 0 0
91/283 parietal
parasagital
0 0 0 0 1 0
91/283 cerebellum 0 0 0 0 1 1
91/283 frontal 0 0 0 0 1 1
91/283 thalamus 0 0 0 0 0 0



























91/59 cerebellum 0 0 0 0 0 0
91/59 parietal para 0 0 0 0 0 0
91/59 occ 0 0 0 0 0 0
92/248 cerebellum 1 1 25 25 0 0
92/248 parietal convex 0 0 0 0 0 II
92/248 thalamus 0 0 0 0 0 (1
92/248 mid brain 0 0 19 19 0 0
93/94 occipital 0 0 0 0 0 0
93/94 mid brain 1 * 0 0 0 (1
93/94 cerebellum 0 0 0 0 0 0
93/94 frontal 0 0 0 0 0 (1
95/10 frontal 0 0 0 0 0 0
95/10 occipital 0 0 0 0 0 0
95/10 cerebellum 0 0 7 6 3 3
95/10 parietal convex 0 0 0 0 1 0
97/101 cerebellum 0 0 0 0 0 0
97/101 temporal
hipocampus
0 0 0 0 2 2
97/101 parietal para 0 0 0 0 0 0
AIDS Cases with no CNS pathology
95/15 thalamus 0 0 0 0 0 (1
95/15 cerebellum 0 0 0 0 1 II
95/15 mid brain 0 0 0 0 1 II
95/15 parietal convexity 0 0 0 0 1 II
96/160 basal ganglia 0 0 0 0 0 0
96/160 parietal convexity 0 0 0 0 0 0
96/160 cerebellum 0 0 0 0 0 0
96/160 temporal
hippocampus
0 0 0 0 0 0
96/267 frontal 0 0 0 0 0 0
96/267 cerebellum 0 0 0 0 0 I)
96/267 basal ganglia 0 0 0 0 0 0
AIDS Cases with pleomorphic infiltrates
93/52 basal ganglia 0 0 1 1 1 1
93/52 cerebellum 0 0 0 0 0 0
95/66 cerebellum 2 2 0 0 1 0
95/66 occipital 0 0 14 14 0 0
95/270 cerebellum 2 2 1 1 0 0
95/270 mid brain 0 0 56 56 1 1
95/270 temporal
hippocampus
2 2 17 17 0 0
AIDS cases with PARIETAL CONVEXITYNSL
89/298 mid brain Lymphoma Lymphoma 0 0 0 0
92/218 medulla Lymphoma Lymphoma 0 0 0 0
92/218 frontal Lymphoma Lymphoma 0 0 0 0
92/218 cerebellum Lymphoma Lymphoma 0 0 0 0




0 0 0 0 II
92/344 parietal convex 0 0 0 0 II II
92/344 frontal 0 0 0 0 0 0
92/446 temporal
hipocampus
0 0 0 0 II II
92/446 frontal 0 0 0 0 0 II
92/446 medulla 0 0 (1 0 0 I)
92/446 basal ganglia 2 2 0 0 I I)




0 0 0 0
96/206 frontal Lymphoma Lymphoma 0 0 0 0
98/369 thalamus 0 0 0 0 0 0
98/369 parietal convexity 0 0 0 0 0 0
98/369 cerebellum Lymphoma Lymphoma 0 0 0 0
98/369 medulla Lymphoma Lymphoma 0 0 1 I
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Appendix C
Table CI: EBERs In-situ hybridisation results
Area of brain Positive / Negative
Lymphoma
00/261 Medulla +
Central white matter +
Basal ganglia +
Frontal +
89/298 Mid brain +





92/344 Parietal parasagital +
92/446 Medulla * -










93/87 Basal ganglia -
95/270 Mid brain -
Medulla -
Parietal parasagital 1 -
Basal ganglia -
Temporal hippocampus 2 -
Parietal parasagital 2 -

















Sections from lymphoma cases which did not contain lymphoma cells
259
tvpe/ number Area of brain Positive / Negative

























































Table Dl: Sections stained using anti-fibrinogen antibody
Case number















































































39 Occipital # -
Cerebellum +









Key: + Atleast one blood vessel with leakage of fibrinogen
- No leakage of fibrinogen
# Sections from lymphoma case which did not contain lymphoma
262
Appendix E








BamW 3' AGG ACC ACT TTA TAC CAG GG
298
Bam W 5' CTT TAG AGG CGA ATG GGC GC
B-globin 3' ACA CAA CTG TGT TCA CTA GC 110
B-globin 5' CAA CTT CAT CCA CGT TCA CC
FR3 5' ACA CGG C(CT)(GC) TGT ATT ACT GT -100
VH1 5' GCGAATTCATCGATAYTCACCATGGACTGG -300
VH2 5' GCGAATTCATCGATACCACCATGGACATAC -300
VH3 5' GCGAATTCATCGATAAGRACTCACCATGGAG -300
VH4 5' GCGAATTCATCGATAAGAACATGAARCACCTG -300
VH5 5' GCGAATTCATCGATGTCCTCCACCATCATG -300
VH6 5' GCGAATTCATCGATATCCAGACAATGTCTGTC -300




IL-2 3' AGG TAA TCC ATC TGT TCA GA
266
IL-2 5' ACT CAC CAG GAT GCT CAC AT
IL-4 3' ACG TAC TCT GGT TGG CTT CCT TCA CAG
GAC AG
344
IL-4 5' CGG CAA CTT TGA CCA CGG ACA CAA GTG
CGA TA
IL-6 3' CAT CCA TCT TTT TCA GCC AT
190
IL-6 5' ATG TAG CCG CCC CAC ACA GA
IL-10 3' AGC TAT CCC AGA GCC CCA GAT CCG ATT
TTGG
328
IL-10 5' AAG CTG AGA ACC AAG ACC CAG ACA TCA
AGG GG
INF Y 3' ACC GAA TAA TTA GTC AGC TT 356
INF y 5' AGT TAT ATC TTG GCT TTT CA
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Table E2: Probe sequences:
Human gene Probe sequence (5' - 3')
(3 actin GGA TAG CAA CGT ACA TGG CT
BamW TGA CTT CAC CAA AGG TCA GG
IL-2 CCC TGG GTC TAA AGT GAA AG
IL-4 GTC TGT TAC GGT CAA CTC GG
IL-6 TCT TGT TAC ATG TCT CCT TTC TCA G
EL-10 CAG GTG AAG AAT GCC TTT AAT AAG GTC
CAA GAG AAA GGC ATC TAC AAA GCC ATG
AGT GAG TTT GAC ATC
INF y GCT ACA TCT GAA TGA CCT GC
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